Muzaffar H. Qazilbash, MD

Peer-Reviewed Articles

1. Marcoux C, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Saeed A, Haider AA, Ramdial J, Irfan S, YagoNieto, Tang G, Aljawai Y, Kebriaei P, Lee HC, Patel KK, Thomas SK, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH, Pasvolsky O. Post-transplant outcomes in IgD multiple myeloma:a propensity score-matched analysis. Transplant Cell Ther, 2025. e-Pub 2025. PMID: 41421540.
2. Pasvolsky O, Marcoux C, Milton DR, Haider AA, Tanner MR, Bashir Q, Srour S, Saini N, Smallbone P, Lin P, Ramdial J, Nieto Y, Mohamedi AH, Siddiqui UR, Jamil A, Tang G, Aljawai Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH. Results of delayed or salvage autologous hematopoietic stem cell transplantation for multiple myeloma. Bone Marrow Transplant, 2025. e-Pub 2025. PMID: 41350936.
3. Smallbone P, Mendt M, Sackstein R, Tanner MR, Kaur I, Basar R, Rafei H, Daher M, Overman B, Al-Atrash G, Alousi AM, Bashir Q, Hosing CM, Im JS, Kebriaei P, Banerjee P, Patel KP, Zou J, Cao K, Khouri I, Mehta R, Molldrem J, Nieto Y, Oran B, Popat UR, Qazilbash MH, Rondon G, Saini N, Srour S, Champlin RE, Rezvani K, Shpall EJ, Olson A. Ex vivo mesenchymal progenitor cell-based cord blood cell expansion and exofucosylation to enhance transplant engraftment. Cytotherapy:102010, 2025. e-Pub 2025. PMID: 41396090.
4. Lin P, Acharya S, Reyes-Silva F, Basar R, Uprety N, Moreno Rueda LY, Lin P, Gilbert AL, Banerjee PP, Fang D, Zhang C, Nunez Cortes AK, Melo Garcia L, Daher M, Muniz-Feliciano L, Deyter GM, Woods V, Rawal S, Li P, Jones CM, Shrestha R, Qazilbash MH, Patel KK, Lee HC, Champlin RE, Marin D, Shpall EJ, Orlowski RZ, Rezvani K. CD70-Targeting CAR-NK Cells Overcome BCMA Downregulation and Improve Survival in High-Risk Multiple Myeloma Models. Blood Cancer Discov, 2025. e-Pub 2025. PMID: 41144785.
5. Marcoux C, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Patel A, Khan HN, Ramdial J, Nieto Y, Tang G, Haider A, Aljawai Y, Kebriaei P, Lee HC, Ye C, Patel KK, Thomas SK, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH, Pasvolsky O. Outcomes of Patients with Multiple Myeloma with deletion 1p Following Autologous Stem Cell Transplant. Transplant Cell Ther 31(10):804.e1-804.e9, 2025. e-Pub 2025. PMID: 40752590.
6. Uryu, H, Saeki, K, Haeno, H, Kapadia, C, Furudate, D.M.D., Ph.D., K, Nangalia, J, Spencer Chapman, M, Zhao, L, Hsu, JI, Zhao, C, Chen, S, Tanaka, T, Li, Z, Ogata, S, Hanache, S, Yang, H, DiNardo, C, Daver, N, Pemmaraju, N, Jain, N, Ravandi-Kashani, F, Zhang, J, Song, X, Thompson, EJ, Tang, H, Little, L, Gumbs, C, Orlowski, R, Qazilbash, MH, Bhalla, K, Colla, S, Kantarjian, HM, Kanagal Shamanna, R, Bueso-Ramos, CE, Nakada, D, Al-Atrash, G, Molldrem, JJ, Futreal, A, Shpall, E, Goodell, MA, Garcia-Manero, G, Takahashi, K. Clonal evolution of hematopoietic stem cells after autologous stem cell transplantation. Nature Genetics 57(7):1695-1707, 2025. e-Pub 2025. PMID: 40596442.
7. Muchtar, E, Sanchorawala, V, Hassan, H, Hegenbart, U, Schonland, SO, Lee, HC, Qazilbash, MH, Kin, A, Zonder, J, Jacob, E, Buadi, F, Dispenzieri, A, Dingli, D, Arai, S, Chin, MM, Chakraborty, R, Lentzsch, S, Magen, H, Shkury, E, Sarubbi, C, Landau, H, Gertz, MA. The Impact of Melphalan Conditioning and CD34+ Cell Dose and Schedule on Post-Transplant Outcomes in AL Amyloidosis. American journal of hematology 100(7):1141-1151, 2025. e-Pub 2025. PMID: 40214172.
8. Nieto, Y, Banerjee, PP, Kaur, I, Basar, R, Li, YE, Daher, M, Rafei, H, Kerbauy, LN, Kaplan, M, Marin, D, Griffin, L, Barnett, M, Bassett Jr, R, Uprety, N, Shrestha, R, Silva, FR, Islam, S, Ganesh, C, Borneo, Z, Ramdial, JL, Ramirez, A, Hosing, C, Alousi, AM, Popat, UR, Qazilbash, MH, Ahmed, S, Iyer, SP, Sainz, TP, Vega Vazquez, F, Fowlkes, NW, Alexis, K, Emig, M, Harstrick, A, Overesch, A, Shpall, E, Rezvani, K. Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma. Nature medicine 31(6):1987-1993, 2025. e-Pub 2025. PMID: 40186077.
9. Pasvolsky O, Marcoux C, Milton DR, Rafaeli N, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Mohamedi AH, Deen AF, Aljawai Y, Lee HC, Patel KK, Becnel MR, Kebriaei P, Thomas SK, Orlowski RZ, Champlin R, Shpall EJ, Qazilbash MH. Outcomes of multiple myeloma patients with prior solid tumors undergoing autologous transplantation. Transplant Cell Ther 31(8):565.e1-565.e9, 2025. e-Pub 2025. PMID: 40383197.
10. Muchtar, E, Dispenzieri, A, Sanchorawala, V, Hassan, H, Mwangi, R, Maurer, MS, Buadi, F, Lee, HC, Qazilbash, MH, Kin, A, Zonder, J, Arai, S, Chin, MM, Chakraborty, R, Lentzsch, S, Magen, H, Shkury, E, Sarubbi, C, Landau, H, Schonland, SO, Hegenbart, U, Gertz, MA. A model for predicting day-100 stem cell transplant-related mortality in AL amyloidosis. Bone marrow transplantation 60(5):595-602, 2025. e-Pub 2025. PMID: 39994333.
11. Sidana S, Ahmed N, Akhtar OS, Brazauskas R, Oloyede T, Bye M, Hansen DK, Ferreri CJ, Freeman CL, Afrough A, Anderson LD Jr, Dhakal B, Dhanda DS, Gowda L, Hashmi H, Harrison MJ, Kitali A, Landau HJ, Mirza AS, Patwardhan P, Qazilbash MH, Usmani SZ, Patel KK, Nishihori T, Ganguly S, Pasquini MC. Standard-of-Care Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis. Blood 146(2):167-177, 2025. e-Pub 2025. PMID: 40198886.
12. Pasvolsky O, Abid MB, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Jatoi A, Khan HN, Lin P, Ramdial J, Nieto Y, Tang G, Siddiqui U, Aljawai Y, Kebriaei P, Lee HC, Patel KK, Gaballa MR, Thomas SK, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH. Outcomes of patients with multiple myeloma undergoing autologous transplant with suboptimal pretransplant response. Br J Haematol 206(6):1730-1736, 2025. e-Pub 2025. PMID: 40159289.
13. Nieto, Y, Ramdial, JL, Valdez, B, Thall, PF, Bassett Jr, R, Barnett, M, Srour, S, Hosing, C, Alousi, AM, Qazilbash, MH, Popat, UR, Gulbis, A, Shigle, TL, Ahmed, S, Pacheco, MG, Champlin, RE, Shpall, E, Andersson, BS. Enhancement of High-Dose Chemotherapy and Autologous SCT with the PARP Inhibitor Olaparib for Refractory Lymphoma. Clinical Cancer Research 31(6):975-982, 2025. e-Pub 2025. PMID: 39804167.
14. Bashir, Q, Konopleva, M, Abueg, G, Ramdial, JL, Hosing, C, Srour, S, Alousi, AM, Popat, UR, Nieto, Y, Al-Atrash, G, Champlin, RE, Shpall, E, Qazilbash, MH, Pemmaraju, N. Tagraxofusp maintenance post-hematopoietic stem cell transplantation provides long-term survival and manageable safety for a patient with blastic plasmacytoid dendritic cell neoplasm. Leukemia Research Reports 24, 2025. e-Pub 2025. PMID: 40612021.
15. Pasvolsky O, Marcoux C, Wang Z, Milton DR, Pal B, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Syed N, Aljawai Y, Lee HC, Patel KK, Becnel MR, Ye C, Kebriaei P, Thomas SK, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH. Outcomes of Standard-Risk Multiple Myeloma Patients Who Undergo Upfront Autologous Hematopoietic Stem Cell Transplantation. Transplant Cell Ther 31(3):166.e1-166.e9, 2024. e-Pub 2024. PMID: 39746546.
16. Akhtar OS, Oloyede T, Brazauskas R, Afrough A, Hashmi H, Sidana S, Ahmed N, Bye M, Hansen DK, Ferreri CJ, Dhakal B, Dhanda DS, Harrison MJ, Kitali A, Landau HJ, Mirza AS, Patel J, Patwardhan P, Qazilbash MH, Patel KK, Nishihori T, Ganguly S, Gowda L, Anderson LD Jr, Pasquini MC, Usmani SZ, Freeman CL. Outcomes of Older Adults and Frail Patients Receiving Idecabtagene Vicleucel: A CIBMTR Study. Blood Adv 9(7):1587-1592, 2024. e-Pub 2024. PMID: 39786391.
17. Ramdial, JL, Lin, R, Thall, PF, Valdez, B, Hosing, C, Srour, S, Popat, U, Qazilbash, MH, Alousi, AM, Barnett, M, Gulbis, A, Shigle, TL, Shpall, EJ, Andersson, BS, Nieto, Y. High activity of the new myeloablative regimen of gemcitabine/clofarabine/busulfan for allogeneic transplant for aggressive lymphomas. Bone marrow transplantation 59(12):1754-1762, 2024. e-Pub 2024. PMID: 39341929.
18. Marcoux, C, Alousi, AM, Im, J, Hill, LC, Smallbone, PI, Popat, U, Hosing, C, Kebriaei, P, Olson, AL, Mehta, RS, Chen, GL, Qazilbash, MH, Shpall, EJ, Champlin, R, Saliba, RM. Gastrointestinal involvement refines prognosis in minnesota standard risk acute graft-vs.-host disease. Bone marrow transplantation 59(11):1594-1600, 2024. e-Pub 2024. PMID: 39187601.
19. Pattali S, Hu S, Bashir Q, Champlin RE, Qazilbash MH. The Synchronous Diagnosis of Multiple Myeloma (MM) and Chronic Myeloid Leukemia (CML). Cureus 16(11):e73583, 2024. e-Pub 2024. PMID: 39677110.
20. Pasvolsky O, Marcoux C, Milton DR, Pal B, Tanner MR, Bashir Q, Srour S, Lee J, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Aljawai Y, Kebriaei P, Becnel MR, Lee HC, Patel KK, Thomas SK, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Optimal infused CD34(+) cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation. Blood Cancer J 14(1):189, 2024. e-Pub 2024. PMID: 39482325.
21. Marcoux C, Pasvolsky O, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Lee HC, Patel KK, Kebriaei P, Ahmed A, Aljawai Y, Thomas SK, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Real-World Outcomes of Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma with Deletion 17p. Transplant Cell Ther 31(1):12.e1-12.e10, 2024. e-Pub 2024. PMID: 39448031.
22. Pasvolsky O, Marcoux C, Dai J, Milton DR, Tanner MR, Syed N, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Aljawai Y, Lee HC, Gaballa MR, Patel KK, Kebriaei P, Thomas SK, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Trends in Outcomes After Upfront Autologous Transplant for Multiple Myeloma over Three Decades. Transplant Cell Ther 30(8):772.e1-772.e11, 2024. e-Pub 2024. PMID: 38852784.
23. Malek E, Kort J, Metheny L, Fu P, Li G, Hari P, Efebera Y, Callander NS, Qazilbash MH, Giralt S, Krishnan A, Stadtmauer EA, Lazarus HM. Impact of Visceral Obesity on Clinical Outcome and Quality of Life for Patients with Multiple Myeloma: A Secondary Data Analysis of STaMINA (BMT CTN 0702) Trial. Transplant Cell Ther 30(7):698.e1-698.e10, 2024. e-Pub 2024. PMID: 38244697.
24. Pasvolsky O, Pasyar S, Bassett RL, Khan HN, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation. Cancer 130(9):1663-1672, 2024. e-Pub 2023. PMID: 38127583.
25. Alzahrani K, Pasvolsky O, Wang Z, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Manasanch EE, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin R, Qazilbash MH. Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation. Br J Haematol 204(5):1944-1952, 2024. e-Pub 2024. PMID: 38448009.
26. Khouri IF, Alzahrani K, Kantarjian H, Milton DR, Gulbis AM, Sasaki K, Jain N, Short NJ, Kadia T, Daher M, Rafei H, Im JS, Marin D, Olson AL, Popat U, Qazilbash M, Ramdial J, Rondon G, Srour S, Kebriaei P, Shpall E, Champlin R, Jabbour EJ. Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single-center phase 1,2 trial. Am J Hematol 99(5):836-843, 2024. e-Pub 2024. PMID: 38400519.
27. Malek AE, Al-Juhaishi T, Milton DR, Ramdial JL, Daher M, Olson AL, Srour SA, Alatrash G, Oran B, Mehta RS, Khouri IF, Bashir Q, Shah N, Ciurea SO, Rondon G, Maadani F, Hosing C, Marin D, Kebriaei P, Rezvani K, Nieto Y, Anderlini P, Alousi AM, Faisal MS, Qazilbash MH, Popat UR, Champlin RE, Shpall EJ, Mulanovich VE, Ahmed S. Outcomes of toxoplasmosis after allogeneic hematopoietic stem cell transplantation and the role of antimicrobial prophylaxis. Bone Marrow Transplant 59(5):699-704, 2024. e-Pub 2024. PMID: 38355908.
28. Pasvolsky O, Wang Z, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Kebriaei P, Aljawai Y, Khan HN, Lee HC, Ye C, Patel KK, Thomas SK, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation. Blood Cancer J 14(1):82, 2024. e-Pub 2024. PMID: 38760362.
29. Uryu H, Saeki K, Haeno H, Kapadia CD, Furudate K, Nangalia J, Chapman MS, Zhao L, Hsu JI, Zhao C, Chen S, Tanaka T, Li Z, Yang H, DiNardo C, Daver N, Pemmaraju N, Jain N, Ravandi F, Zhang J, Song X, Thompson E, Tang H, Little L, Gumbs C, Orlowski RZ, Qazilbash M, Bhalla K, Colla S, Kantarjian H, Shamanna RK, Ramos CB, Nakada D, Futreal PA, Shpall E, Goodell M, Garcia-Manero G, Takahashi K. Clonal evolution of hematopoietic stem cells after cancer chemotherapy. bioRxiv, 2024. e-Pub 2024. PMID: 38826462.
30. Ahmed S, Bashir Q, Bassett RL, Ullah F, Aung F, Valdez BC, Alousi AM, Hosing C, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Qazilbash MH, Rezvani K, Mehta R, Shpall EJ, Ciurea S, Andersson BS, Champlin RE, Popat UR. Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation: Results of a Phase II study. Am J Hematol 99(4):562-569, 2024. e-Pub 2024. PMID: 38314663.
31. Marcoux C, Saliba RM, Wallis W, Khazal SJ, Ragoonanan D, Rondon G, Tewari P, Popat UR, Oran B, Olson AL, Bashir Q, Qazilbash MH, Alousi A, Hosing C, Nieto Y, Alatrash G, Marin DC, Rezvani K, Khouri IF, Srour SA, Champlin RE, Shpall EJ, Kebriaei P. Incidence and Risk Factors of Early Onset VOD/SOS Differ in Younger vs Older Adults After Stem Cell Transplantation. Blood Adv 8(5):1128-1136, 2024. e-Pub 2024. PMID: 38266155.
32. Kalariya, N, Lee, HC, Qazilbash, MH, Patel, K. Secondary monoclonal gammopathy of unknown significance with isotype switching after CAR T-cell therapy for multiple myeloma. Current Problems in Cancer: Case Reports 13, 2024. e-Pub 2024.
33. Marin D, Li Y, Basar R, Rafei H, Daher M, Dou J, Mohanty V, Dede M, Nieto Y, Uprety N, Acharya S, Liu E, Wilson J, Banerjee P, Macapinlac HA, Ganesh C, Thall PF, Bassett R, Ammari M, Rao S, Cao K, Shanley M, Kaplan M, Hosing C, Kebriaei P, Nastoupil LJ, Flowers CR, Moseley SM, Lin P, Ang S, Popat UR, Qazilbash MH, Champlin RE, Chen K, Shpall EJ, Rezvani K. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial. Nat Med 30(3):772-784, 2024. e-Pub 2024. PMID: 38238616.
34. Yalniz FF, Greenbaum U, Pasvolsky O, Milton DR, Kanagal-Shamanna R, Ramdial J, Srour S, Mehta R, Alousi A, Popat UR, Nieto Y, Kebriaei P, Al-Atrash G, Oran B, Hosing C, Ahmed S, Champlin RE, Shpall EJ, Qazilbash MH, Bashir Q. Characteristics and outcomes of patients with Multiple Myeloma who developed therapy- relates Acute Myeloid Leukemia and Myelodysplastic Syndrome following Autologous Cell Transplantation. Transplant Cell Ther 30(2):205.e1-205.e12, 2024. e-Pub 2023. PMID: 37437764.
35. Nieto Y, Yang Z, Valdez BC, Kundu S, Bashir Q, Ramdial J, Srour S, Qazilbash M. Safety and efficacy of a new high-dose regimen of panobinostat, gemcitabine, busulfan, and melphalan for 1st or 2nd salvage ASCT for refractory/relapsed or high-risk myeloma: Matched-pair comparisons with concurrent control cohorts. Am J Hematol 99(2):245-253, 2024. e-Pub 2024. PMID: 38100199.
36. Pasvolsky O, Ghanem S, Milton DR, Rauf M, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Aljawai Y, Khan HN, Kebriaei P, Lee HC, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience. Blood Cancer J 14(1):4, 2024. e-Pub 2024. PMID: 38199987.
37. Pasvolsky O, Ghanem S, Milton DR, Masood A, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma. Transplant Cell Ther 29(12):757-762, 2023. e-Pub 2023. PMID: 37673125.
38. Pasvolsky O, Bassett RL, Ghanem S, Cuglievan B, Tewari P, Hosing C, Srour S, Ramdial J, Mahadeo KM, Khazal S, Petropoulos D, Popat U, Qazilbash M, Kebriaei P, Champlin R, Shpall EJ, Nieto Y. Characteristics and outcomes of children, adolescents and young adults with relapsed/refractory non-hodgkin lymphoma undergoing autologous stem cell transplant. BMC Cancer 23(1):1258, 2023. e-Pub 2023. PMID: 38124057.
39. Joseph J, Srour SA, Milton DR, Ramdial JL, Saini NY, Olson AL, Bashir Q, Oran B, Alousi AM, Hosing C, Qazilbash MH, Kebriaei P, Shpall EJ, Champlin RE, Popat UR. Transplant Outcomes of Myelofibrosis with Busulfan and Fludarabine Myeloablative Conditioning. Transplant Cell Ther 29(12):770.e1-770.e6, 2023. e-Pub 2023. PMID: 37742746.
40. Tang G, Wu Y, Lin P, Toruner GA, Hu S, Li S, Qazilbash MH, Orlowski RZ, Ye C, Xu J, Nahmod KA, Medeiros LJ, Tang Z. Cytogenetic Profile in Monoclonal Gammopathy of Undetermined Significance, Smoldering and Symptomatic Multiple Myeloma: A Study of 1087 Patients with Highly Purified Plasma Cells. Cancers (Basel) 15(23), 2023. e-Pub 2023. PMID: 38067393.
41. Alkhaldi H, Reinhardt A, Barnett M, Kundu S, Hosing C, Ramdial J, Saini N, Srour S, Alousi A, Kebriaei P, Popat U, Qazilbash M, Champlin R, Shpall EJ, Gulbis A, Shigle TL, Dabaja B, Pinnix C, Ahmed S, Steiner R, Andersson BS, Nieto Y. High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. Transplant Cell Ther 29(11):690-694, 2023. e-Pub 2023. PMID: 37607645.
42. Bal S, Estrada-Merly N, Costa LJ, Qazilbash MH, Kumar S, D'Souza A. Outcomes of t(11;14) light chain (AL) amyloidosis after autologous stem cell transplantation: benchmark for new therapies. Blood Cancer J 13(1):170, 2023. e-Pub 2023. PMID: 37968258.
43. Popat UR, Pasvolsky O, Bassett R, Mehta RS, Olson AL, Chen J, Alousi AM, Al-Atrash G, Bashir Q, Gulbis AM, Hosing CM, Im JS, Kebriaei P, Khouri IF, Marin DC, Nieto Y, Oran B, Saini NY, Shigle TL, Srour SA, Ramdial JL, Rezvani K, Qazilbash MH, Andersson BS, Champlin RE, Shpall EJ. Myeloablative Fractionated Busulfan for Allogeneic Stem Cell Transplant in Older Patients or Patients with Comorbidities. Blood Adv 7(20):6196-6205, 2023. e-Pub 2023. PMID: 37611156.
44. Pasvolsky O, Milton DR, Masood A, Sami SS, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Saeed A, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Single-agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: The MD Anderson experience. Am J Hematol 98(10):1571-1578, 2023. e-Pub 2023. PMID: 37461327.
45. Malek E, Kort J, Metheny L, Fu P, Hari P, Li G, Efebera Y, Callander N, Qazilbash M, Giralt S, Krishnan A, Stadtmauer E, Lazarus H. Impact of Visceral Obesity on Clinical Outcome and Quality of Life for Patients with Multiple Myeloma: A Secondary Data Analysis of STaMINA (BMT CTN 0702) Trial. Res Sq, 2023. e-Pub 2023. PMID: 37790413.
46. Al-Juhaishi T, Wang Y, Milton DR, Xu-Monette ZY, Jabbour E, Daher M, Im JS, Bashir Q, Iyer SP, Marin D, Olson AL, Popat U, Qazilbash M, Rondon G, Gulbis AM, Champlin RE, Young KH, Khouri IF. Clinical relevance of MYC/BCL2 expression and cell of origin in patients with diffuse large b-cell lymphoma treated with autologous transplant. Bone Marrow Transplant 58(9):1000-1007, 2023. e-Pub 2023. PMID: 37198234.
47. Pasvolsky O, Marcoux C, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Tewari P, Crawford-Suber L, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Outcomes of young adults (aged = 40 years) with newly diagnosed multiple myeloma after up-front autologous stem cell transplant. Br J Haematol 202(4):866-873, 2023. e-Pub 2023. PMID: 37376789.
48. Ragon BK, Shah MV, D'Souza A, Estrada-Merly N, Gowda L, George G, DeLima M, Hashmi S, Kharfan-Dabaja MA, Majhail NS, Banerjee R, Saad A, Hildebrandt GC, Mian H, Abid MB, Battiwalla M, Lekakis LJ, Patel SS, Murthy HS, Nieto Y, Strouse CS, Badawy SM, Al Hadidi SA, Dholaria B, Aljurf M, Vesole DH, Lee CH, Pawarode A, Gergis U, Miller KC, Holmberg LA, Afrough A, Solh MM, Munshi P, Nishihori T, Anderson LD, Wirk B, Kaur G, Qazilbash MH, Shah N, Kumar SK, Usmani SZ. Impact of Second Primary Malignancy Post-Autologous Transplantation on Outcomes of Multiple Myeloma: A CIBMTR Analysis. Blood Adv 7(12):2746-2757, 2023. e-Pub 2023. PMID: 36827681.
49. Jelloul FZ, Quesada AE, Yang RK, Li S, Wang W, Xu J, Tang G, Yin CC, Fang H, El Hussein S, Khoury J, Bassett RL, Garcia-Manero G, Manasanch EE, Orlowski RZ, Qazilbash MH, Patel KP, Medeiros LJ, Lin P. Clinicopathologic features of therapy-related myeloid neoplasms in myeloma patients in the era of novel therapies. Mod Pathol 36(6):100166, 2023. e-Pub 2023. PMID: 36990279.
50. Beird HC, Yin CC, Khoury JD, Pierce SR, Abbas HA, Zhao L, Skwarska A, Qazilbash MH, Konopleva MY, Futreal A, Pemmaraju N. TET2 truncating mutations predict a worse outcome in blastic plasmacytoid dendritic cell neoplasm. Blood Adv 7(10):2000-2003, 2023. e-Pub 2023. PMID: 36689729.
51. Pasvolsky O, Milton DR, Rauf M, Ghanem S, Masood A, Mohamedi AH, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Rezvani K, Champlin R, Shpall EJ, Lin P, Qazilbash MH. Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients. Blood Cancer J 13(1):68, 2023. e-Pub 2023. PMID: 37137874.
52. Pasvolsky O, Saliba RM, Masood A, Mohamedi AH, Tanner MR, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Impact of gender on outcomes of patients with multiple myeloma undergoing autologous Haematopoietic stem cell transplant. Br J Haematol 201(4):e37-e41, 2023. e-Pub 2023. PMID: 36916461.
53. Bumma N, Dhakal B, Fraser R, Estrada-Merly N, Anderson K, Freytes CO, Hildebrandt GC, Holmberg L, Krem MM, Lee C, Lekakis L, Lazarus HM, Mian H, Murthy HS, Nathan S, Nishihori T, Parrondo R, Patel SS, Solh M, Strouse C, Vesole DH, Kumar S, Qazilbash MH, Shah N, D'Souza A, Sidana S. Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma. Cancer. e-Pub 2023. PMID: 37021929.
54. Afrough A, Alsfeld LC, Milton DR, Delgado R, Popat UR, Nieto Y, Kebriaei P, Oran B, Saini N, Srour S, Hosing C, Cheema FH, Ahmed S, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Weber DM, Orlowski RZ, Pinnix CC, Dabaja BS, Thomas SK, Champlin RE, Shpall EJ, Qazilbash MH, Bashir Q. Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma. Transplant Cell Ther 29(4):264.e1-264.e9, 2023. e-Pub 2022. PMID: 35605883.
55. Pasvolsky O, Gaballa MR, Milton DR, Masood A, Sami SS, Tanner MR, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Tang G, Lin P, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4;14): The MD Anderson Cancer Center Experience: Transplant in t(4;14) MM. Transplant Cell Ther 29(4):260.e1-260.e6, 2023. e-Pub 2023. PMID: 36646323.
56. Crees ZD, Rettig MP, Jayasinghe RG, Stockerl-Goldstein K, Larson SM, Arpad I, Milone GA, Martino M, Stiff P, Sborov D, Pereira D, Micallef I, Moreno-Jiménez G, Mikala G, Coronel MLP, Holtick U, Hiemenz J, Qazilbash MH, Hardy N, Latif T, García-Cadenas I, Vainstein-Haras A, Sorani E, Gliko-Kabir I, Goldstein I, Ickowicz D, Shemesh-Darvish L, Kadosh S, Gao F, Schroeder MA, Vij R, DiPersio JF. Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial. Nat Med 29(4):869-879, 2023. e-Pub 2023. PMID: 37069359.
57. Mehta RS, Cao K, Saliba RM, Al-Atrash G, Alousi AM, Lontos K, Marcoux C, Carmazzi Y, Rondon G, Bashir Q, Hosing CM, Kebriaei P, Khouri I, Marin D, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial J, Rezvani K, Champlin RE, Shpall EJ. HLA Factors Versus Non-HLA Factors for Haploidentical Donor Selection. Transplant Cell Ther 29(3):189-198, 2023. e-Pub 2022. PMID: 36470579.
58. Ngo-Huang A, Ombres R, Saliba RM, Szewczyk N, Adekoya L, Soones TN, Ferguson J, Fontillas RC, Gulbis AM, Hosing C, Kebriaei P, Lindsay R, Marin DC, Mehta RS, Alousi AM, Srour S, Oran B, Olson AL, Qazilbash MH, Rivera Z, Champlin RE, Shpall EJ, Popat UR. Enhanced Recovery Stem-Cell Transplantation: Multidisciplinary Efforts to Improve Outcomes in Older Adults Undergoing Hematologic Stem-Cell Transplant. JCO Oncol Pract 19(3):OP2200520, 2023. e-Pub 2023. PMID: 36626702.
59. Pemmaraju N, Kantarjian HM, Sweet KL, Wang ES, Senapati J, Wilson NR, Konopleva MY, Frankel AE, Gupta V, Mesa RA, Ulrickson ML, Gorak E, Bhatia S, Budak-Alpdogan T, Mason JR, Garcia-Romero MT, Lopez-Santiago NC, Cesarman-Maus G, Vachhani P, Lee S, Bhatt VR, Blum W, Walter RB, Bixby D, Gojo I, Duvic M, Rampal RK, de Lima M, Foran JM, Fathi AT, Hall A, Jacoby MA, Lancet JE, Mannis GN, Stein AS, Mims AS, Rizzieri D, Olin RL, Perl AE, Schiller GJ, Shami PJ, Stone RM, Strickland S, Wieduwilt MJ, Daver NG, Ravandi F, Vasu S, Guzman ML, Roboz GJ, Khoury JD, Qazilbash MH, Aung P, Cuglievan B, Madanat YF, Kharfan-Dabaja MA, Pawlowska AB, Taylor J, Tallman MS, Dhakal P, Lane AA. North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: Position on Standards of Care and Areas of Need. Blood 141(6):567-578, 2023. e-Pub 2022. PMID: 36399715.
60. Nieto Y, Pasvolsky O, Bassett R, Ghanem S, Cuglievan B, Tewari P, Hosing C, Sr S, Ramdial J, Mahadeo K, Khazal S, Petropoulos D, Popat U, Qazilbash M, Kebriaei P, Champlin R, Shpall E. Characteristics and Outcomes of Children, Adolescents and Young Adults with Relapsed/Refractory Non-Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplant. Res Sq, 2023. e-Pub 2023. PMID: 36798261.
61. Pasvolsky O, Saliba RM, Ledesma C, Popat UR, Alousi A, Olson A, Oran B, Hosing C, Bashir Q, Qazilbash MH, Short NJ, Ravandi F, Champlin R, Shpall EJ, Kebriaei P. Prognostic significance of measurable residual disease in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation in second or later complete remission. Am J Hematol 98(2):E35-E37, 2023. e-Pub 2022. PMID: 36502492.
62. D'Souza A, Brazauskas R, Stadtmauer EA, Pasquini MC, Hari P, Bashey A, Callander N, Devine S, Efebera Y, Ganguly S, Gasparetto C, Geller N, Horowitz MM, Koreth J, Landau H, Brunstein C, McCarthy P, Qazilbash MH, Giralt S, Krishnan A, Flynn KE. Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma. Am J Hematol 98(1):140-147, 2023. e-Pub 2022. PMID: 35567778.
63. Qazilbash MH, Kwak LW. Personalized Medicine's Coming of Age: One Drug, One Patient. Clin Cancer Res 29(23):4703-4705, 2023. e-Pub 2023. PMID: 37733765.
64. Pasvolsky O, Milton DR, Rauf M, Tanner MR, Bashir Q, Srour S, Tang G, Saini N, Ramdial J, Masood A, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Lenalidomide-Based Maintenance After Autologous Hematopoietic Stem Cell Transplant for Patients with High-Risk Multiple Myeloma. Transplant Cell Ther 28(11):752.e1-752.e6, 2022. e-Pub 2022. PMID: 35940528.
65. Popat UR, Andersson BS, Bassett R, Kawedia J, Valdez BC, Alousi AM, Al-Atrash G, Bashir Q, Hosing CM, Im JS, Kebriaei P, Marin D, Nieto Y, Oran B, Olson A, Qazilbash MH, Srour SA, Shpall EJ, Champlin RE, Mehta RS. Myeloablative fractionated busulfan conditioning regimen with post-transplant cyclophosphamide in HLA matched and haploidentical transplantation: results of a phase II study. Haematologica 107(10):2496-2500, 2022. e-Pub 2022. PMID: 35770531.
66. Mehta RS, Saliba RM, Rondon G, Al-Atrash G, Bashir Q, Hosing CM, Kebriaei P, Khouri I, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial J, Srour SA, Champlin RE, Rezvani K, Shpall EJ, Alousi AM. Post-Transplantation Cyclophosphamide vs Tacrolimus and Methotrexate Graft-versus-Host Disease Prophylaxis For HLA-Matched Donor Transplantation. Transplant Cell Ther 28(10):695.e1-695.e10, 2022. e-Pub 2022. PMID: 35902049.
67. Kalariya N, Ferreri C, Dillard C, Hawkins M, Manasanch E, Lee H, Weber D, Thomas S, Steiner R, Hosing C, Qazilbash M, Popat U, Orlowski R, Hildebrandt M, Patel K. CT-511 Clinical Characteristics and Response Outcomes in Older Multiple Myeloma Patients Who Received Idecabtagene Vicleucel: A Single Center Study. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S446, 2022. e-Pub 2022. PMID: 36164224.
68. Pasvolsky O, Milton D, Rauf M, Ghanem S, Masood A, Mohamedi A, Tanner M, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Tang G, Lee H, Patel K, Kebriaei P, Thomas S, Weber D, Orlowski R, Shpall E, Champlin R, Lin P, Qazilbash M. MM-403 Impact of Clonal Plasma Cells in Autografts on the Outcome of High-Risk Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplant. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S421-S422, 2022. e-Pub 2022. PMID: 36164172.
69. Alatrash G, Saberian C, Bassett R, Thall PF, Ledesma C, Lu Y, Daher M, Valdez BC, Kawedia J, Popat U, Mehta R, Oran B, Nieto Y, Olson A, Anderlini P, Marin D, Hosing C, Alousi AM, Shpall EJ, Rondon G, Chen J, Qazilbash M, Champlin RE, Andersson BS, Kebriaei P. Vorinostat Combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-Term Study Outcomes. Transplant Cell Ther 28(8):501.e1-501.e7, 2022. e-Pub 2022. PMID: 35618218.
70. Mehta RS, Saliba RM, Hayase E, Jenq RR, Abraham S, Rashid A, Rondon G, Al-Atrash G, Bashir Q, Hosing CM, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Popat UR, Qazilbash MH, Ramdial J, Srour S, Champlin RE, Rezvani K, Shpall EJ, Alousi AM. Mycophenolate Mofetil: A Friend or a Foe with PTCy and Tacrolimus Prophylaxis in HLA-Matched donors?. Transplant Cell Ther 28(8):500.e1-500.e10, 2022. e-Pub 2022. PMID: 35662592.
71. Kansagra A, Dispenzieri A, Fraser R, Estrada-Merly N, Sidana S, Nishihori T, Hansen DK, Anderson LD, Banerjee R, Bumma N, Dhakal B, Khouri J, Landau H, Lee CH, Mian H, Nathan S, Savani BN, Kumar SK, Qazilbash MH, Shah N, D'Souza A. Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma. Blood Adv 6(13):3991-3995, 2022. e-Pub 2022. PMID: 35507742.
72. Mehta RS, Saliba RM, Ghanem S, Alousi AM, Rondon G, Anderlini P, Al-Atrash G, Bashir Q, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Popat UR, Qazilbash MH, Ramdial J, Saini N, Srour SA, Champlin RE, Rezvani K, Shpall EJ. Haploidentical versus Matched Unrelated versus Matched Sibling Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplant Cell Ther 28(7):395.e1-395.e11, 2022. e-Pub 2022. PMID: 35513252.
73. Gaballa MR, Ma J, Rauf M, Bassett R, Pasvolsky O, Tanner MR, Bashir Q, Srour SA, Saini N, Ramdial J, Nieto Y, Murphy R, Rezvani K, Tang G, Lin P, Lee HC, Patel KK, Ullah MR, Kaufman GP, Manasanch EE, Kebriaei P, Thomas SK, Weber DM, Shpall EJ, Champlin RE, Orlowski RZ, Qazilbash MH. KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma. Bone Marrow Transplant 57(7):1142-1149, 2022. e-Pub 2022. PMID: 35523847.
74. Kawedia JD, Ramchandran S, Liu X, Gulbis AM, Titus M, Bashir Q, Qazilbash MH, Champlin RE, Ciurea SO. Stability of Captisol-enabled versus propylene glycol-based melphalan at room temperature and after refrigeration. Am J Health Syst Pharm 79(12):1011-1018, 2022. e-Pub 2022. PMID: 35176751.
75. Afrough A, Pasvolsky O, Ma J, Srour S, Bashir Q, Saini N, Hosing C, Popat UR, Kebriaei P, Delgado R, Ullah MR, Murphy R, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Impact of Induction with VCD vs. VRD on the Outcome of Patients with Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation. Transplant Cell Ther 28(6):307.e1-307.e8, 2022. e-Pub 2022. PMID: 35331973.
76. Pemmaraju N, Wilson NR, Garcia-Manero G, Sasaki K, Khoury JD, Jain N, Borthakur G, Ravandi F, Daver NG, Kadia TM, DiNardo CD, Jabbour EJ, Pierce SR, Qazilbash MH, Konopleva MY, Kantarjian HM. Characteristics and Outcomes of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm Treated with Frontline HCVAD. Blood Adv 6(10):3027-3035, 2022. e-Pub 2022. PMID: 35061885.
77. Akin S, Hosing C, Khouri IF, Ahmed S, Alousi A, Fowler NH, Joseph J, Truxillo J, Ramdial J, Maadani F, Rondon G, Daher M, Im JS, Steiner RE, Westin JR, Iyer SP, Dabaja BS, Anderlini P, Popat UR, Qazilbash MH, Flowers CR, Shpall EJ, Champlin RE, Nieto Y, Srour SA. Autologous Stem Cell Transplantation for Large B-cell Lymphoma with Secondary Central Nervous System Involvement. Blood Adv 6(7):2267-2274, 2022. e-Pub 2022. PMID: 35008100.
78. Nieto Y, Gruschkus S, Valdez BC, Jones RB, Anderlini P, Hosing C, Popat U, Qazilbash M, Kebriaei P, Alousi A, Saini N, Srour S, Rezvani K, Ramdial J, Barnett M, Gulbis A, Shigle TL, Ahmed S, Iyer S, Lee H, Nair R, Parmar S, Steiner R, Dabaja B, Pinnix C, Gunther J, Cuglievan B, Mahadeo K, Khazal S, Chuang H, Champlin R, Shpall EJ, Andersson BS. Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis. Haematologica 107(4):899-908, 2022. e-Pub 2021. PMID: 33951890.
79. Patel KK, Shah JJ, Feng L, Lee HC, Manasanch EM, Olsem J, Morphey A, Huo XJ, Thomas SK, Bashir Q, Qazilbash MH, Weber DM, Orlowski RZ. Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Post-transplant Myeloma Patients. Clin Cancer Res 28(7):1277-1284, 2022. e-Pub 2022. PMID: 34992070.
80. Qazilbash MH, Saini NY, Cha SC, Wang Z, Stadtmauer EA, Baladandayuthapani V, Lin H, Tross B, Honhar M, Rao SS, Kim K, Popescu M, Szymura S, Zhang T, Anderson A, Bashir Q, Shpall EJ, Orlowski RZ, Levine BL, Kerr N, Garfall A, Cohen A, Vogl DT, Dengel K, June CH, Champlin R, Kwak LW. A Randomized Phase II Trial of Idiotype Vaccination and Adoptive Autologous T-Cell Transfer in Multiple Myeloma patients. Blood 139(9):1289-1301, 2022. e-Pub 2022. PMID: 34521108.
81. Dispenzieri A, Krishnan A, Arendt B, Blackwell B, Wallace PK, Dasari S, Vogl DT, Efebera Y, Fei M, Geller N, Giralt S, Hahn T, Howard A, Kohlhagen M, Landau H, Hari P, Pasquini MC, Qazilbash MH, McCarthy P, Shah N, Vesole DH, Stadtmauer E, Murray D. Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT). Blood Cancer J 12(2):27, 2022. e-Pub 2022. PMID: 35145071.
82. Tan CR, Estrada-Merly N, Landau H, Lekakis L, Banerjee R, Mian H, Usmani SZ, Hanbali A, Lazarus HM, Kyle RA, Dholaria B, Bal S, Strouse C, Murthy HS, Wirk B, Nishihori T, Kumar S, Shah N, Qazilbash M, D'Souza A. A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients. Bone Marrow Transplant 57(2):295-298, 2022. e-Pub 2021. PMID: 34802047.
83. Ahmed S, Zhao Q, Hanel W, Qazilbash MH, Patel K, Narra R, Kansagra A, Iqbal M, Awan FT, Christian B, Jaglowski SM, Kharfan-Dabaja MA, Hamadani M, Epperla N. Post-relapse survival in Waldenstrom macroglobulinemia patients experiencing therapy failure following autologous transplantation. Hematol Oncol 40(1):48-56, 2022. e-Pub 2021. PMID: 34763367.
84. Sidana S, Kumar S, Fraser R, Estrada-Merly N, Giralt S, Agrawal V, Anderson LD, Aljurf M, Banerjee R, Bashey A, Battiwalla M, Beitinjaneh A, Chakraborty R, Chhabra S, Dhakal B, Dholaria B, Hashmi S, Janakiram M, Lee C, Lekakis L, Murthy HS, Parrondo R, Wangjam T, Usmani S, Shah N, Qazilbash M, D'Souza A. Title: Impact of Induction Therapy with VRD vs. VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation. Transplant Cell Ther 28(2):83.e1-83.e9, 2022. e-Pub 2022. PMID: 34781066.
85. Bashir Q, Milton DR, Popat UR, Kebriaei P, Hosing C, Khouri IF, Rezvani K, Nieto Y, Oran B, Srour SA, Saini NY, Olson AL, Ahmed S, Al-Atrash G, Rondon G, Konopleva MY, Champlin RE, Shpall EJ, Qazilbash MH, Pemmaraju N. Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Bone Marrow Transplant 57(1):51-56, 2022. e-Pub 2021. PMID: 34629467.
86. Pasvolsky O, Yeshurun M, Fraser R, Estrada-Merly N, Rozovski U, Shargian-Alon L, Assal A, Banerjee R, Bumma N, Gale RP, Hagen P, Holmberg L, Hossain NM, Lazarus HM, Lee C, Mian H, Miller KC, Nathan S, Nagler A, Nishihori T, Parrondo RD, Patel S, Schroeder MA, Usmani SZ, Wang T, Wirk B, Kumar S, Shah N, Qazilbash MH, D'Souza A. Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis. Bone Marrow Transplant 57(1):31-37, 2022. e-Pub 2021. PMID: 34608275.
87. Gaballa MR, Ma J, Tanner MR, Al-Juhaishi T, Bashir Q, Srour SA, Saini NY, Ramdial JL, Nieto Y, Murphy R, Rezvani K, Tang G, Lee HC, Patel KK, Kaufman GP, Manasanch EE, Ullah MR, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance. Leuk Lymphoma 63(3):1-12, 2022. e-Pub 2021. PMID: 34686083.
88. Patel R, Ma J, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Daher M, Mehta R, Srour S, Weber DM, Thomas SK, Lee HC, Patel KK, Orlowski RZ, Shpall ES, Champlin RE, Saini N, Qazilbash MH. Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to Whites: A propensity-score matched analysis. Am J Hematol 96(12):E455-E457, 2021. e-Pub 2021. PMID: 34559916.
89. Srour SA, Milton DR, Bashir Q, Nieto Y, Saini N, Daher M, Ramdial J, Im J, Hosing C, Delgado R, Manasanch E, Lee HC, Thomas S, Kaufman G, Patel K, Popat U, Weber D, Orlowski R, Shpall E, Champlin RE, Qazilbash MH. Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma. Haematologica 106(12):3211-3214, 2021. e-Pub 2021. PMID: 34407606.
90. Mehta RS, Saliba RM, Alsfeld LC, Jorgensen JL, Wang SA, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Popat UR, Qazilbash MH, Ramdial J, Rondon G, Saini N, Srour SA, Rezvani K, Shpall EJ, Champlin RE, Alousi AM. Bone Marrow versus Peripheral Blood Graft for Haploidentical HCT with Post Transplantation Cyclophosphamide. Transplant Cell Ther 27(12):1003.e1-1003.e13, 2021. e-Pub 2021. PMID: 34537419.
91. Yin CC, Pemmaraju N, You MJ, Li S, Xu J, Wang W, Tang Z, Alswailmi O, Bhalla KN, Qazilbash MH, Konopleva M, Khoury JD. Integrated Clinical Genotype-Phenotype Characteristics of Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancers (Basel) 13(23), 2021. e-Pub 2021. PMID: 34884997.
92. Khouri IF, Milton DR, Gulbis AM, Jabbour EJ, Nastoupil L, Ledesma C, Anderlini P, Bashir Q, Daher M, Im JS, Iyer SP, Marin D, Mehta RS, Olson AL, Popat UR, Qazilbash M, Saini N, Samaniego F, Rondon G, Medeiros LJ, Champlin RE. Nine-Year Follow-up of Patients with Relapsed Follicular Lymphoma after Nonmyeloablative Allogeneic Stem Cell Transplant and Autologous Transplant. Clin Cancer Res 27(21):5847-5856, 2021. e-Pub 2021. PMID: 34380640.
93. Munshi PN, Vesole DH, St Martin A, Davila O, Kumar S, Qazilbash M, Shah N, Hari PN, D'Souza A. Outcomes of upfront autologous hematopoietic cell transplantation in patients with multiple myeloma who are 75 years old or older. Cancer 127(22):4233-4239, 2021. e-Pub 2021. PMID: 34374445.
94. Mehta RS, Bassett R, Chen J, Valdez BC, Kawedia J, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Qazilbash MH, Ramdial J, Saini N, Srour SA, Rezvani K, Shpall EJ, Andersson BS, Champlin RE, Popat UR. Myeloablative Fractionated Busulfan With Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial. Transplant Cell Ther 27(11):913.e1-913.e12, 2021. e-Pub 2021. PMID: 34329753.
95. Pemmaraju N, Wilson NR, Khoury JD, Jain N, Daver NG, Pierce SR, Jabbour EJ, Kadia TM, DiNardo CD, Garcia-Manero G, Qazilbash MH, Konopleva MY, Kantarjian HM. Central Nervous System Involvement in Blastic Plasmacytoid Dendritic Cell Neoplasm. Blood 138(15):1373-1377, 2021. e-Pub 2021. PMID: 34098573.
96. Olson A, Lin R, Marin D, Rafei H, Bdaiwi MH, Thall PF, Basar R, Abudayyeh A, Banerjee P, Aung FM, Kaur I, Abueg G, Rao S, Chemaly R, Mulanovich V, Al-Atrash G, Alousi AM, Andersson BS, Anderlini P, Bashir Q, Castro KM, Daher M, Galvan IM, Hosing C, Im JS, Jones RB, Kebriaei P, Khouri I, Mehta R, Molldrem J, Nieto Y, Oran B, Popat U, Qazilbash M, Rondon G, Saini N, Spencer B, Srour S, Washington D, Barnett M, Champlin RE, Shpall EJ, Rezvani K. Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. J Clin Oncol 39(24):JCO2002608, 2021. e-Pub 2021. PMID: 33929874.
97. Ramdial JL, Mehta RS, Saliba RM, Alousi AM, Bashir Q, Hosing C, Kebriaei P, Olson AL, Oran B, Qazilbash MH, Srour SA, Andersson BS, Champlin RE, Popat U. Acute graft-versus-host disease is the foremost cause of late nonrelapse mortality. Bone Marrow Transplant 56(8):2005-2012, 2021. e-Pub 2021. PMID: 33846563.
98. Yalniz FF, Saliba RM, Greenbaum U, Ramdial J, Popat U, Oran B, Alousi A, Olson A, Alatrash G, Marin D, Rezvani K, Hosing C, Im J, Mehta R, Qazilbash M, Joseph JJ, Rondon G, Kanagal-Shamanna R, Shpall E, Champlin R, Kebriaei P. Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Myeloid Leukemia. Transplant Cell Ther 27(8):689-695, 2021. e-Pub 2021. PMID: 34023569.
99. Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Hari P, D'Souza A. Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia 35(7):2141, 2021. e-Pub 2021. PMID: 34091601.
100. Koller P, Saliba RM, Ledesma C, Rondon G, Popat U, Alousi A, Mehta R, Oran B, Olson A, Hosing C, Qazilbash M, Khouri I, Ciurea S, Shpall E, Jorgensen J, Wang S, Jain N, Jabbour E, Kantarjian H, Champlin R, Konopleva M, Kebriaei P. Outcomes in patients with CRLF2 overexpressed acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 56(7):1746-1749, 2021. e-Pub 2021. PMID: 33767403.
101. Balmaceda N, Aziz M, Chandrasekar VT, McClune B, Kambhampati S, Shune L, Abdallah AO, Anwer F, Majeed A, Qazilbash M, Ganguly S, McGuirk J, Mohyuddin GR. Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019. BMC Cancer 21(1):730, 2021. e-Pub 2021. PMID: 34172037.
102. Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Hari P, D'Souza A. Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia 35(6):1828, 2021. e-Pub 2021. PMID: 33782538.
103. Mehta RS, Bassett R, Rondon G, Overman BJ, Popat UR, Hosing CM, Rezvani K, Qazilbash MH, Anderlini P, Jones RB, Kebriaei P, Marin D, Khouri IF, Oran B, Ciurea SO, Kondo K, Couriel DR, Shpall EJ, Champlin RE, Alousi AM. Randomized phase II trial of extracorporeal phototherapy and steroids vs. steroids alone for newly diagnosed acute GVHD. Bone Marrow Transplant 56(6):1316-1324, 2021. e-Pub 2021. PMID: 33398094.
104. Kunacheewa C, Feng L, Manasanch EE, Bashir Q, Patel KK, Mehta R, Kaufman GP, Srour S, Saini N, Iyer SP, Thomas SK, Weber DM, Orlowski RZ, Qazilbash MH, Lee HC. Outcomes of lenalidomide retreatment with novel triplet regimens in patients with multiple myeloma progressing on lenalidomide-based maintenance therapy. Br J Haematol 193(3):e23-e26, 2021. e-Pub 2021. PMID: 33748943.
105. Ahmed S, Bashir Q, Bassett R, Poon MC, Valdez B, Konoplev S, Alousi AM, Andersson BS, Ciurea S, Hosing C, Jones R, Kebriaei P, Khouri I, Kim S, Nieto Y, Olson A, Oran B, Parmar S, Qazilbash MH, Rezvani K, Shah N, Shpall EJ, Champlin R, Popat U. Eltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled Trial. Transplant Cell Ther 27(5):430.e1-430.e7, 2021. e-Pub 2021. PMID: 33965187.
106. Joseph J, Ma J, Hennawy F, Abdulrazzaq MN, Saini N, Patel RD, Hosing CM, Alousi AM, Anderlini P, Popat UR, Qazilbash MH, Shpall EJ, Srour S, Kebriaei P, Bashir Q, Nastoupil LJ, Westin JR, Rondon G, Champlin RE, Andersson BS, Nieto Y, Muzzafar T, Ahmed S. Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Transplant Cell Ther 27(5):404.e1-404.e5, 2021. e-Pub 2021. PMID: 33965178.
107. Mehta RS, Saliba RM, Jan A, Shigle TL, Wang E, Nieto Y, Ciurea SO, Oran B, Im J, Olson A, Marin D, Qazilbash M, Khouri I, Rondon G, Anderlini P, Rezvani K, Popat U, Kebriaei P, Shpall E, Champlin R, Alousi A. Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft-Versus-Host Disease. Transplant Cell Ther 27(3):272.e1-272.e5, 2021. e-Pub 2021. PMID: 33781539.
108. Srour SA, Saliba RM, Bashir Q, Popat UR, Ahmed S, Mehta RS, Delgado R, Rondon G, Parmar S, Kebriaei P, Hosing C, Manasanch EE, Lee HC, Patel KK, Orlowski RZ, Shpall E, Champlin RE, Qazilbash MH, Nieto Y. Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. Transplant Cell Ther 27(3):243.e1-243.e6, 2021. e-Pub 2021. PMID: 33781521.
109. Cornell RF, Fraser R, Costa L, Goodman S, Estrada-Merly N, Lee C, Hildebrandt G, Gergis U, Farhadfar N, Freytes CO, Kamble RT, Krem M, Kyle RA, Lazarus HM, Marks DI, Meehan K, Patel SS, Ramanathan M, Olsson RF, Wagner JL, Kumar S, Qazilbash MH, Shah N, Hari P, D'Souza A. Bortezomib-Based Induction Is Associated with Superior Outcomes in Light Chain Amyloidosis Patients Treated with Autologous Hematopoietic Cell Transplantation Regardless of Plasma Cell Burden. Transplant Cell Ther 27(3):264.e1-264.e7, 2021. e-Pub 2021. PMID: 33781533.
110. Manasanch EE, Berrios D, Fountain E, Claussen CM, Chuang T, Kaufman G, Amini B, Bashir Q, Nieto Y, Qazilbash M, Patel K, Thomas SK, Weber DM, Berkova Z, Toruner G, Lin P, Feng L, Lee HC, Orlowski RZ, Kunacheewa C. Gene expression profiling predicts relapse-free and overall survival in newly diagnosed myeloma patients treated with novel therapies. Br J Haematol 192(4):e115-e120, 2021. e-Pub 2021. PMID: 33486754.
111. Ali T, Qazilbash MH. POEMS syndrome: A multisystem clonal disorder. Eur J Haematol 106(1):14-18, 2021. e-Pub 2020. PMID: 32889731.
112. Olson AL, Saliba RM, Oran B, Chen J, Alousi A, Ahmed S, Bashir Q, Ciurea SO, Hosing C, Seon Im J, Kebriaei P, Khouri IF, Mehta R, Nieto Y, Parmar S, Rezvani K, Shah N, Shpall E, Srour SA, Qazilbash M, Andersson BS, Champlin R, Popat UR. Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia. Acta Haematol 144(1):1-8, 2021. e-Pub 2020. PMID: 32604096.
113. Munshi PN, Vesole D, Jurczyszyn A, Zaucha JM, St Martin A, Davila O, Agrawal V, Badawy SM, Battiwalla M, Chhabra S, Copelan E, Kharfan-Dabaja MA, Farhadfar N, Ganguly S, Hashmi S, Krem MM, Lazarus HM, Malek E, Meehan K, Murthy HS, Nishihori T, Olin RL, Olsson RF, Schriber J, Seo S, Shah G, Solh M, Tay J, Kumar S, Qazilbash MH, Shah N, Hari PN, D'Souza A. Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. Cancer 126(23):5077-5087, 2020. e-Pub 2020. PMID: 32965680.
114. Abudayyeh A, Lin H, Mamlouk O, Abdelrahim M, Saliba R, Rondon G, Martinez CS, Delgado R, Page V, Rajasekaran A, Sanders PW, Qazilbash M. Impact of autologous stem cell transplantation on long term renal function and associated progression-free and overall survival in multiple myeloma. Leuk Lymphoma 61(13):3101-3111, 2020. e-Pub 2020. PMID: 32723196.
115. Dhakal B, D'Souza A, Callander N, Chhabra S, Fraser R, Davila O, Anderson K, Assal A, Badawy SM, Berdeja J, Cerny J, Comenzo R, Chakraborty R, Peter Gale R, Kamble R, Kharfan-Dabaja MA, Krem M, Ganguly S, Janakiram M, Kansagra A, Munker R, Murthy H, Patel S, Kumar S, Shah N, Qazilbash M, Hari P. Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma. Br J Haematol 191(3):442-452, 2020. e-Pub 2020. PMID: 33094839.
116. Saini N, Bashir Q, Milton DR, Tang G, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Mehta R, Srour S, Khouri IF, Weber DM, Thomas SK, Lee HC, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM. Blood Adv 4(19):4834-4837, 2020. e-Pub 2020. PMID: 33027527.
117. Saini N, Marin D, Ledesma C, Delgado R, Rondon G, Popat UR, Bashir Q, Hosing CM, Nieto Y, Alousi AM, Qazilbash MH, Ciurea S, Shpall E, Khouri I, Kantarjian H, Jabbour E, Ravandi F, Champlin RE, Kebriaei P. Impact of TKI maintenance post-allogeneic transplant in Philadelphia positive acute lymphoblastic leukemia. Blood 136(15):1786-1789, 2020. e-Pub 2020. PMID: 32492706.
118. Popat U, Mehta RS, Bassett R, Kongtim P, Chen J, Alousi AM, Anderlini P, Ciurea S, Hosing C, Jones R, Kebriaei P, Khouri I, Lindsay R, Nieto Y, Olson A, Oran B, Qazilbash MH, Rondon G, Shpall EJ, Verstovsek S, Andersson BS, Champlin RE. Optimizing the Conditioning Regimen for Hematopoietic Cell Transplant in Myelofibrosis: Long-Term Results of a Prospective Phase II Clinical Trial. Biol Blood Marrow Transplant 26(8):1439-1445, 2020. e-Pub 2020. PMID: 32438043.
119. Srour SA, Kongtim P, Rondon G, Chen J, Petropoulos D, Ramdial J, Popat U, Kebriaei P, Qazilbash M, Shpall EJ, Champlin RE, Ciurea SO. Haploidentical Transplants for Patients with Relapse After the First Allograft. Am J Hematol. e-Pub 2020. PMID: 32619033.
120. Kunacheewa C, Lee HC, Patel K, Thomas S, Amini B, Srour S, Bashir Q, Nieto Y, Qazilbash MH, Weber DM, Feng L, Orlowski RZ, Lin P, Manasanch EE. Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study. Clin Lymphoma Myeloma Leuk 20(5):e221-e238, 2020. e-Pub 2020. PMID: 32037287.
121. Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Hari P, D'Souza A. Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia. e-Pub 2020. PMID: 32313109.
122. Varma A, Abraham SC, Mehta RS, Saini NY, Honhar M, Rashid M, Chen J, Srour SA, Bashir Q, Rondon G, Oran B, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Marin D, Khouri IF, Ciurea SO, Qazilbash MH, Rezvani K, Anderlini P, Andersson BS, Shpall EJ, Champlin RE, Popat UR. Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity. Blood Adv 4(7):1296-1306, 2020. e-Pub 2020. PMID: 32236526.
123. Varma A, Sui D, Milton DR, Tang G, Saini N, Hasan O, Mukherjee A, Joseph JJ, Bashir Q, Rondon G, Srour S, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Mehta R, Khouri IF, Ahmed H, Iyer S, Weber DM, Thomas SK, Manasanch E, Lee HC, Patel K, Ciurea SO, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Multiple Myeloma With Chromosome 1q Gain and 1p Deletion After Autologous Hematopoietic Stem Cell Transplantation: propensity-score matched analysis: Outcome of 1q+/1p- MM pts after auto-HCT. Biol Blood Marrow Transplant 26(4):665-671, 2020. e-Pub 2020. PMID: 31881283.
124. Srour SA, Qazilbash MH. Impact of renal impairment on light chain amyloidosis outcomes after autologous hematopoietic stem cell transplantation. Ann Transl Med 8(7):509, 2020. e-Pub 2020. PMID: 32395553.
125. Giralt S, Costa LJ, Maloney D, Krishnan A, Fei M, Antin JH, Brunstein C, Geller N, Goodman S, Hari P, Logan B, Lowsky R, Qazilbash MH, Sahebi F, Somlo G, Rowley S, Vogl DT, Vesole DH, Pasquini M, Stadtmauer E. Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma: Long-term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 Trial. Biol Blood Marrow Transplant 26(4):798-804, 2020. e-Pub 2020. PMID: 31756536.
126. Srour SA, Singh H, McCarty J, de Groot E, Huls H, Rondon G, Qazilbash M, Ciurea S, Bardelli G, Buck J, Alousi A, Nieto Y, Rezvani K, Marin D, Popat U, Hosing C, Shpall EJ, Wierda WG, Kantarjian H, Champlin RE, Cooper LJ, Kebriaei P. Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas. Blood 135(11):862-865, 2020. e-Pub 2020. PMID: 31961918.
127. Kongtim P, Hasan O, Perez JMR, Varma A, Wang SA, Patel KP, Chen J, Rondon G, Srour S, Bashir Q, Qazilbash M, Mehta R, Shpall EJ, Alousi A, Khouri I, Kebriaei P, Popat U, Champlin RR, Ciurea SO. A Novel Disease Risk Model for Patients with AML Receiving Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 26(1):197-203, 2020. e-Pub 2020. PMID: 31518645.
128. Valdez BC, Li Y, Murray D, Liu Y, Nieto Y, Bashir Q, Qazilbash MH, Andersson BS. Panobinostat and venetoclax enhance the cytotoxicity of gemcitabine, busulfan, and melphalan in multiple myeloma cells. Exp Hematol 81:32-41, 2020. e-Pub 2020. PMID: 31954171.
129. Mohyuddin GR, Aziz M, McClune B, Abdallah AO, Qazilbash M. Antibiotic Prophylaxis for Patients with Newly Diagnosed Multiple Myeloma: Systematic Review and Meta-Analysis. Eur J Haematol. e-Pub 2019. PMID: 31880853.
130. Bashir Q, Chamoun K, Milton DR, Khan M, Ahmed S, Mehta R, Popat UR, Kebriaei P, Nieto Y, Oran B, Ciurea SO, Hosing C, Khouri I, Patel K, Manasanch EE, Lee HC, Orlowski RZ, Champlin RE, Qazilbash MH. Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged =75 years. Leuk Lymphoma 60(14):1-8, 2019. e-Pub 2019. PMID: 31282244.
131. Cordas Dos Santos DM, Saliba RM, Patel R, Bashir Q, Saini N, Hosing C, Kebriaei P, Khouri IF, Nieto Y, Popat U, Ahmed H, Lee HC, Manasanch EE, Patel KK, Thomas SK, Weber DM, Orlowski RJ, Champlin RE, Qazilbash MH. Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. e-Pub 2019. PMID: 31786242.
132. Saini N, Ma J, Milton DR, Patel R, Varma A, Bashir Q, Delgado R, Mukherjee A, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Tang G, Mehta R, Srour S, Khouri IF, Iyer S, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Impact of autologous transplantation in multiple myeloma patients with t(11;14): a propensity-score matched analysis. Clin Cancer Res 25(22):6781-6787, 2019. e-Pub 2019. PMID: 31481508.
133. Saini NY, Patel RD, Varma A, Bashir Q, Delgado R, Rondon G, Mukherjee A, Popat U, Hosing C, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK. Outcomes of autologous stem cell transplantation in Waldenström's macroglobulinemia. Ann Hematol. e-Pub 2019. PMID: 31243571.
134. Tabchi S, Nair R, Kunacheewa C, Patel KK, Lee HC, Thomas SK, Amini B, Ahmed S, Mehta RS, Bashir Q, Qazilbash MH, Weber DM, Orlowski RZ, Alexanian R, Feng L, Manasanch EE. Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia. Clin Lymphoma Myeloma Leuk. e-Pub 2019. PMID: 31201134.
135. Mehta RS, Bassett R, Olson A, Chen J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Molldrem JJ, Nieto Y, Oran B, Rezvani K, Qazilbash MH, Srour SA, Shpall EJ, Andersson BS, Champlin RE, Popat UR. Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long term results of a prospective phase II clinical trial. Haematologica. e-Pub 2019. PMID: 30948491.
136. Bashir Q, Thall PF, Milton DR, Fox PS, Kawedia JD, Kebriaei P, Shah N, Patel K, Andersson BS, Nieto YL, Valdez BC, Parmar S, Rondon G, Delgado R, Hosing C, Popat UR, Oran B, Ciurea SO, Lin P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Williams LA, Champlin RE, Qazilbash MH. Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. Lancet Haematol. e-Pub 2019. PMID: 30910541.
137. Stadtmauer EA, Pasquini MC, Blackwell B, Hari P, Bashey A, Devine S, Efebera Y, Ganguly S, Gasparetto C, Geller N, Horowitz MM, Koreth J, Knust K, Landau H, Brunstein C, McCarthy P, Nelson C, Qazilbash MH, Shah N, Vesole DH, Vij R, Vogl DT, Giralt S, Somlo G, Krishnan A. Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial. J Clin Oncol 37(7):589-597, 2019. e-Pub 2019. PMID: 30653422.
138. Saini NY, Saliba RM, Rondon G, Maadani F, Popat U, Hosing CM, Betul O, Bashir Q, Olson A, Nieto Y, Alousi A, Kebriaei P, Srour S, Mehta R, Anderlini P, Shpall EJ, Qazilbash MH, Khouri IF, Fayad L, Lee H, Fowler N, Parmar S, Westin J, Hagemeister F, Champlin RE, Ciurea SO. Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma. Biol Blood Marrow Transplant. e-Pub 2019. PMID: 30763728.
139. Ghobadi A, Milton DR, Gowda L, Rondon G, Chemaly RF, Hamdi A, Alousi A, Afrough A, Oran B, Ciurea S, Kebriaei P, Popat UR, Qazilbash MH, Shpall EJ, Champlin RE, Bashir Q. HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant. Curr Res Transl Med. e-Pub 2019. PMID: 30683577.
140. Maymani H, Lin P, Saliba RM, Popat U, Bashir Q, Shah N, Patel K, Parmar S, Kebriaei P, Hosing C, Ciurea S, Andersson B, Shpall E, Champlin R, Srour SA, Qazilbash MH. Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens. Biol Blood Marrow Transplant. e-Pub 2019. PMID: 30639822.
141. Saini NY, Patel R, Varma A, Bashir Q, Delgado R, Rondon G, Popat U, Hosing C, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK. Long-term durable efficacy of autologous stem cell transplantation in POEMS syndrome. Am J Hematol. e-Pub 2018. PMID: 30548467.
142. Gowda L, Shah M, Badar I, Bashir Q, Shah N, Patel K, Kanagal-Shamanna R, Mehta R, Weber DM, Lee HC, Manasanch EE, Shah A, Thomas SK, Parmar S, Nieto Y, Orlowski RZ, Champlin R, Qazilbash MH. Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs. Bone Marrow Transplant. e-Pub 2018. PMID: 30446740.
143. Popat UR, Mehta RS, Bassett R, Chen J, Valdez BC, Kawedia J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Jones R, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Parmar S, Rezvani K, Qazilbash MH, Shah N, Srour SA, Shpall EJ, Champlin RE, Andersson BS. Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. Lancet Haematol 5(11):e532-e542, 2018. e-Pub 2018. PMID: 30389035.
144. Shah MV, Saliba RM, Rondon G, Chen J, Soebbing D, Rus I, Alousi A, Oran B, Kebriaei P, Qazilbash M, Parmar S, Hosing C, Khouri IF, Popat UR, Champlin RE, Ciurea SO. Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation. Bone Marrow Transplant. e-Pub 2018. PMID: 30337700.
145. Saini NY, Patel R, Varma A, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Melphalan based autologous transplant in octogenarian multiple myeloma patients. Am J Hematol. e-Pub 2018. PMID: 30300461.
146. Veltri L, Rezvani K, Oran B, Mehta R, Rondon G, Kebriaei P, Popat U, Nieto Y, Hosing C, Qazilbash M, Khouri I, Shpall E, Champlin R, Marin D. Allotransplants for patients 65 years or older with high-risk acute myeloid leukemia. Biol Blood Marrow Transplant. e-Pub 2018. PMID: 30308325.
147. Afrough A, Saliba RM, Hamdi A, Honhar M, Varma A, Cornelison AM, Rondon G, Parmar S, Shah ND, Bashir Q, Hosing C, Popat U, Weber DM, Thomas S, Orlowski RZ, Champlin RE, Qazilbash MH. Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. e-Pub 2018. PMID: 30016656.
148. Nieto Y, Thall PF, Ma J, Valdez BC, Ahmed S, Anderlini P, Popat U, Jones RB, Shpall EJ, Hosing C, Qazilbash M, Kebriaei P, Alousi A, Timmons M, Gulbis A, Myers A, Oki Y, Fanale M, Dabaja B, Pinnix C, Milgrom S, Champlin R, Andersson BS. Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem-Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin's Lymphoma. Biol Blood Marrow Transplant 24(8):1602-1609, 2018. e-Pub 2018. PMID: 29501779.
149. Trujillo-Ocampo A, Cho HW, Herrmann AC, Ruiz-Vazquez W, Thornton AB, He H, Li D, Qazilbash MA, Ma Q, Porcelli SA, Shpall EJ, Molldrem J, Im JS. Rapid ex vivo expansion of highly enriched human invariant natural killer T cells via single antigenic stimulation for cell therapy to prevent graft-versus-host disease. Cytotherapy. e-Pub 2018. PMID: 30076070.
150. Hu B, Thall P, Milton DR, Sasaki K, Bashir Q, Shah N, Patel K, Popat U, Hosing C, Nieto Y, Lin P, Delgado R, Jorgensen J, Manasanch E, Weber D, Thomas S, Orlowski RZ, Champlin R, Qazilbash MH. High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes. Leuk Lymphoma:1-11. e-Pub 2018. PMID: 30032678.
151. Shah N, Shi Q, Giralt S, Williams L, Bashir Q, Qazilbash M, Champlin RE, Cleeland CS, Wang XS. Utility of a patient-reported outcome in measuring functional impairment during autologous stem cell transplant in patients with multiple myeloma. Qual Life Res 27(4):979-985, 2018. e-Pub 2018. PMID: 29260444.
152. Yeh JC, Shank BR, Milton DR, Qazilbash MH. Adverse Prognostic Factors for Morbidity and Mortality during Peripheral Blood Stem Cell Mobilization in Patients with Light Chain Amyloidosis. Biol Blood Marrow Transplant 24(4):815-819, 2018. e-Pub 2018. PMID: 29223373.
153. Oran B, Saliba RM, Carmazzi Y, de Lima M, Rondon G, Ahmed S, Alousi A, Andersson BS, Anderlini P, Alvarez M, Bashir Q, Ciurea S, Fernandez-Vina M, Hosing C, Kebriaei P, Korbling M, Cano P, Khouri I, Marin D, Nieto Y, Olson A, Popat U, Rezvani K, Qazilbash M, Shpall EJ, Champlin RE, Cao K. Effect of non-permissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T cell depletion. Blood 131(11):1248-1257, 2018. e-Pub 2018. PMID: 29386198.
154. Ragon BK, Mehta RS, Gulbis AM, Saliba RM, Chen J, Rondon G, Popat UR, Nieto Y, Oran B, Olson AL, Patel K, Hosing CM, Qazilbash MH, Shah N, Kebriaei P, Shpall EJ, Champlin RE, Alousi AM. Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit. Bone Marrow Transplant 53(3):315-325, 2018. e-Pub 2018. PMID: 29269797.
155. Mohyuddin GR, Faisal MS, Badar T, Shah N, Bashir Q, Patel KK, Hosing C, Popat UR, Rondon G, Delgado R, Shah JJ, Weber DM, Thomas SK, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH. A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center. Leuk Lymphoma 59(2):1-4, 2018. e-Pub 2018. PMID: 28673185.
156. Malek E, Gupta V, Creger R, Caimi P, Vatsayan A, Covut F, Bashir Q, Champlin R, Delgado R, Rondon G, Cooper B, de Lima M, Lazarus HM, Qazilbash M. Amifostine reduces gastro-intestinal toxicity after autologous transplantation for multiple myeloma. Leuk Lymphoma:1-8. e-Pub 2018. PMID: 29295650.
157. Kharfan-Dabaja MA, Al Malki MM, Deotare U, Raj RV, El-Jurdi N, Majhail N, Cherry MA, Bashir Q, Darrah J, Nishihori T, Sibai H, Hamadani M, de Lima M, Gerds AT, Selby G, Qazilbash MH, Forman SJ, Ayala E, Lipton JH, Hari PN, Muzzafar T, Zhang L, Olteanu H, Perkins J, Sokol L, Kumar A, Ahmed S. Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study. Br J Haematol. e-Pub 2017. PMID: 28980314.
158. Shah N, Cornelison AM, Saliba R, Ahmed S, Nieto YL, Bashir Q, Parmar S, Hosing C, Popat U, Shpall EJ, Champlin RE, Qazilbash M. Inpatient vs outpatient autologous hematopoietic stem cell transplantation for multiple myeloma. Eur J Haematol. e-Pub 2017. PMID: 28895206.
159. Im JS, Abraham SC, Saliba RM, Rondon G, Ross WA, Rashid A, Shpall EJ, Popat U, Qazilbash MH, Hosing C, Oran B, Shah N, Tewari P, Nieto Y, Kebriaei P, Champlin RE, Alousi AM. Histologic Grade 1 is Associated With Increased Nonrelapsed Mortality in Lower Gastrointestinal Graft Versus Host Disease. Am J Surg Pathol. e-Pub 2017. PMID: 28834808.
160. Holstein SA, Jung SH, Richardson PG, Hofmeister CC, Hurd DD, Hassoun H, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, van Besien K, Gentile TG, Isola L, Maziarz RT, Bashey A, Landau H, Martin T, Qazilbash MH, Rodriguez C, McClune B, Schlossman RL, Smith SE, Hars V, Owzar K, Jiang C, Boyd M, Schultz C, Wilson M, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Linker C, Anderson KC, McCarthy PL. Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol. e-Pub 2017. PMID: 28826616.
161. Pingali SR, Saliba RM, Anderlini P, Hosing C, Khouri I, Alousi AM, Nieto Y, Qazilbash MH, Champlin R, Popat UR. Age Over 55 Years at Diagnosis Increases Risk of Second Malignancies after Auto-Transplantation for Hodgkin's Lymphoma Patients. Biol Blood Marrow Transplant 23(7):1059-1063, 2017. e-Pub 2017. PMID: 28389254.
162. Bachegowda LS, Saliba RM, Ramlal R, Kongtim P, Chen J, Rondon G, Wallis W, Alousi A, Ahmed S, Hosing CM, Parmar S, Qazilbash M, Khouri IF, Bashir Q, Oran B, Popat U, Shpall EJ, Marin D, Rezvani K, Kebriaei P, Champlin RE, Ciurea SO. Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation. Blood 129(22):3031-3033, 2017. e-Pub 2017. PMID: 28351938.
163. Nieto Y, Valdez BC, Pingali SR, Bassett R, Delgado R, Nguyen J, Shah N, Popat U, Jones RB, Andersson BS, Gulbis A, Ahmed S, Bashir Q, Parmar S, Patel K, Myers A, Rondon G, Orlowski RZ, Champlin R, Qazilbash M. High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan. Lancet Haematol 4(6):e283-e292, 2017. e-Pub 2017. PMID: 28522110.
164. Veltri LW, Milton DR, Delgado R, Shah N, Patel K, Nieto Y, Kebriaei P, Popat UR, Parmar S, Oran B, Ciurea S, Hosing C, Lee HC, Manasanch E, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Bashir Q. Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma. Cancer. e-Pub 2017. PMID: 28513828.
165. Srour SA, Li S, Popat UR, Qazilbash MH, Lozano-Cerrada S, Maadani F, Alousi A, Kebriaei P, Anderlini P, Nieto Y, Jones R, Shpall E, Champlin RE, Hosing C. A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results. Br J Haematol. e-Pub 2017. PMID: 28485023.
166. Shah N, Li L, McCarty J, Kaur I, Yvon E, Shaim H, Muftuoglu M, Liu E, Orlowski RZ, Cooper L, Lee D, Parmar S, Cao K, Sobieiski C, Saliba R, Hosing C, Ahmed S, Nieto Y, Bashir Q, Patel K, Bollard C, Qazilbash M, Champlin R, Rezvani K, Shpall EJ. Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. Br J Haematol 177(3):457-466, 2017. e-Pub 2017. PMID: 28295190.
167. Thompson PA, Stingo F, Keating MJ, Wierda WG, O'Brien SM, Estrov Z, Ledesma C, Rezvani K, Qazilbash M, Shah N, Parmar S, Popat U, Anderlini P, Yago N, Ciurea SO, Kebriaei P, Champlin R, Shpall EJ, Hosing CM. Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival. Br J Haematol 177(4):567-577, 2017. e-Pub 2017. PMID: 28295181.
168. Ge I, Saliba RM, Maadani F, Popat UR, Qazilbash MH, Ravi Pingali S, Shah N, Ahmed S, Bashir Q, Nieto Y, Champlin RE, Hosing C. Patient age and number of apheresis days may predict development of secondary myelodysplastic syndrome and acute myelogenous leukemia after high-dose chemotherapy and autologous stem cell transplantation for lymphoma. Transfusion 57(4):1052-1057, 2017. e-Pub 2017. PMID: 28185276.
169. Gettys SC, Gulbis A, Wilhelm K, Sasaki K, Dinh Y, Rondon G, Qazilbash MH. Modified-CVAD And Modified-CBAD Compared To High Dose Cyclophosphamide For Peripheral Blood Stem Cell Mobilization In Patients With Multiple Myeloma. Eur J Haematol 98(4):388-392, 2017. e-Pub 2017. PMID: 28009447.
170. Varma A, Biritxinaga L, Saliba RM, Stich M, Jauch SF, Afrough A, Honhar M, Popat UR, Shafi MA, Shah N, Bashir Q, Dinh Y, Hosing C, Champlin RE, Qazilbash MH. Impact of Hepatitis B Core Antibody (HBcAb) Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Biol Blood Marrow Transplant 23(4):581-587, 2017. e-Pub 2017. PMID: 28063964.
171. Badar T, Srour S, Bashir Q, Shah N, Al-Atrash G, Hosing C, Popat U, Nieto Y, Orlowski RZ, Champlin R, Qazilbash MH. Predictors of inferior clinical outcome in patients with standard risk multiple myeloma. Eur J Haematol 98(3):263-268, 2017. e-Pub 2017. PMID: 27862330.
172. Qazilbash MH, Wieder E, Thall PF, Wang X, Rios R, Lu S, Kanodia S, Ruisaard KE, Giralt SA, Estey EH, Cortes J, Komanduri KV, Clise-Dwyer K, Alatrash G, Ma Q, Champlin RE, Molldrem JJ. PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies. Leukemia 31(3):697-704, 2017. e-Pub 2017. PMID: 27654852.
173. Kebriaei P, Bassett R, Lyons G, Valdez B, Ledesma C, Rondon G, Oran B, Ciurea S, Alousi A, Popat U, Patel K, Ahmed S, Olson A, Bashir Q, Shah N, Jones R, Marin D, Rezvani K, Nieto Y, Khouri I, Qazilbash M, Hosing C, Shpall E, Champlin RE, Andersson BS. Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results. Biol Blood Marrow Transplant 23(2):285-292, 2017. e-Pub 2017. PMID: 27816651.
174. Mohyuddin GR, Uy J, Medhavi H, Faisal MS, Qazilbash MH. Immune-Mediated Neuropathies following Autologous Stem Cell Transplantation for Multiple Myeloma: Case Series and Review of the Literature. Acta Haematol 137(2):86-88, 2017. e-Pub 2017. PMID: 28092909.
175. Khan M, Carmona S, Sukhumalchandra P, Roszik J, Philips A, Perakis AA, Kerros C, Zhang M, Qiao N, John LSS, Zope M, Goldberg J, Qazilbash M, Jakher H, Clise-Dwyer K, Qiu Y, Mittendorf EA, Molldrem JJ, Kornblau SM, Alatrash G. Cathepsin G Is Expressed by Acute Lymphoblastic Leukemia and Is a Potential Immunotherapeutic Target. Front Immunol 8:1975, 2017. e-Pub 2017. PMID: 29422892.
176. Bock F, Lu G, Srour SA, Gaballa S, Lin HY, Baladandayuthapani V, Honhar M, Stich M, Shah ND, Bashir Q, Patel K, Popat U, Hosing C, Korbling M, Delgado R, Rondon G, Shah JJ, Thomas SK, Manasanch EE, Isermann B, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 22(12):2159-2164, 2016. e-Pub 2016. PMID: 27638366.
177. Badar T, Cornelison AM, Shah ND, Bashir Q, Parmar S, Patel K, Hosing C, Popat U, Weber DM, Thomas SK, Shah JJ, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Patients with Systemic Light chain (AL) Amyloidosis with Concurrent Renal and Cardiac Involvement. Eur J Haematol 97(4):342-7, 2016. e-Pub 2016. PMID: 26773409.
178. Mian I, Milton DR, Shah N, Nieto Y, Popat UR, Kebriaei P, Parmar S, Oran B, Shah JJ, Manasanch EE, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Bashir Q. Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma. Cancer. e-Pub 2016. PMID: 27680710.
179. Kebriaei P, Singh H, Huls MH, Figliola MJ, Bassett R, Olivares S, Jena B, Dawson MJ, Kumaresan PR, Su S, Maiti S, Dai J, Moriarity B, Forget MA, Senyukov V, Orozco A, Liu T, McCarty J, Jackson RN, Moyes JS, Rondon G, Qazilbash M, Ciurea S, Alousi A, Nieto Y, Rezvani K, Marin D, Popat U, Hosing C, Shpall EJ, Kantarjian H, Keating M, Wierda W, Do KA, Largaespada DA, Lee DA, Hackett PB, Champlin RE, Cooper LJ. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J Clin Invest. e-Pub 2016. PMID: 27482888.
180. Gaballa S, Saliba RM, Srour S, Lu G, Brammer JE, Shah N, Bashir Q, Patel K, Bock F, Parmar S, Hosing C, Popat U, Delgado R, Rondon G, Shah JJ, Manasanch EE, Orlowski RZ, Champlin R, Qazilbash M. Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant. Am J Hematol. e-Pub 2016. PMID: 27420405.
181. Gaballa S, Ge I, El Fakih R, Brammer JE, Kongtim P, Tomuleasa C, Wang SA, Lee D, Petropoulos D, Cao K, Rondon G, Chen J, Hammerstrom A, Lombardi L, Alatrash G, Korbling M, Oran B, Kebriaei P, Ahmed S, Shah N, Rezvani K, Marin D, Bashir Q, Alousi A, Nieto Y, Qazilbash M, Hosing C, Popat U, Shpall EJ, Khouri I, Champlin RE, Ciurea SO. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Cancer. e-Pub 2016. PMID: 27404668.
182. Thompson PA, Perera T, Marin D, Oran B, Popat U, Qazilbash M, Shah N, Parmar S, Rezvani K, Olson A, Kebriaei P, Anderlini P, Rondon G, Alousi A, Ciurea S, Champlin RE, Bajel A, Szer J, Shpall EJ, Ritchie D, Hosing CM. Double Umbilical Cord Blood Transplantation (dUCB) is effective therapy for relapsed or refractory Hodgkin Lymphoma. Leuk Lymphoma 57(7):1-23, 2016. e-Pub 2016. PMID: 26472485.
183. D'Souza A, Pasquini M, Logan B, Giralt S, Krishnan A, Antin J, Howard A, Goodman S, Qazilbash M, Knust K, Sahebi F, Weisdorf D, Vesole D, Stadtmauer E, Maloney D, Hari P. Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a BMT CTN 0102 correlative study. Br J Haematol. e-Pub 2016. PMID: 27292583.
184. Nieto Y, Valdez BC, Thall PF, Jones RB, Wei W, Myers A, Hosing C, Ahmed S, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Shah N, Bashir Q, Alousi A, Oki Y, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BS. Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. Cancer. e-Pub 2016. PMID: 27203405.
185. Varma A, Saliba RM, Torres HA, Afrough A, Hosing C, Khouri IF, Nieto Y, Shah ND, Parmar S, Bashir Q, Ahmed S, Jones RB, Kebriaei P, Olson AL, Shpall EJ, Alousi AM, Qazilbash MH, Champlin RE, Popat U. Outcomes in hepatitis C virus seropositive lymphoma and myeloma patients after autologous stem cell transplantation. Bone Marrow Transplant. e-Pub 2016. PMID: 26950376.
186. Mehta RS, Saliba RM, Chen J, Rondon G, Hammerstrom AE, Alousi A, Qazilbash M, Bashir Q, Ahmed S, Popat U, Hosing C, Khouri I, Shpall EJ, Champlin RE, Ciurea SO. Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation. Br J Haematol. e-Pub 2016. PMID: 26947769.
187. Wang Y, Yang F, Shen Y, Zhang W, Wang J, Chang VT, Andersson BS, Qazilbash MH, Champlin RE, Berenson JR, Guan X, Wang ML. Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review. J Natl Cancer Inst 108(3), 2016. e-Pub 2016. PMID: 26582244.
188. Aung FM, Lichtiger B, Rondon G, Yin CC, Alousi A, Ahmed S, Andersson BS, Bashir Q, Ciurea SO, Hosing C, Jones R, Kebriaei P, Khouri I, Nieto Y, Oran B, Parmar S, Qazilbash M, Shah N, Shpall EJ, Champlin RE, Popat U. Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia. Biol Blood Marrow Transplant. e-Pub 2016. PMID: 26921820.
189. Jacobs RW, Saliba RM, Sasaki K, Farhan S, Armas A, Shah ND, Bashir Q, Qureshi S, Rondon G, Hosing C, Popat U, Parmar S, Shah JJ, Wang M, Weber DM, Thomas SK, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk 16(1):36-42, 2016. e-Pub 2016. PMID: 26702475.
190. Shah JJ, Feng L, Thomas SK, Berkova Z, Weber DM, Wang M, Qazilbash MH, Champlin RE, Mendoza TR, Cleeland C, Orlowski RZ. Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial. Blood Cancer J 6:e396, 2016. e-Pub 2016. PMID: 26871714.
191. Pinnix CC, Shah JJ, Chuang H, Costelloe CM, Medeiros LJ, Wogan CF, Reed V, Smith GL, Milgrom S, Patel K, Huo J, Turturro F, Romaguera J, Fayad L, Oki Y, Fanale MA, Westin J, Nastoupil L, Hagemeister FB, Rodriguez A, Qazilbash M, Shah N, Bashir Q, Ahmed S, Nieto Y, Hosing C, Rohren E, Dabaja B. Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review. Clin Lymphoma Myeloma Leuk. e-Pub 2015. PMID: 26795083.
192. Cornelison AM, Saliba RM, Afrough A, Dinh Y, Nieto Y, Bashir Q, Shah N, Parmar S, Hosing C, Popat U, Shpall E, Champlin R, Qazilbash MH. Autologous hematopoietic stem cell transplantation in light chain amyloidosis (AL) with renal involvement. Bone Marrow Transplant. e-Pub 2015. PMID: 26479980.
193. Hosing C, Bassett R, Dabaja B, Talpur R, Alousi A, Ciurea S, Popat U, Qazilbash M, Shpall EJ, Oki Y, Nieto Y, Pinnix C, Fanale M, Maadani F, Donato M, Champlin R, Duvic M. Allogeneic Stem Cell Transplantation in Patients With Cutaneous Lymphoma: Updated Results From a Single Institution. Ann Oncol. e-Pub 2015. PMID: 26416896.
194. Shah N, Shi Q, Williams LA, Mendoza TR, Wang XS, Reuben JM, Dougherty PM, Bashir Q, Qazilbash MH, Champlin RE, Cleeland CS, Giralt SA. Higher Stem Cell Dose Infusion after Intensive Chemotherapy Does Not Improve Symptom Burden in Older Patients with Multiple Myeloma and Amyloidosis. Biol Blood Marrow Transplant. e-Pub 2015. PMID: 26253006.
195. Kazmi SM, Nusrat M, Gunaydin H, Cornelison AM, Shah N, Kebriaei P, Nieto Y, Parmar S, Popat UR, Oran B, Shah JJ, Orlowski RZ, Champlin RE, Qazilbash MH, Bashir Q. Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation. Clin Lymphoma Myeloma Leuk. e-Pub 2015. PMID: 26361647.
196. Cao X, Ye Q, Orlowski RZ, Wang X, Loghavi S, Tu M, Thomas SK, Shan J, Li S, Qazilbash M, Yin CC, Weber D, Miranda RN, Xu-Monette ZY, Medeiros LJ, Young KH. Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis. J Hematol Oncol 8(1):74. e-Pub 2015. PMID: 26104577.
197. Nieto Y, Valdez BC, Thall PF, Ahmed S, Jones RB, Hosing C, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Alousi A, Shah N, Bashir Q, Liu Y, Oki Y, Hagemeister F, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BS. Vorinostat Combined with High-Dose Gemcitabine, Busulfan and Melphalan with Autologous Stem-Cell Transplantation in Patients with Refractory Lymphomas. Biol Blood Marrow Transplant. e-Pub 2015. PMID: 26071868.
198. Popat U, Mehta RS, Rezvani K, Fox P, Kondo K, Marin D, McNiece I, Oran B, Hosing C, Olson A, Parmar S, Shah N, Andreeff M, Kebriaei P, Kaur I, Yvon E, de Lima M, Cooper LJ, Tewari P, Champlin RE, Nieto Y, Andersson BS, Alousi A, Jones RB, Qazilbash MH, Bashir Q, Ciurea S, Ahmed S, Anderlini P, Bosque D, Bollard C, Molldrem JJ, Chen J, Rondon G, Thomas M, Miller L, Wolpe S, Simmons P, Robinson S, Zweidler-McKay PA, Shpall EJ. Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood 125(19):2885-92, 2015. e-Pub 2015. PMID: 25778529.
199. Kongtim P, Qazilbash MH, Shah JJ, Hamdi A, Shah N, Bashir Q, Wang M, Champlin R, Manasanch EE, Weber D, Orlowski RZ, Parmar S. High-dose therapy with auto-SCT is feasible in high-risk cardiac amyloidosis. Bone Marrow Transplant 50(5):668-72, 2015. e-Pub 2015. PMID: 25730192.
200. Wang XI, Yin CC, Qazilbash MH, Hu S, Lu G. Clinical Significance of Acquired Cytogenetic Clones in Patients With Treated Follicular Lymphoma. Clin Lymphoma Myeloma Leuk 15(5):262-9, 2015. e-Pub 2015. PMID: 25573378.
201. Alousi AM, Brammer JE, Saliba RM, Andersson B, Popat U, Hosing C, Jones R, Shpall EJ, Khouri I, Qazilbash M, Nieto Y, Shah N, Ahmed S, Oran B, Al Atrash G, Ciurea S, Kebriaei P, Chen J, Rondon G, Champlin RE. Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies. Biol Blood Marrow Transplant 21(5):906-12, 2015. e-Pub 2015. PMID: 25667989.
202. Afrough A, Saliba RM, Hamdi A, El Fakih R, Varma A, Dinh YT, Rondon G, Cornelison AM, Shah ND, Bashir Q, Shah JJ, Hosing C, Popat U, Orlowski RZ, Champlin RE, Parmar S, Qazilbash MH. Outcome of Patients with Immunoglobulin Light Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. e-Pub 2015. PMID: 25842049.
203. Oran B, Jimenez AM, De Lima M, Popat UR, Bassett R, Andersson BS, Borthakur G, Bashir Q, Chen J, Ciurea SO, Jabbour E, Cortes J, Kebriaei P, Khouri IF, Qazilbash MH, Ravandi F, Rondon G, Lu X, Shpall EJ, Champlin RE. Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. e-Pub 2015. PMID: 25840338.
204. El Fakih R, Fox P, Popat U, Nieto Y, Shah N, Parmar S, Oran B, Ciurea S, Kebriaei P, Hosing C, Ahmed S, Shah J, Orlowski R, Champlin R, Qazilbash M, Bashir Q. Autologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients. Clin Lymphoma Myeloma Leuk. e-Pub 2015. PMID: 25963284.
205. Glitza IC, Lu G, Shah R, Bashir Q, Shah N, Champlin RE, Shah J, Orlowski RZ, Qazilbash MH. Chromosome 8q24.1/c-MYC Abnormality: A Marker for High-Risk Myeloma. Leuk Lymphoma 56(3):1-18, 2015. e-Pub 2015. PMID: 24844357.
206. Shah N, Thall PF, Fox PS, Bashir Q, Shah JJ, Parmar S, Lin P, Kebriaei P, Nieto Y, Popat UR, Hosing CM, Cornelison A, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Phase I/II trial of lenalidomide and high dose melphalan with autologous stem cell transplantation for relapsed myeloma. Leukemia. e-Pub 2015. PMID: 25721897.
207. Gul Z, Bashir Q, Cremer M, Yusuf SW, Gunaydin H, Arora S, Slone S, Nieto Y, Sherwani N, Parmar S, Shah N, Dinh YT, Hosing CM, Popat UR, Kebriaei P, Shpall EJ, Giralt SA, Champlin RE, Qazilbash MH. Short-term Cardiac Toxicity of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Leuk Lymphoma 56(2):1-8, 2015. e-Pub 2015. PMID: 24882259.
208. Pemmaraju N, Shah D, Kantarjian H, Orlowski RZ, Nogueras González GM, Baladandayuthapani V, Jain N, Wagner V, Garcia-Manero G, Shah J, Ravandi F, Pierce S, Takahashi K, Daver N, Nazha A, Verstovsek S, Jabbour E, De Lima M, Champlin R, Cortes J, Qazilbash MH. Characteristics and Outcomes of Patients With Multiple Myeloma Who Develop Therapy-Related Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 15(2):110-4, 2015. e-Pub 2015. PMID: 25107338.
209. Di Stasi A, Milton DR, Poon LM, Hamdi A, Rondon G, Chen J, Pingali SR, Konopleva M, Kongtim P, Alousi A, Qazilbash MH, Ahmed S, Bashir Q, Al-atrash G, Oran B, Hosing CM, Kebriaei P, Popat U, Shpall EJ, Lee DA, de Lima M, Rezvani K, Khouri IF, Champlin RE, Ciurea SO. Similar Transplant Outcomes for AML/MDS Patients with Haploidentical versus 10/10 HLA Matched Unrelated and Related Donors. Biol Blood Marrow Transplant 20(12):1975-81, 2014. e-Pub 2014. PMID: 25263628.
210. Hamdi A, Afrough A, Muzzafar T, Popat UR, Hosing CM, Qazilbash MH, Lu G. Donor Cell-Derived Myelodysplastic Syndrome With Ring Chromosome 7 After Allogeneic Hematopoietic Stem Cell Transplant in 2 Patients With Lymphomas as Primary Disease. Clin Lymphoma Myeloma Leuk 14(5):e151-5, 2014. e-Pub 2014. PMID: 25022600.
211. Parmar S, Kongtim P, Champlin R, Dinh Y, Elgharably Y, Wang M, Bashir Q, Shah JJ, Shah N, Popat U, Giralt SA, Orlowski RZ, Qazilbash MH. Auto-SCT improves survival in systemic light chain amyloidosis: a retrospective analysis with 14-year follow-up. Bone Marrow Transplant 49(8):1036-41, 2014. e-Pub 2014. PMID: 24887378.
212. Tang G, Wang SA, Lu V, Lee HC, Qazilbash MH, Wang XI, Yin CC, Orlowski R, Wang Y, Patel A, Medeiros LJ, Lu G. Clinically silent clonal cytogenetic abnormalities arising in patients treated for lymphoid neoplasms. Leuk Res 38(8):896-900, 2014. e-Pub 2014. PMID: 24939217.
213. Zhou Y, Slack R, Jorgensen JL, Wang SA, Rondon G, de Lima M, Shpall E, Popat U, Ciurea S, Alousi A, Qazilbash M, Hosing C, O'Brien S, Thomas D, Kantarjian H, Medeiros LJ, Champlin RE, Kebriaei P. The Effect of Peritransplant Minimal Residual Disease in Adults With Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk 14(4):319-26, 2014. e-Pub 2014. PMID: 24548609.
214. Alsina M, Becker PS, Zhong X, Adams A, Hari P, Rowley S, Stadtmauer EA, Vesole DH, Logan B, Weisdorf D, Qazilbash M, Popplewell LL, McClune B, Bensinger W, Riches M, Giralt SA, Pasquini MC. Lenalidomide Maintenance for High-Risk Multiple Myeloma after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 20(8):1183-9, 2014. e-Pub 2014. PMID: 24769014.
215. Wu W, Merriman K, Nabaah A, Seval N, Seval D, Lin H, Wang M, Qazilbash MH, Baladandayuthapani V, Berry D, Orlowski RZ, Lee MH, Yeung SC. The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma. Br J Cancer 111(3):628-36, 2014. e-Pub 2014. PMID: 24921909.
216. Hosing C, Saliba RM, Hamerschlak N, Kutner JM, Sakashita AM, Kondo AT, Rodrigues M, Fernande JF, Chiattone A, Chiattone VC, Barros JC, Chiattone CS, Chiattone R, Popat U, Qazilbash M, Tang XW, Wu D, Majilis A, de Lima M, Anguita T. Peripheral blood stem cell yield calculated using preapheresis absolute CD34+ cell count, peripheral blood volume processed, and donor body weight accurately predicts actual yield at multiple centers. Transfusion 54(4):1081-7, 2014. e-Pub 2014. PMID: 24118027.
217. Wang XS, Shi Q, Shah ND, Heijnen CJ, Cohen EN, Reuben JM, Orlowski RZ, Qazilbash MH, Johnson VE, Williams LA, Mendoza TR, Cleeland CS. Inflammatory Markers and Development of Symptom Burden in Patients with Multiple Myeloma during Autologous Stem Cell Transplantation. Clin Cancer Res 20(5):1366-74, 2014. e-Pub 2014. PMID: 24423611.
218. Patel K, Nusrat M, Shah N, Bashir Q, Parmar S, Shah J, Thomas S, Weber D, Orlowski RZ, Champlin R, Qazilbash MH. Durable responses with autologous hematopoietic SCT in patients with POEMS syndrome. Bone Marrow Transplant 49(3):465-6, 2014. e-Pub 2014. PMID: 24419515.
219. Alexanian R, Wang M, Delasalle K, Wang S, Qazilbash M, Handy B, Weber D. Value of novel agents and intensive therapy for patients with multiple myeloma. Bone Marrow Transplant 49(3):422-5, 2014. e-Pub 2014. PMID: 24317125.
220. Yusuf SW, Solhpour A, Banchs J, Lopez-Mattei JC, Durand JB, Iliescu C, Hassan SA, Qazilbash MH. Cardiac amyloidosis. Expert Rev Cardiovasc Ther 12(2):265-77, 2014. e-Pub 2014. PMID: 24386926.
221. Mehta RS, Di Stasi A, Andersson BS, Nieto Y, Jones R, de Lima M, Hosing C, Popat U, Kebriaei P, Oran B, Alousi A, Rezvani K, Qazilbash M, Bashir Q, Bollard C, Cooper L, Worth L, Tewari P, McNiece I, Willhelm K, Champlin R, Shpall EJ. The Development of a Myeloablative, Reduced-Toxicity, Conditioning Regimen for Cord Blood Transplantation. Clin Lymphoma Myeloma Leuk 14(1):e1-5, 2014. e-Pub 2014. PMID: 24169268.
222. Bashir Q, Khan H, Thall PF, Liu P, Shah N, Kebriaei P, Parmar S, Oran B, Ciurea S, Nieto Y, Jones R, Hosing CM, Popat UR, Dinh YT, Rondon G, Orlowski RZ, Shah JJ, De Lima M, Shpall E, Champlin R, Giralt S, Qazilbash MH. A Randomized Phase II Trial of Fludarabine/Melphalan 100 versus Fludarabine/Melphalan 140 Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma. Biol Blood Marrow Transplant 19(10):1453-8, 2013. e-Pub 2013. PMID: 23872222.
223. Thall PF, Nguyen HQ, Braun TM, Qazilbash MH. Using joint utilities of the times to response and toxicity to adaptively optimize schedule-dose regimes. Biometrics 69(3):1-10, 2013. e-Pub 2013. PMID: 23957592.
224. Yilmaz M, Chemaly RF, Han XY, Thall PF, Fox PS, Tarrand JJ, De Lima MJ, Hosing CM, Popat UR, Shpall E, Champlin RE, Qazilbash MH. Adenoviral infections in adult allogeneic hematopoietic SCT recipients: a single center experience. Bone Marrow Transplant 48(9):1218-23, 2013. e-Pub 2013. PMID: 23503529.
225. Smith VR, Popat U, Ciurea S, Nieto Y, Anderlini P, Rondon G, Alousi A, Qazilbash M, Kebriaei P, Khouri I, de Lima M, Champlin R, Hosing C. Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization. Am J Hematol 88(9):754-7, 2013. e-Pub 2013. PMID: 23749720.
226. Valdez BC, Wang G, Murray D, Nieto Y, Li Y, Shah J, Turturro F, Wang M, Weber DM, Champlin RE, Qazilbash MH, Andersson BS. Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma; relevance of p53 and its clinical implications. Exp Hematol 41(8):719-30, 2013. e-Pub 2013. PMID: 23648290.
227. Pemmaraju N, Tanaka MF, Ravandi F, Lin H, Baladandayuthapani V, Rondon G, Giralt SA, Chen J, Pierce S, Cortes J, Kantarjian H, Champlin RE, De Lima M, Qazilbash MH. Outcomes in Patients With Relapsed or Refractory Acute Promyelocytic Leukemia Treated With or Without Autologous or Allogeneic Hematopoietic Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk 13(4):485-92, 2013. e-Pub 2013. PMID: 23769669.
228. Sasaki K, Lu G, Saliba RM, Bashir Q, Hosing C, Popat U, Shah N, Parmar S, Dinh Y, Ahmed S, Shpall EJ, Kebriaei P, Shah JJ, Orlowski RZ, Champlin R, Qazilbash MH. Impact Of t(11;14)(q13;q32) On The Outcome Of Autologous Hematopoietic Cell Transplantation In Multiple Myeloma. Biol Blood Marrow Transplant 19(8):1227-32, 2013. e-Pub 2013. PMID: 23733001.
229. Poon LM, Hamdi A, Saliba R, Rondon G, Ledesma C, Kendrick M, Qazilbash M, Hosing C, Jones RB, Popat UR, Nieto Y, Alousi A, Ciurea S, Shpall EJ, Champlin RE, Kebriaei P. Outcomes of adults with acute lymphoblastic leukemia (ALL) following relapse post allogeneic hematopoietic stem cell transplantation (HSCT). Biol Blood Marrow Transplant 19(7):1059-64, 2013. e-Pub 2013. PMID: 23644077.
230. Karuturi M, Hosing C, Fanale M, Medeiros LJ, Alousi AM, de Lima MJ, Qazilbash MH, Kebriaei P, Younes A, Khouri I, Andersson BS, Champlin R, Anderlini P, Popat U. High-dose chemotherapy and Autologous Stem Cell Transplantation For Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). Biol Blood Marrow Transplant 19(6):991-4, 2013. e-Pub 2013. PMID: 23507470.
231. Lu G, Muddasani R, Orlowski RZ, Abruzzo LV, Qazilbash MH, You MJ, Wang Y, Zhao M, Chen S, Glitza IC, Medeiros LJ. Plasma cell enrichment enhances detection of high-risk cytogenomic abnormalities by fluorescence in situ hybridization and improves risk stratification of patients with plasma cell neoplasms. Arch Pathol Lab Med 137(5):625-31, 2013. e-Pub 2013. PMID: 23627452.
232. Poon LM, Bassett R, Rondon G, Hamdi A, Qazilbash M, Hosing C, Jones RB, Shpall EJ, Popat UR, Nieto Y, Worth LL, Cooper L, De Lima M, Champlin RE, Kebriaei P. Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia. Bone Marrow Transplant 48(5):666-670, 2013. e-Pub 2013. PMID: 23085830.
233. Aung FM, Lichtiger B, Bassett R, Liu P, Alousi A, Bashier Q, Ciurea SO, de Lima MJ, Hosing C, Kebriaei P, Nieto Y, Oran B, Parmar S, Qazilbash M, Shah N, Khouri I, Champlin RE, Popat U. Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation. Br J Haematol 160(6):798-805, 2013. e-Pub 2013. PMID: 23330820.
234. Nieto Y, Popat U, Anderlini P, Valdez B, Andersson B, Liu P, Hosing C, Shpall EJ, Alousi A, Kebriaei P, Qazilbash M, Parmar S, Bashir Q, Shah N, Khouri I, Rondon G, Champlin R, Jones RB. Autologous Stem-Cell Transplantation for Refractory or Poor-Risk Relapsed Hodgkin's Lymphoma: Effect of the Specific High-Dose Chemotherapy Regimen on Outcome. Biol Blood Marrow Transplant 19(3):410-417, 2013. e-Pub 2013. PMID: 23128322.
235. Bayraktar UD, Bashir Q, Qazilbash M, Champlin RE, Ciurea SO. Fifty Years of Melphalan Use in Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 19(3):344-356, 2013. e-Pub 2013. PMID: 22922522.
236. Foglietta M, Neelapu SS, Kwak LW, Jiang Y, Nattamai D, Lee ST, Fowler DH, Sportes C, Gress RE, Steinberg SM, Vence LM, Radvanyi L, Dwyer KC, Qazilbash MH, Bryant RN, Bishop MR. Neoantigen and tumor antigen-specific immunity transferred from immunized donors is detectable early after allogeneic transplantation in myeloma patients. Bone Marrow Transplant 48(2):269-277, 2013. e-Pub 2013. PMID: 22773122.
237. Oran B, Popat U, Rondon G, Ravandi F, Garcia-Manero G, Abruzzo L, Andersson BS, Bashir Q, Chen J, Kebriaei P, Khouri IF, Koca E, Qazilbash MH, Champlin R, de Lima M. Significance of Persistent Cytogenetic Abnormalities at Myeloablative Allogeneic Stem Cell Transplantation in First Complete Remission. Biol Blood Marrow Transplant 19(2):214-220, 2013. e-Pub 2013. PMID: 22982533.
238. Kebriaei P, Madden T, Wang X, Thall PF, Ledesma C, de Lima M, Shpall EJ, Hosing C, Qazilbash M, Popat U, Alousi A, Nieto Y, Champlin RE, Jones RB, Andersson BS. Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL. Bone Marrow Transplant 48(1):26-31, 2013. e-Pub 2013. PMID: 22732703.
239. de Lima M, McNiece I, Robinson SN, Munsell M, Eapen M, Horowitz M, Alousi A, Saliba R, McMannis JD, Kaur I, Kebriaei P, Parmar S, Popat U, Hosing C, Champlin R, Bollard C, Molldrem JJ, Jones RB, Nieto Y, Andersson BS, Shah N, Oran B, Cooper LJ, Worth L, Qazilbash MH, Korbling M, Rondon G, Ciurea S, Bosque D, Maewal I, Simmons PJ, Shpall EJ. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med 367(24):2305-15, 2012. e-Pub 2012. PMID: 23234514.
240. Kebriaei P, Basset R, Ledesma C, Ciurea S, Parmar S, Shpall EJ, Hosing C, Khouri I, Qazilbash M, Popat U, Alousi A, Nieto Y, Jones RB, de Lima M, Champlin RE, Andersson BS. Clofarabine Combined with Busulfan Provides Excellent Disease Control in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 18(12):1819-1826, 2012. e-Pub 2012. PMID: 22750645.
241. Ciurea SO, Mulanovich V, Saliba RM, Bayraktar UD, Jiang Y, Bassett R, Wang SA, Konopleva M, Fernandez-Vina M, Montes N, Bosque D, Chen J, Rondon G, Alatrash G, Alousi A, Bashir Q, Korbling M, Qazilbash M, Parmar S, Shpall E, Nieto Y, Hosing C, Kebriaei P, Khouri I, Popat U, de Lima M, Champlin RE. Improved Early Outcomes Using a T Cell Replete Graft Compared with T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplant. Biol Blood Marrow Transplant 18(12):1835-1844, 2012. e-Pub 2012. PMID: 22796535.
242. Nieto Y, Thall P, Valdez B, Andersson B, Popat U, Anderlini P, Shpall EJ, Bassett R, Alousi A, Hosing C, Kebriaei P, Qazilbash M, Frazier E, Gulbis A, Chancoco C, Bashir Q, Ciurea S, Khouri I, Parmar S, Shah N, Worth L, Rondon G, Champlin R, Jones RB. High-Dose Infusional Gemcitabine Combined with Busulfan and Melphalan with Autologous Stem-Cell Transplant in Patients with Refractory Lymphoid Malignancies. Biol Blood Marrow Transplant 18(11):1677-1686, 2012. e-Pub 2012. PMID: 22643322.
243. Beitinjaneh AM, Saliba R, Bashir Q, Shah N, Parmar S, Hosing C, Popat U, Anderlini P, Dinh Y, Qureshi S, Rondon G, Champlin RE, Giralt SA, Qazilbash MH. Durable Responses after Donor Lymphocyte Infusion for Patients with Residual Multiple Myeloma following Non-myeloablative Allogeneic Stem Cell Transplantation. Leuk Lymphoma 53(8):1525-1529, 2012. e-Pub 2012. PMID: 22242817.
244. Shah N, Ahmed F, Bashir Q, Qureshi S, Dinh Y, Rondon G, Wen S, Thall P, Khan H, Giralt S, Champlin R, Qazilbash MH. Durable remission with salvage second autotransplants in patients with multiple myeloma. Cancer 118(14):3549-3555, 2012. e-Pub 2012. PMID: 22086552.
245. Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Ledesma C, Andersson BS, Jones R, Popat UR, Hosing CM, Nieto Y, Qazilbash MH, Ueno NT, Giralt SA, de Lima MJ, Champlin RE. Donor leukocyte infusions (DLIs) in recurrent hodgkin lymphoma (HL) following allogeneic stem cell transplantation: ten-year experience at the M.D. anderson cancer center. Leuk Lymphoma 53(6):1239-1241, 2012. e-Pub 2012. PMID: 22132837.
246. McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, Van Besien K, Gentile T, Isola L, Maziarz RT, Gabriel DA, Bashey A, Landau H, Martin T, Qazilbash MH, Levitan D, McClune B, Schlossman R, Hars V, Postiglione J, Jiang C, Bennett E, Barry S, Bressler L, Kelly M, Seiler M, Rosenbaum C, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Anderson KC, Linker C. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 366(19):1770-81, 2012. e-Pub 2012. PMID: 22571201.
247. Sharma M, Khan H, Thall PF, Orlowski RZ, Bassett RL, Shah N, Bashir Q, Parmar S, Wang M, Shah JJ, Hosing CM, Popat UR, Giralt SA, Champlin RE, Qazilbash MH. A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer 118(9):2507-2515, 2012. e-Pub 2012. PMID: 21887685.
248. Bashir Q, Munsell MF, Giralt S, de Padua Silva L, Sharma M, Couriel D, Chiattone A, Popat U, Qazilbash MH, Fernandez-Vina M, Champlin RE, de Lima MJ. Randomized phase II trial comparing two dose levels of thymoglobulin in patients undergoing unrelated donor hematopoietic cell transplantation. Leuk Lymphoma 53(5):915-919, 2012. e-Pub 2012. PMID: 22023525.
249. Ciurea SO, Saliba RM, Hamerschlak N, Karduss Aurueta AJ, Bassett R, Fernandez-Vina M, Petropoulos D, Worth LL, Chan KW, Couriel DR, Rondon G, Sharma M, Qazilbash M, Jones RB, Kebriaei P, McMannis J, Hosing CM, Nieto Y, Champlin RE, Shpall EJ, de Lima M. Fludarabine, Melphalan, Thiotepa and ATG Conditioning for Unrelated Cord Blood Transplantation. Leuk Lymphoma 53(5):901-906, 2012. e-Pub 2012. PMID: 21988645.
250. Bashir Q, Khan H, Orlowski RZ, Amjad AI, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Thomas SK, Shah JJ, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol 87(2):272-276, 2012. e-Pub 2012. PMID: 22231283.
251. Howell JE, Gulbis AM, Champlin RE, Qazilbash MH. Retrospective analysis of weekly intravenous immunoglobulin prophylaxis versus intravenous immunoglobulin by IgG level monitoring in hematopoietic stem cell transplant recipients. Am J Hematol 87(2):172-174, 2012. e-Pub 2012. PMID: 22081487.
252. Popat U, de Lima MJ, Saliba RM, Anderlini P, Andersson BS, Alousi AM, Hosing C, Nieto Y, Parmar S, Khouri IF, Kebriaei P, Qazilbash M, Champlin RE, Giralt SA. Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR. Bone Marrow Transplant 47(2):212-6, 2012. e-Pub 2012. PMID: 21423123.
253. Bashir Q, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Orlowski RZ, Thomas SK, Shah J, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Feasibility of autologous hematopoietic stem cell transplantation in patients aged =70 years with multiple myeloma. Leuk Lymphoma 53(1):118-22, 2012. e-Pub 2012. PMID: 21780997.
254. Krishnan A, Pasquini MC, Logan B, Stadtmauer EA, Vesole DH, Alyea E, Antin JH, Comenzo R, Goodman S, Hari P, Laport G, Qazilbash MH, Rowley S, Sahebi F, Somlo G, Vogl DT, Weisdorf D, Ewell M, Wu J, Geller NL, Horowitz MM, Giralt S, Maloney DG, Trials Network BMTC. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol 12(13):1195-1203, 2011. e-Pub 2011. PMID: 21962393.
255. Sharma M, Ravandi F, Bayraktar UD, Chiattone A, Bashir Q, Giralt S, Chen J, Qazilbash M, Kebriaei P, Konopleva M, Andreeff M, Cortes J, McCue D, Kantarjian H, Champlin RE, de Lima M. Treatment of FLT3-ITD Positive Acute Myeloid Leukemia Relapsing After Allogeneic Stem Cell Transplantation with Sorafenib. Biol Blood Marrow Transplant 17(12):1874-7, 2011. e-Pub 2011. PMID: 21767516.
256. Joseph RW, Alousi A, Konda B, Komanduri K, Neumann J, Trevino C, Stolar K, Qazilbash M, Hosing C, Kebriaei P, Couriel DR, Champlin RE, Saliba R, Popat U. High incidence of vitamin D deficiency in patients undergoing allogeneic stem cell transplantation. Am J Hematol 86(11):954-6, 2011. e-Pub 2011. PMID: 21948087.
257. Alatrash G, de Lima M, Hamerschlak N, Pelosini M, Wang X, Xiao L, Kerbauy F, Chiattone A, Rondon G, Qazilbash MH, Giralt SA, de Padua Silva L, Hosing C, Kebriaei P, Zhang W, Nieto Y, Saliba RM, Champlin RE, Andersson BS. Myeloablative Reduced-Toxicity i.v. Busulfan-Fludarabine and Allogeneic Hematopoietic Stem Cell Transplant for Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome in the Sixth Through Eighth Decades of Life. Biol Blood Marrow Transplant 17(10):1490-6, 2011. e-Pub 2011. PMID: 21338705.
258. Hosing C, Smith V, Rhodes B, Walters K, Thompson R, Qazilbash M, Khouri I, de Lima M, Balzer RJ, McMannis J, Champlin R, Giralt S, Popat U. Assessing the charges associated with hematopoietic stem cell mobilization and remobilization in patients with lymphoma and multiple myeloma undergoing autologous hematopoietic peripheral blood stem cell transplantation. Transfusion 51(6):1300-13, 2011. e-Pub 2011. PMID: 21575005.
259. Kazmi SM, Saliba RM, Donato M, Wang M, Hosing C, Qureshi S, Anderlini P, Popat U, Champlin RE, Giralt SA, Qazilbash MH. Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma. Bone Marrow Transplant 46(4):510-5, 2011. e-Pub 2011. PMID: 20581887.
260. Kebriaei P, Madden T, Kazerooni R, Wang X, Thall PF, Ledesma C, Nieto Y, Shpall EJ, Hosing C, Qazilbash M, Popat U, Khouri I, Champlin RE, Jones RB, Andersson BS. Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with Advanced Lymphoid Malignancies. Biol Blood Marrow Transplant 17(3):412-20, 2011. e-Pub 2011. PMID: 20674757.
261. Bashir Q, Langford LA, Parmar S, Champlin RE, Qazilbash MH. Primary Systemic Amyloid Light Chain Amyloidosis Decompensating After Filgrastim-Induced Mobilization and Stem-Cell Collection. J Clin Oncol 29(4):e79-80, 2011. e-Pub 2011. PMID: 21060030.
262. Anderlini P, Acholonu SA, Okoroji GJ, Bassett RE, Shpall EJ, Qazilbash MH, Popat UR, Worth LL, Giralt SA, Champlin RE. Fludarabine, cyclophosphamide, and antithymocyte globulin for matched related and unrelated allogeneic stem cell transplant in severe aplastic anemia. Leuk Lymphoma 52(1):137-41, 2011. e-Pub 2011. PMID: 20939697.
263. Westin JR, Saliba RM, De Lima M, Alousi A, Hosing C, Qazilbash MH, Khouri IF, Shpall EJ, Anderlini P, Rondon G, Andersson BS, Champlin R, Couriel DR. Steroid-Refractory Acute GVHD: Predictors and Outcomes. Adv Hematol 2011:601953, 2011. e-Pub 2011. PMID: 22110505.
264. Ma Q, Wang C, Jones D, Quintanilla KE, Li D, Wang Y, Wieder ED, Clise-Dwyer K, Alatrash G, Mj Y, Munsell MF, Lu S, Qazilbash MH, Molldrem JJ. Adoptive transfer of PR1 cytotoxic T lymphocytes associated with reduced leukemia burden in a mouse acute myeloid leukemia xenograft model. Cytotherapy 12(8):1056-62, 2010. e-Pub 2010. PMID: 20735170.
265. Efebera YA, Qureshi SR, Cole SM, Saliba R, Pelosini M, Patel RM, Koca E, Mendoza FL, Wang M, Shah J, Alousi A, Hosing C, Popat U, Kebriaei P, Anderlini P, Khouri IF, Champlin R, Giralt S, Qazilbash MH. Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed Multiple Myeloma. Biol Blood Marrow Transplant 16(8):1122-1129, 2010. e-Pub 2010. PMID: 20178853.
266. Bashir Q, De Lima MJ, McMannis JD, Garcia-Manero G, Shpall E, Kantarjian H, Cortes JE, O'Brien SM, Jones D, Qazilbash M, Wei W, Giralt SA, Champlin RE, Hosing C. Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy. Leuk Lymphoma 51(8):1478-84, 2010. e-Pub 2010. PMID: 20658954.
267. Sharma M, Qureshi SR, Champlin RE, Popat U, Giralt S, Qazilbash MH. The outcome of IgD myeloma after autologous hematopoietic stem cell transplantation is similar to other Ig subtypes. Am J Hematol 85(7):502-4, 2010. e-Pub 2010. PMID: 20575022.
268. Wang M, Delasalle K, Feng L, Thomas S, Giralt S, Qazilbash M, Handy B, Lee JJ, Alexanian R. CR represents an early index of potential long survival in multiple myeloma. Bone Marrow Transplant 45(3):498-504, 2010. e-Pub 2010. PMID: 19633690.
269. Ciurea SO, Saliba R, Rondon G, Pesoa S, Cano P, Fernandez-Vina M, Qureshi S, Worth LL, McMannis J, Kebriaei P, Jones RB, Korbling M, Qazilbash M, Shpall EJ, Giralt S, de Lima M, Champlin RE, Gajewski J. Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT. Bone Marrow Transplant 45(3):429-36, 2010. e-Pub 2010. PMID: 19668237.
270. Hosing C, Munsell MF, Reuben JM, Popat U, Lee BN, Gao H, Körbling M, Shpall EJ, Kebriaei P, Alousi A, De Lima M, McMannis J, Qazilbash M, Anderlini P, Giralt S, Champlin RE, Khouri I. A randomized study comparing chemotherapy followed by G-CSF alone or in combination with GM-CSF for mobilization of peripheral blood stem cells in patients with non-Hodgkin's lymphomas. J Blood Med 1:49-55, 2010. e-Pub 2010. PMID: 22282683.
271. Parmar S, Del Lima M, Zou Y, Patah PA, Liu P, Cano P, Rondon G, Pesoa S, de Padua Silva L, Qazilbash MH, Hosing C, Popat U, Kebriaei P, Shpall EJ, Giralt S, Champlin RE, Stastny P, Fernandez-Vina M. Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease. Blood 114(14):2884-7, 2009. e-Pub 2009. PMID: 19654407.
272. Qazilbash MH, Amjad AI, Qureshi S, Qureshi SR, Saliba RM, Khan ZU, Hosing C, Giralt SA, De Lima MJ, Popat UR, Yusuf SW, Champlin RE. Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Low Left Ventricular Ejection Fraction. Biol Blood Marrow Transplant 15(10):1265-70, 2009. e-Pub 2009. PMID: 19747634.
273. de Souza JA, Saliba RM, Patah P, Rondon G, Ribeiro R, de Padua Silva L, Qazilbash MH, Hosing C, Popat U, Efebera Y, Champlin RE, de Lima M. Moderate renal function impairment does not affect outcomes of reduced-intensity conditioning with fludarabine and melphalan for allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 15(9):1094-9, 2009. e-Pub 2009. PMID: 19660722.
274. Parikh GC, Amjad AI, Saliba RM, Kazmi SM, Khan ZU, Lahoti A, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Popat U, Alousi AM, Champlin RE, Giralt SA, Qazilbash MH. Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biol Blood Marrow Transplant 15(7):812-6, 2009. e-Pub 2009. PMID: 19539212.
275. Hosing C, Saliba RM, Ahlawat S, Körbling M, Kebriaei P, Alousi A, De Lima M, Okoroji JG, McMannis J, Qazilbash M, Anderlini P, Giralt S, Champlin RE, Khouri I, Popat U. Poor hematopoietic stem cell mobilizers: A single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. Am J Hematol 84(6):335-7, 2009. e-Pub 2009. PMID: 19384931.
276. Popat U, Saliba R, Thandi R, Hosing C, Qazilbash M, Anderlini P, Shpall E, McMannis J, Körbling M, Alousi A, Andersson B, Nieto Y, Kebriaei P, Khouri I, de Lima M, Weber D, Thomas S, Wang M, Jones R, Champlin R, Giralt S. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant 15(6):718-23, 2009. e-Pub 2009. PMID: 19450756.
277. Qazilbash MH, Saliba RM, Nieto Y, Parikh G, Pelosini M, Khan FB, Jones RB, Hosing C, Mendoza F, Weber DM, Wang M, Popat U, Alousi A, Anderlini P, Champlin RE, Giralt S. Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan: Results of a Phase II Randomized Trial. Biol Blood Marrow Transplant 14(12):1401-7, 2008. e-Pub 2008. PMID: 19041063.
278. Alousi AM, Saliba RM, Okoroji GJ, Macapinlac HA, Hosing C, Korbling M, Samuels BI, Popat U, Kebriaei P, Anderlini P, Qazilbash MH, de Lima M, Giralt SA, Champlin RE, Khouri IF. Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation. Br J Haematol 142(5):786-92, 2008. e-Pub 2008. PMID: 18564354.
279. Hosing C, Saliba RM, Okoroji GJ, Popat U, Couriel D, Ali T, De Padua Silva L, Kebriaei P, Alousi A, De Lima M, Qazilbash M, Anderlini P, Giralt S, Champlin RE, Khouri I. High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin's lymphoma in patients >65 years of age. Ann Oncol 19(6):1166-1171, 2008. e-Pub 2008. PMID: 18272911.
280. Jones JA, Qazilbash MH, Shih YC, Cantor SB, Cooksley CD, Elting LS. In-hospital complications of autologous hematopoietic stem cell transplantation for lymphoid malignancies : clinical and economic outcomes from the nationwide inpatient sample. Cancer 112(5):1096-105, 2008. e-Pub 2008. PMID: 18286506.
281. de Lima M, Champlin RE, Thall PF, Wang X, TGrd M, Cook JD, McCormick G, Qazilbash M, Kebriaei P, Couriel D, Shpall EJ, Khouri I, Anderlini P, Hosing C, Chan KW, Andersson BS, Patah PA, Caldera Z, Jabbour E, Giralt S. Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. Leukemia 22(2):258-64, 2008. e-Pub 2008. PMID: 17989720.
282. Anderlini P, Saliba R, Acholonu S, Giralt SA, Andersson B, Ueno NT, Hosing C, Khouri IF, Couriel D, de Lima M, Qazilbash MH, Pro B, Romaguera J, Fayad L, Hagemeister F, Younes A, Munsell MF, Champlin RE. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin’s lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica 93(2):257-264, 2008. e-Pub 2008. PMID: 18223284.
283. Qazilbash MH, Saliba RM, Ahmed B, Parikh G, Mendoza F, Ashraf N, Hosing C, Flosser T, Weber DM, Wang M, Couriel DR, Popat U, Kebriaei P, Alousi AM, Anderlini P, Naeem RC, Champlin RE, Giralt SA. Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant. Biol Blood Marrow Transplant 13(9):1066-72, 2007. e-Pub 2007. PMID: 17697969.
284. Ozdemir E, Saliba RM, Champlin RE, Couriel DR, Giralt SA, de Lima M, Khouri IF, Hosing C, Kornblau SM, Anderlini P, Shpall EJ, Qazilbash MH, Molldrem JJ, Chemaly RF, Komanduri KV. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant 40(2):125-36, 2007. e-Pub 2007. PMID: 17530009.
285. Ozdemir E, Saliba RM, Champlin RE, Couriel DR, Giralt SA, de Lima M, Khouri IF, Hosing C, Kornblau SM, Anderlini P, Shpall EJ, Qazilbash MH, Molldrem JJ, Chemaly RF, Komanduri KV. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant 40(2):125-36, 2007. e-Pub 2007.
286. Oran B, Giralt S, Couriel D, Hosing C, Shpall EJ, de Meis E, Khouri IF, Qazilbash M, Anderlini P, Kebriaei P, Popat U, Carrasco-Yalan A, Champlin RE, de Lima M. Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation. Leukemia 5, 2007. e-Pub 2007. PMID: 17611563.
287. Christoforidou AV, Saliba RM, Williams P, Qazilbash M, Roden L, Aleman A, Weber D, Mendoza F, Podoloff D, Rrd W, Breitz H, Alexanian R, Champlin R, Giralt S. Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes. Biol Blood Marrow Transplant 13(5):543-9, 2007. e-Pub 2007. PMID: 17448913.
288. Oran B, Giralt S, Saliba R, Hosing C, Popat U, Khouri I, Couriel D, Qazilbash M, Anderlini P, Kebriaei P, Ghosh S, Carrasco-Yalan A, de Meis E, Anagnostopoulos A, Donato M, Champlin RE, de Lima M. Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant 13(4):454-62, 2007. e-Pub 2007. PMID: 17382251.
289. Qazilbash MH, Saliba, R, Hosing, C, Lima D, M, Couriel, D, Mendoza, F, Qureshi, S R, Weber, D M, Wang, M, Flosser, T, Kebriaei, P, Popat, U, Alousi, A M, Champlin, R, Giralt, S. Autologous Stem Cell Transplantation is Safe and Feasible in Elderly Patients with Multiple Myeloma. Bone Marrow Transplant 39(5):279-83, 2007. e-Pub 2007. PMID: 17262062.
290. Kurian S, Qazilbash M, Fay J, Wolff S, Herzig R, Hobbs G, Bunner P, Weisenborn R, Aya-Ay M, Lynch J, Ericson S. Complete response after high-dose chemotherapy and autologous hemopoietic stem cell transplatation in metastatic breast cancer results in survival benefit. Breast Journal 12(6):531-5, 2006. e-Pub 2006.
291. Saliba RM, de Lima M, Giralt S, Andersson B, Khouri IF, Hosing C, Ghosh S, Neumann J, Hsu Y, De Jesus J, Qazilbash MH, Champlin RE, Couriel DR. Hyper-acute GVHD: risk factors, outcomes, and clinical implications. Blood 109(7):2751-8, 2006. e-Pub 2006. PMID: 17138825.
292. Kebriaei P, Saliba RM, Ma C, Ippoliti C, Couriel DR, de Lima M, Giralt S, Qazilbash MH, Gajewski JL, Ha CS, Champlin RE, Khouri IF. Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia. Bone Marrow Transplant 38:203-9, 2006. e-Pub 2006. PMID: 16799614.
293. Qazilbash MH, Saliba RM, Aleman A, Lei X, Weber D, Carrasco A, Champlin RE, Giralt SA. Risk factors for relapse after complete remission with high-dose therapy for multiple myeloma. Leuk Lymphoma 47:1360-4, 2006. e-Pub 2006. PMID: 16923569.
294. Hosing C, Qazilbash MH, Kebriaei P, Giralt S, Davis MS, Popat U, Anderlini P, Shpall EJ, McMannis J, Korbling M, Champlin RE. Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma. Br J Haematol 133:533-7, 2006. e-Pub 2006. PMID: 16681642.
295. Couriel DR, Hosing C, Saliba R, Shpall EJ, Anderlini P, Rhodes B, Smith V, Khouri I, Giralt S, de Lima M, Hsu Y, Ghosh S, Neumann J, Andersson B, Qazilbash M, Hymes S, Kim S, Champlin R, Donato M. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood 107:3074-80, 2006. e-Pub 2006. PMID: 16368882.
296. Qazilbash MH, Saliba R, De Lima M, Hosing C, Couriel D, Aleman A, Roden L, Champlin R, Giralt SA. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer 106:1084-9, 2006. e-Pub 2006. PMID: 16456814.
297. Qazilbash MH, Ueno N, Hosing C, de Lima M, Cortes J, Massaro A, Rivera Z, Deavers M, Adachi JA, Champlin RE. Strongyloidiasis after Unrelated Non-myeloablative Allogeneic Stem Cell Transplantation. Bone Marrow Transplant 38(5):393-4, 2006. e-Pub 2006. PMID: 16845427.
298. Qazilbash MH, Qu Z, Hosing C, Couriel D, Donato M, Giralt S, Champlin R. Rituximab-induced acute liver failure after an allogeneic transplantation for chronic myeloid leukemia. Am J Hematol 80:43-5, 2005. e-Pub 2005. PMID: 16138357.
299. Devetten MP, Qazilbash MH, Beall CL, Bunner P, Weisenborn R, Lynch JP, Ericson SG. Thiotepa and fractionated TBI conditioning prior to allogeneic stem cell transplantation for advanced hematologic malignancies: a phase II single institution trial. Bone Marrow Transplant 34:577-80, 2004. e-Pub 2004. PMID: 15286685.
300. Qazilbash MH, Devetten MP, Abraham J, Lynch JP, Beall CL, Auber M, Weisenborn R, Bunner P, Ericson SG. High-dose therapy and autologous stem cell transplantation in relapsed and refractory Hodgkin's disease: outcome based on a prognostic model. Acta Haematol 110:173-8, 2003. e-Pub 2003. PMID: 14663160.
301. Qazilbash MH, Devetten MP, Abraham J, Lynch JP, Beall CL, Weisenborn R, Bunner P, Ericson SG. Utility of a prognostic scoring system for allogeneic stem cell transplantation in patients with chronic myeloid leukemia. Acta Haematol 109:119-23, 2003. e-Pub 2003. PMID: 12714820.
302. Paul D, Qazilbash MH, Song K, Xu H, Sinha BK, Liu J, Cowan KH. Construction of a recombinant adeno-associated virus (rAAV) vector expressing murine interleukin-12 (IL-12). Cancer Gene Ther 7:308-15, 2000. e-Pub 2000. PMID: 10770641.
303. Hoshino T, Jiang YZ, Dunn D, Paul D, Qazilbash M, Cowan K, Wang J, Barrett J, Liu J. Transfection of interleukin-12 cDNAs into tumor cells induces cytotoxic immune responses against native tumor: implications for tumor vaccination. Cancer Gene Ther 5:150-7, 1998. e-Pub 1998. PMID: 9622098.
304. Qazilbash MH, Xiao X, Seth P, Cowan KH, Walsh CE. Cancer gene therapy using a novel adeno-associated virus vector expressing human wild-type. Gene Ther 4:675-82, 1997. e-Pub 1997. PMID: 9282168.
305. Qazilbash MH, Liu JM, Vlachos A, Fruchtman S, Messner H, Zipursky A, Alter BP, Young NS. A new syndrome of familial aplastic anemia and chronic liver disease. Acta Haematol 97:164-7, 1997. e-Pub 1997. PMID: 9066711.
306. Malik IA, Khan WA, Qazilbash M, Ata E, Butt A, Khan MA. Clinical efficacy of lorazepam in prophylaxis of anticipatory, acute, and delayed nausea and vomiting induced by high doses of cisplatin. A prospective randomized trial. Am J Clin Oncol 18:170-5, 1995. e-Pub 1995. PMID: 7900711.
307. Qazilbash MH, Walsh CE, Russell SM, Noguchi M, Mann MM, Leonard WJ, Liu JM. Retroviral vector for gene therapy of X-linked severe combined immunodeficiency syndrome. J Hematother 4:91-8, 1995. e-Pub 1995. PMID: 7633846.

Invited Articles

1. Qazilbash MH, Giralt S, Champlin R. Non-Myeloablative Transplantation for Chronic Myeloid Leukemia. Hematology-Oncology Clinics of North America, 2004. e-Pub 2004.
2. Qazilbash, M, Liu, J. Recent developments in gene therapy for severe combined immunodeficiency and Fanconi anemia. Molecular Therapeutics 1:151-155, 1998. e-Pub 1998.
3. Qazilbash, M, Young, N, Liu, J. Vectors and target cells for gene therapy of blood diseases. Trends in Cardiovascular Medicine 6:25-30, 1996. e-Pub 1996.

Review Articles

1. Shah D, Shah V, Shah K, Shah PJ, Alsadhan M, Haslam A, Prasad V, Qazilbash MH, Chakraborty R, Mohyuddin GR. Therapeutic anti-cancer vaccines: a systematic review of prospective intervention trials for common hematological malignancies. EClinicalMedicine 86:103378, 2025. e-Pub 2025. PMID: 40735344.
2. Damron EP, Qazilbash MH, Fang PQ, Wu SY, Dabaja BS, Rondon G, Hosing C, Champlin RE, Bashir Q, Shpall EJ, Knafl MK, Lee HC, Manasanch EE, Patel K, Thomas SK, Orlowski RZ, Weber DM, Pinnix CC, Gunther JR. Radiation Therapy Can Be Safely Incorporated into Pretransplantation Treatment Regimens for Patients with Multiple Myeloma. Transplant Cell Ther 29(1):37.e1-37.e7, 2023. e-Pub 2023. PMID: 37753818.
3. Ouchveridze E, Banerjee R, Desai A, Aziz M, Lee-Smith W, Mian H, Berger K, McClune B, Sborov D, Qazilbash M, Kumar S, Mohyuddin GR. Financial toxicity in hematological malignancies: a systematic review. Blood Cancer J 12(4):74, 2022. e-Pub 2022. PMID: 35459862.
4. Andrabi T, French KE, Qazilbash MH. New Cancer Therapies: Implications for the Perioperative Period. Curr Anesthesiol Rep 8(4):362-367, 2018. e-Pub 2018. PMID: 32288653.
5. Wallis WD, Qazilbash MH. Peripheral blood stem cell mobilization in multiple myeloma: Growth factors or chemotherapy?. World J Transplant 7(5):250-259, 2017. e-Pub 2017. PMID: 29104859.
6. Pemmaraju N, Thompson MA, Qazilbash M. Disease-specific hashtags and the creation of Twitter medical communities in hematology and oncology. Semin Hematol 54(4):189-192, 2017. e-Pub 2017. PMID: 29153079.
7. Bashir Q, Qazilbash MH. Allogeneic Hematopoietic Cell Transplantation for Myeloma: When and in Whom Does It Work. Curr Hematol Malig Rep 12(2):126-135, 2017. e-Pub 2017. PMID: 28285435.
8. Giralt S, Garderet L, Durie B, Cook G, Gahrton G, Bruno B, Hari P, Lokhorst H, McCarthy P, Krishnan A, Sonneveld P, Goldschmidt H, Jagannath S, Barlogie B, Mateos M, Gimsing P, Sezer O, Mikhael J, Jin L, Dimopoulos M, Mazumder A, Palumbo A, Abonour R, Anderson K, Attal M, Blade J, Bird J, Cavo M, Comenzo R, de la Rubia J, Einsele H, Garcia Sanz R, Hillengass J, Holstein S, Johnsen H, Joshua D, Koehne G, Kumar S, Kyle R, Leleu X, Lonial S, Ludwig H, Nahi H, Nooka A, Orlowski R, Rajkumar V, Reiman A, Richardson P, Rivas E, San Miguel J, Turreson I, Usmani S, Vesole D, Bensinger W, Qazilbash M, Efebera Y, Mohty M, Gasparreto C, Gajewski J, LeMaistre C, Bredeson C, Moreau P, Pasquini M, Kroeger N, Stadtmauer E. American Society of Blood and Marrow Transplant, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. Biol Blood Marrow Transplant. e-Pub 2015. PMID: 26428082.
9. Champlin R, de Lima M, Kebriaei P, Rondon G, Fisher T, Jabbour E, Cortés JE, Kantarjian H, Anderlini P, Alousi A, Hosing C, Shpall E, Popat U, Qazilbash M, Andersson B, Giralt S. Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era. Clin Lymphoma Myeloma 9 Suppl 3:S261-5, 2009. e-Pub 2009. PMID: 19778850.
10. Qazilbash MH, Giralt SA, Champlin RE. Nonmyeloablative stem cell transplantation for chronic myeloid leukemia. Hematol Oncol Clin North Am 18:703-13, xi, 2004. e-Pub 2004. PMID: 15271401.

Other Articles

1. Uryu, H, Saeki, K, Haeno, H, Kapadia, C, Furudate, D.M.D., Ph.D., K, Nangalia, J, Spencer Chapman, M, Zhang, L, Padilla, J, Zhao, L, Hsu, JI, Zhao, C, Chen, S, Tanaka, T, Li, Z, Ogata, S, Hanache, S, Yang, H, DiNardo, C, Daver, N, Pemmaraju, N, Jain, N, Ravandi-Kashani, F, Zhang, J, Song, X, Thompson, EJ, Tang, H, Little, L, Gumbs, C, Orlowski, R, Qazilbash, MH, Bhalla, K, Colla, S, Kantarjian, HM, Kanagal Shamanna, R, Bueso-Ramos, CE, Nakada, D, Al-Atrash, G, Molldrem, JJ, Futreal, A, Shpall, E, Goodell, MA, Garcia-Manero, G, Takahashi, K Author Correction. Nature Genetics 57(9):2339, 2025. PMID: 40789920.
2. Nieto, Y, Banerjee, PP, Kaur, I, Basar, R, Li, YE, Daher, M, Rafei, H, Kerbauy, LN, Kaplan, M, Marin, D, Griffin, L, Barnett, M, Bassett Jr, R, Uprety, N, Shrestha, R, Silva, FR, Islam, S, Ganesh, C, Borneo, Z, Ramdial, JL, Ramirez, A, Hosing, C, Alousi, AM, Popat, UR, Qazilbash, MH, Ahmed, S, Iyer, SP, Sainz, TP, Vega Vazquez, F, Fowlkes, NW, Alexis, K, Emig, M, Harstrick, A, Overesch, A, Shpall, E, Rezvani, K Correction to. Nature medicine 31(8):2816, 2025. PMID: 40571757.

Editorials

1. Alatrash G, Molldrem JJ, Qazilbash MH. Targeting PR1 in myeloid leukemia. Oncotarget 9(4):4280-4281, 2018. PMID: 29435102.

Abstracts

1. Popat UR, Lontos K, Bassett RL, Alousi AM, Alatrash G, Bashir Q, Hosing CM, Im JS, Kebriaei P, Marin D, Mehta RS, Nieto Y, Betul O, Olson AL, Qazilbash MH, Ramdial JL, Srour SA, Shpall EJ, Champlin RE, Andersson BS. Myeloablative fractionated busulfan-based conditioning regimen in patients with AML and MDS: Results of a randomized clinical trial comparing 2 fractionation schedules. ASCO 2023 41(Supplement 16):7051-7051, 2023. e-Pub 2023.
2. Nieto Y, Valdez BC, Thall F, Ramdial JL, Srour SA, Hosing C, Saini N, Alousi AM, Qazilbash MH, Popat UR, Gulbis A, Shigle TL, Bassett R, Guillermo-Pacheco M, Ledesma C, Strati P, Ahmed S, Steiner R, Westin J, Nair R, Iyer SP, Champlin RE, Shpall EJ, Andersson BS. High Efficacy of the PARP Inhibitor Olaparib Combined with High-Dose Chemotherapy and Autologous Stem-Cell Transplant for Refractory Lymphomas. ASH 2022 140(Supplement 1):1183–1184, 2022. e-Pub 2022.
3. Lee HC, Kaufman GP, Feng L, Murga A, Johnson RJ, Weber DM, Thomas SK, Bashir Q, Qazilbash MH, Iyer SP, Patel K, Becnel MR, Manasanch EE, Orlowski RZ. Initial Results of a Phase 1 Study of Daratumumab, Ixazomib, and Dexamethasone in Newly Diagnosed and Previously Treated AL Amyloidosis. ASH 2022 140(Supplement 1):4428–4430, 2022. e-Pub 2022.
4. Pasvolsky O, Milton DR, Masood A, SS Shehzad SS, Tanner MR, Bashir Q, Srour SA, Saini N, Ramdial JL, Nieto Y, Lee HC, Patel K, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4:14): The MD Anderson Cancer Center Experience. ASH 2022 140(Supplement 1):10589-10591, 2022. e-Pub 2022.
5. Pemmaraju N, Kantarjian H, Khoury JD, Jain N, Qazilbash MH, Loghavi S, Pierce SA, Patel KP, Garcia-Manero G, Jabbour E, Daver N, Borthakur G, Konopleva M. Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Long-Term Outcomes and Novel Observations from a Large BPDCN Cohort. ASH 2022 140(Supplement 1):1293-1294, 2022. e-Pub 2022.
6. Mehta RS, Saliba RM, Alousi AM, Alatrash G, Bashir Q, Kebriaei P, Khouri IF, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial JL, Rondon G, Srour SA, Rezvani K, Champlin RE, Shpall EJ, Cao K. Mother Vs Father Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis. ASH 2022 140(Supplement 1):10530–10531, 2022. e-Pub 2022.
7. Mehta RS, Saliba RM, Alousi AM, Alatrash G, Bashir Q, Hosing C, Kebriaei P, Khouri IF, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial JL, Rondon G, Srour SA, Rezvani K, Champlin RE, Shpall EJ, Cao K. HLA B-Leader Mismatch Is Associated with Poor Outcomes in NIMA/NIPA Mismatched Haploidentical Sibling Donor HCT. ASH 2022 140(Supplement 1):4880–4881, 2022. e-Pub 2022.
8. Mehta RS, MD, Saliba RM, PhD, Alousi AM, MD, Alatrash G, PhD, DO, Bashir Q, MD, Hosing C, MD, Kebriaei P, MD, Khouri IF, MD, Nieto Y, MD, Oran B, MD, MS, Popat UR, MD, Qazilbash MH, MD, Ramdial JL, MD, Rondon G, MD, Srour SA, MD, MS, Rezvani K, MD, Champlin RE, MD, Shpall EJ, MD, Cao K, MS, MD. Son Vs Daughter Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis. ASH 2022 140(Supplement 1):7649-7650, 2022. e-Pub 2022.
9. Uryu H, Saeki K, Nangalia J, Chapman MS, Zhao ML, Hsu JI, Bueso-Ramos CE, Chen S, Yang H, Kantarjian H, DiNardo CD, Daver N, Colla S, Ganan-Gomez I, Zhang J, Song X, Thompson E, Tang H, Orlowski RZ, Champlin RE, Qazilbash MH, Shpall EJ, Garcia-Manero G, Haeno H, Futreal A, Takahashi K. Cancer Chemotherapy Accelerates the Loss of Clonal Diversity in Hematopoietic Stem Cells and Promotes the Convergent Evolution of Therapy-Related Clonal Hematopoiesis. ASH 2022 140(Supplement 1):2232-2233, 2022. e-Pub 2022.
10. Pasvolsky O, Milton DR, Rauf M, Ghanem S, Masood A, Mohamedi AH, Tanner MR, Bashir Q, Srour SA, Saini N, Lin P, Ramdial JL, Nieto Y, Tang G, Lee HC, Kr P, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Rezvani K, Shpall EJ, Champlin RE, Lin P, Qazilbash MH. Impact of Presence and Amount of Clonal Plasma Cells in Autografts Affect Outcomes in High-Risk Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplant. ASH 2022 140(Supplement 1):284–286, 2022. e-Pub 2022.
11. Pasvolsky O, Saliba RM, Ledesma C, Popat UR, Alousi AM, Olson AL, Oran B, Hosing C, Bashir Q, Qazilbash MH, Short N, Ravandi F, Champlin RE, Shpall EJ, Kebriaei P. Prognostic Significance of Measurable Residual Disease for Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Stem Cell Transplant in Second Complete Remission and Beyond. ASH 2022 140(Supplement 1):7695–7696, 2022. e-Pub 2022.
12. Popat UR, MD, Mehta RS, MD, MPH, MS, Bassett R, MS, Alousi AM, MD, Al-Atrash G, Bashir Q, MD, Hosing C, MD, Im JS, MD, PhD, Kebriaei P, MD, Gulbis AM, PharmD, Marin D, MD, Nieto Y, MD, PhD, Olson A, MD, Oran DB, MD, MSc, Ramdial J, MD, Saini NY, MD, Srour SA, MD, Valdez BC, PhD, Rezvani K, MD, PhD, Qazilbash MH, MD, Kadia TM, MD, Konopleva M, MD, PhD, Shpall EJ, MD, Andersson BS, MD, PhD, Champlin RE, MD. Myeloablative Fractionated Busulfan Conditioning Regimen with Venetoclax in Patients with AML/MDS: Prospective Phase II Clinical Trial. Transplantation and Cellular Therapy 28(3):S82-S83, 2022. e-Pub 2022.
13. Popat UR, MD, Mehta RS, MD, MPH, MS, Bassett R, MS, Alousi AM, MD, Al-Atrash G, Bashir Q, MD, Hosing C, MD, Im JS, MD, PhD, Kebriaei P, MD, Kawedia JD, PharmD, PhD, Khouri IF, MD, Marin D, MD, Nieto Y, MD, PhD, Olson A, MD, Oran DB, MD, MSc, Ramdial J, MD, Saini NY, MD, Srour SA, MD, Rezvani K, MD, PhD, Qazilbash MH, MD, Shpall EJ, MD, Andersson BS, MD, PhD, Champlin RE, MD. Optimizing Myeloablative Fractionated Busulfan, Fludarabine and Thiotepa Regimen: Results of Two Parallel Cohorts in a Phase 2 Prospective Clinical Trial. Transplantation and Cellular Therapy 28(3):S83-S84, 2022. e-Pub 2022.
14. Kawedia JD, PharmD, PhD, Liu X, PhD, Ramdial J, MD, Srour SA, MD, Mehta RS, MD, MPH, MS, Popat UR, MD, Nieto Y, MD, PhD, Saini NY, MD, Kebriaei P, MD, Knape C, Gulbis AM, PharmD, Champlin RE, MD, Shpall EJ, MD, Qazilbash MH, MD, Bashir Q, MD. Captisol-Enabled Melphalan (Evomela) Pharmacokinetics between Short and Long Infusion Arms in Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy 28(3):S461-S462, 2022. e-Pub 2022.
15. Popat UR, MD, Mehta RS, MD, MPH, MS, Thall P, PhD, Bassett R, MS, Alousi AM, MD, Al-Atrash G, Bashir Q, MD, Hosing C, MD, Im JS, MD, PhD, Kebriaei P, MD, Marin D, MD, Nieto Y, MD, PhD, Olson A, MD, Oran DB, MD, MSc, Ramdial J, MD, Saini NY, MD, Srour SA, MD, Valdez BC, PhD, Rezvani K, MD, PhD, Qazilbash MH, MD, Daver N, MD, Ravandi F, MD, Shpall EJ, MD, Champlin RE, MD, Andersson BS, MD, PhD. Myeloablative Fractionated Busulfan Conditioning Regimen with Sorafenib in Patients with AML: Results of Phase I Clinical Trial. Transplantation and Cellular Therapy 28(3):S-78-S79, 2022. e-Pub 2022.
16. Srour SA, MD, Saengboon S, Nelson BE, MBBS, Ramdial J, MD, Bashir Q, MD, Vickers MR, Saini NY, MD, Hosing C, MD, Popat UR, MD, Delgado R, Lee HC, MD, Kaufman G, MD, Orlowski RZ, MD, PhD, Champlin RE, MD, Qazilbash MH, MD. Melphalan Dose Intensity for Autologous Stem Cell Transplantation (ASCT) in AL Amyloidosis. Transplantation and Cellular Therapy 28(3):S426, 2022. e-Pub 2022.
17. Gaballa M, MD, Ma J, Tanner MR, PhD, Rauf M, Bashir Q, MD, Srour SA, MD, Saini NY, MD, Ramdial J, MD, Nieto Y, MD, PhD, Murphy R, PA-C, Rezvani K, MD, PhD, Tang G, MD, PhD, Lin P, MD, Lee HC, MD, Patel KK, MD, MSc, Ullah MR, MD, Kaufman G, MD, Manasanch E, MD, Kebriaei P, MD, Thomas S, MD, Weber D, MD, Orlowski RZ, MD, PhD, Shpall EJ, MD, Champlin RE, MD, Qazilbash MH, MD. KRD vs. VRD as Induction before Autologous Hematopoietic Progenitor Cell Transplantation for High-Risk Newly Diagnosed Multiple Myeloma. Transplantation and Cellular Therapy 28(3):S406-S407, 2022. e-Pub 2022.
18. Saengboon S, Cox N, Olson A, MD, Khawaja F, MD, Daher M, MD, Im JS, MD, PhD, Chen J, BS, Hosing C, MD, Qazilbash MH, MD, Shpall EJ, MD, Champlin RE, MD, Srour SA, MD. Impact of Letermovir Prophylaxis on Clinically Significant CMV Infection and Overall Survival after Haploidentical Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy 28(3):S367, 2022. e-Pub 2022.
19. Nelson BE, MBBS, Ramdial J, MD, Bashir Q, MD, Saini NY, MD, Hosing C, MD, Popat UR, MD, Delgado R, Lee HC, MD, Kaufman G, MD, Orlowski RZ, MD, PhD, Champlin RE, MD, Qazilbash MH, MD, Srour SA, MD. Autologous Hematopoietic Stem Cell Transplantation for AL Amyloidosis Refractory to Induction Therapy. Transplantation and Cellular Therapy 28(3):S414-S415, 2022. e-Pub 2022.
20. Popat UR, MD, Mehta RS, MD, MPH, MS, Bassett R, MS, Alousi AM, MD, Al-Atrash G, Bashir Q, MD, Hosing C, MD, Im JS, MD, PhD, Kebriaei P, MD, Kawedia JD, PharmD, PhD, Khouri IF, MD, Marin D, MD, Nieto Y, MD, PhD, Olson A, MD, Oran DB, MD, MSc, Ramdial J, MD, Saini NY, MD, Srour SA, MD, Valdez BC, PhD, Rezvani K, MD, PhD, Qazilbash MH, MD, Kadia TM, MD, Kantarjian H, MD, Shpall EJ, MD, Champlin RE, MD, Andersson BS, MD, PhD. Post-Transplant Cyclophosphamide Versus Tacrolimus and Methotrexate to Prevent Graft-Versus-Host Disease in Recipients of Matched Donor Transplantation: Comparison of Sequential Cohorts in a Prospective Trial. Transplantation and Cellular Therapy 28(3):S293, 2022. e-Pub 2022.
21. Saengboon S, Cox N, Olson A, MD, Qazilbash MH, MD, Shpall EJ, MD, Champlin RE, MD, Srour SA, MD. Impact of Vitamin D Deficiency on Survival for Patients Received Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT). Transplantation and Cellular Therapy 28(3):S161, 2022. e-Pub 2022.
22. Qazilbash MH, MD, Bashir Q, MD, Rauf M, Sui D, MS, Srour SA, MD, Popat UR, MD, Saini NY, MD, Hosing C, MD, Ramdial J, MD, Manasanch E, MD, Lee HC, MD, Kaufman G, MD, Thomas S, MD, Weber D, MD, Becnel M, MD, Tang G, MD, PhD, Orlowski RZ, MD, PhD, Guzman M, Champlin CRN, MD, Shpall EJ, MD, Patel KK, MD, MSc. Daratumumab-Based Maintenance in Patients with Relapsed Multiple Myeloma after Salvage Autologous Hemaptopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy 28(3):S404-S405, 2022. e-Pub 2022.
23. Popat UR, Bassett R, Thall PF, Alousi AM, Alatrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Marin D, Nieto Y, Olson AL, Oran B, Ramdial JL, Saini N, Srour SA, Valdez BC, Rezvani K, Qazilbash MH, Daver N, Ravandi F, Shpall EJ, Champlin RE, Andersson BS, Mehta RS. Myeloablative Fractionated Busulfan Conditioning Regimen with Sorafenib in Patients with AML: Results of Phase I Clinical Trial. ASH 2021 138(Supplement 1):556, 2021. e-Pub 2021.
24. Nelson BE, Ramdial JL, Bashir Q, Saini N, Hosing C, Popat UR, Delgado R, Lee HC, Kaufman GP, Orlowski RZ, Champlin RE, Qazilbash MH, Srour SA. Autologous Hematopoietic Stem Cell Transplantation for AL Amyloidosis Refractory to Induction Therapy. ASH 2021 138(Supplement 1):482, 2021. e-Pub 2021.
25. Popat UR, Mehta RS, Bassett R, Alousi AM, Alatrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Kawedia JD, Khouri IF, Marin D, Nieto Y, Olson AL, Oran B, Ramdial JL, Saini N, Srour SA, Valdez BC, Rezvani K, Qazilbash MH, Kadia TM, Kantarjian H, Shpall EJ, Champlin RE, Andersson BS. Post-Transplant Cyclophosphamide Versus Tacrolimus and Methotrexate to Prevent Graft-Versus-Host Disease in Recipients of Matched Donor Transplantation: Comparison of Sequential Cohorts in a Prospective Trial. ASH 2021 138(Supplement 1):1803, 2021. e-Pub 2021.
26. Popat UR, Mehta RS, Bassett R, Alousi AM, Alatrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Gulbis A, Marin D, Nieto Y, Olson AL, Oran B, Ramdial JL, Saini N, Srour SA, Valdez BC, Rezvani K, Qazilbash MH, Kadia TM, Konopleva M, Shpall EJ, Andersson BS, Champlin RE. Myeloablative Fractionated Busulfan Conditioning Regimen with Venetoclax in Patients with AML/MDS: Prospective Phase II Clinical Trial. ASH 2021 138(Supplement 1):2879, 2021. e-Pub 2021.
27. Pemmaraju N, Wilson NR, Garcia-Manero G, Sasaki K, Khoury JD, Jain N, Borthakur G, Ravandi F, Daver N, Kadia TM, DiNardo CD, Jabbour EJ, Pierce SA, Villarreal J, Qazilbash MH, Konopleva M, Kantarjian H. Outcomes for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Treated with Frontline HCVAD-Based Chemotherapy. ASH 2021 138(Supplement 1):2319, 2021. e-Pub 2021.
28. Al-Juhaishi T, Malek AE, Milton DR, Ramdial JL, Daher M, Olson AL, Srour SA, Alatrash G, Oran B, Mehta RS, Khouri IF, Bashir Q, Shah N, Ciurea SO, Rondon G, Maadani F, Hosing C, Marin D, Partow K, Rezvani K, Nieto Y, Anderlini P, Alousi AM, |pQazilbash MH, Popat UR, Champlin RE, Shpall EJ, Mulanovich V, Ahmed S. Incidence and Outcomes of Toxoplasma Reactivation in Patients with Hematologic Diseases after Allogeneic Hematopoietic Stem Cell Transplantation. ASH 2021 138(Supplement 1):1779, 2021. e-Pub 2021.
29. Bashir Q, Thall PF, Sui D, Ramdial JL, Srour SA, Mehta RS, Popat UR, Nieto Y, Saini N, Kebriaei P, Manasanch EE, Lee HC, Kaufman GP, Thomas SK, Patel KK, Orlowski RZ, Knape CG, Kawedia JD, Champlin RE, Shpall EJ, Liu X, Qazilbash MH. A Prospective Phase I/II Trial to Jointly Optimize the Administration Schedule and Dose of Melphalan for Injection (Evomela) As a Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma. ASH 2021 138(Supplement 1):3941, 2021. e-Pub 2021.
30. Crees ZD, Stockerl-Goldstein KE, Larson S, Á I, Milone G, Martino M, Stiff P, Sborov DW, Pereira DL, Micallef IN, Moreno JG, Mikala G, Mlp C, Holtick U, Hiemenz JW, Qazilbash MH, Hardy NH, Latif T, García-Cadenas I, Vainstein A, Sorani E, Gliko-Kabir I, Goldstein I, Kadosh S, DiPersio JF. Motixafortide (BL-8040) and G-CSF Versus Placebo and G-CSF to Mobilize Hematopoietic Stem Cells for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: The Genesis Trial. ASH 2021 138(Supplement 1):475, 2021. e-Pub 2021.
31. Crees ZD, Stockerl-Goldstein KE, Retting M, Larson SM, Illes A, Milone G, Martino M, Stiff P, Sborov DW, Pereira Denise L, Micallef IN, Jiménez GM, Mikala G, Coronel MLP, Holtick U, Hiemenz JW, Qazilbash MH, Hardy NM, Latif T, García-Cadenas I, Sorani E, Shemesh-Darvish L, Vainstein A, Kadosh S, DiPersio JF. Hematopoietic Cell Transplantation of Higher CD34+ Cell Doses and Specific CD34+ Subsets Mobilized with Motixafortide and/or G-CSF Is Associated with Rapid Engraftment – a Post-Hoc Analysis of the Genesis Trial. ASH 2021 138(Supplement 1):2849, 2021. e-Pub 2021.
32. Kansagra A, Dispenzieri A, Fraser R, Estrada-Merly N, Kumar SK, Qazilbash MQ, Shah N, D'Souza A. Efficacy and Long-Term Outcomes of Autologous Stem Cell Transplant (ASCT) for Patients with POEMS Syndrome (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Protein, Skin Changes): A CIBMTR Analysis. ASH 2021 138(Supplement 1):120, 2021. e-Pub 2021.
33. Popat UR, Mehta RS, Bassett R, Alousi AM, Alatrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Kawedia JD, Khouri IF, Marin D, Nieto Y, Olson AL, Oran B, Ramdial Jeremy L, Saini N, Srour SA, Rezvani K, Qazilbash MH, Shpall EJ, Andersson BS, Champlin RE. Optimizing Myeloablative Fractionated Busulfan, Fludarabine and Thiotepa Regimen: Results of Two Parallel Cohorts in a Phase 2 Prospective Clinical Trial. ASH 2021 138(Supplement 1):1802, 2021. e-Pub 2021.
34. Abedi M, Scordo M, Budde LE, Mulroney C, Fakhri B, Pawardoe A, Dholaria B Kavalerchik E, Aggarwal SK, Qazilbash MH, Finnegan P, Giralt S. Trial of AB-205 (E-CEL® CELLS) in Adults With Systemic Lymphoma Undergoing High-Dose Therapy And Autologous Hematopoietic Cell Transplantation (HDT-AHCT) Results of AB-205-001 by Age Subgroup. EHA 2021, 2021. e-Pub 2021.
35. Saini N, Ma J, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing C, Nieto Y, Kebriaei P, Alousi AM, Mehta RS, Srour SA, MS, Khouri IF, Weber DM, Thomas SK, Lee HC, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. African-Americans Multiple-Myeloma Patients Undergoing Upfront Autologous Stem Cell Transplant Have Similar Survival Outcomes Compared to Whites: A Propensity-Score Matched Analysis. ASH 2020 136(Supplement 1):9–10, 2020. e-Pub 2020.
36. Bashir Q, Rezvani K, Saini N, Shpall EJ, Srour SA, Popat UR, Milton DR, Pemmaraju N, Champlin RE, Qazilbash MH. Phase 2 Study of Tagraxofusp Therapy for BPDCN Patients Post-Autologous or Post-Allogeneic Hematopoietic Cell Transplantation. ASH 2020 136(Supplement 1):5, 2020. e-Pub 2020.
37. Ramdial JL, Ma J, Milton DR, Delgado R, Bashir Q, Srour SA, Saini N, Nieto Y, Hosing C, Popat UR, Murphy R, PA-C, Lee HC, Patel KK, Manasanch EE, Thomas SK, Kaufman GP, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MH. PBSC Mobilization for Auto-HSCT in Myeloma: Growth Factors Vs Growth Factors + Chemotherapy. ASH 2020 136(Supplement 1):6–7, 2020. e-Pub 2020.
38. Saini N, Ma J, Timmons M, PA-C, Alousi AM, Anderlini P, Andersson BS, Hosing C, Ramdial J, Kebriaei P, Popat UR, Qazilbash MH, Shpall EJ, Srour SA, Valdez BC, Dabaja BS, Pinnix CC, Gunther JR, Maadani F, Rondon G, Champlin RE, Nieto Y. High-Dose Chemotherapy (HDC) with Autologous Stem-Cell Transplant (ASCT) with Consolidative Radiation Therapy (RT) for Relapsed or Refractory (R/R) Primary Mediastinal B-Cell Lymphoma (PMBCL): 20-Year Experience at MD Anderson Cancer Center (MDACC). ASH 2020 136(Supplement 1):32–33, 2020. e-Pub 2020.
39. Srour SA, Bashir Q, Milton DR, Nieto Y, Mehta RS, Saini N, Delgado R, Rondon G, Hosing H, Ciurea SO, Daher M, Popat UR, Khouri IF, Kebriaei P, Manasanch EE, Kaufman GP, Patel KK, Shpall EJ, Lee HC, Orlowski RZ, Champlin RE, Qazilbash MH. Survival Trends in Multiple Myeloma after Autologous Hematopoietic Stem Cell Transplantation. ASH 2020 136(Supplement 1):24–25, 2020. e-Pub 2020.
40. Manasanch EE, Han G, Zhang Z, Dang M, Singh M, Khan M, Singh M, Lee HC, Patel KK, Kaufman GP, Amini B, Bashir Q, Srour QA, Nieto Y, Qazilbash MH, Berkova Z, Lin P, Berry D, Thomas SK, Weber DM, Futreal PA, Wang L, Orlowski RZ, Neelapu SS. Extensive Changes of the Immune Microenvironment Are Associated with Progression from Precursor Stages to Multiple Myeloma. ASH 2020 135(Supplement 1):37–38, 2020. e-Pub 2020.
41. Scordo M, Budde LE, Abedi M, Mulroney C, Fakhri B, Pawarode A, Dholaria B, Kavalerchik E, Aggarwal SK, Qazilbash MH, Finnegan P, Giralt S. Results of a Phase 1 Open Label Dose Escalation Trial of AB-205 (Allogeneic Engineered Endothelial Cell Therapy) in Adults with Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT). ASH 2020 136(Supplement 1):14–15, 2020. e-Pub 2020.
42. Thomas SK, Shah JJ, Morin A, Morphey AN, Lee HC, Manasanch EE, Patel KK, Kaufman GP, Iyer SP, Feng L, Amini B, Qazilbash MH, Bashir Q, Saini N, Srour SA, Johnson RJ, Crumpton BN, Stafford MD, Weber DM, Orlowski RZ. Update of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant (AuSCT) in Patients (Pts) with Multiple Myeloma (MM). ASH 2020 136(Supplement 1):46–47, 2020. e-Pub 2020.
43. Afrough A, Alsfeld LC, Srour SA, Bashir Q, Saini N, Hosing C, Popat UR, Kebriaei P, Shpall EJ, Delgado R, Murphy R, PA-C, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with t(11;14) Undergoing Autologous Hematopoietic Stem Cell Transplantation. ASH 2020 136(Supplement 1):18–19, 2020. e-Pub 2020.
44. Nieto Y, Gruschkus SK, Jones RB, Valdez BC, Timmons M, PA-C, Hosing C, Anderlini P, Kebriaei P, Popat UR, Qazilbash MH, Alousi AM, Srour SA, Saini N, Ramdial J, Im JS, Shpall EJ, Rezvani K, Gulbis A, Shigle TL, PharmD, Mahadeo KM, Khazal S, Khouri IF, Dabaja BS, Pinnix CC, Gunther JR, Lee H, Ahmed S, Steiner RE, Iyer SP, Nair R, Parmar S, MSCI, Cuglievan B, Maadani F, Rondon G, Champlin RE, Andersson BS. Factors Associated with the Improvement of Outcomes of High-Risk Relapsed Hodgkin Lymphoma (HL) Patients Receiving High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT): The MD Anderson Cancer Center Experience. ASH 2020 136(Supplement 1):17–18, 2020. e-Pub 2020.
45. Gaballa MR, Al-Juhaishi T, Bashir Q, Srour SA, Saini N, Ramdial J, Nieto Y, Murphy R, PA-C, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MH. Outcomes of Patients with Multiple Myeloma Who Received VRD Induction, Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance. ASH 2020 136(Supplement 1):14–15, 2020. e-Pub 2020.
46. Afrough A, Srour SA, Bashir Q, Saini N, Hosing C, Popat UR, Kebriaei P, Shpall EJ, Delgado R, Murphy R, PA-C, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Thomas AK, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MH. Prognostic Impact of Beta 2 Microglobulin in Patients with Immunoglobulin Light-Chain Amyloidosis Undergoing Autologous Hematopoietic Stem Cell Transplantation. ASH 2020 136(Supplement 1):20–21, 2020. e-Pub 2020.
47. Khouri IF, Gruschkus SK, Ledesma C, Anderlini P, Bashir Q, Daher M, Iyer SP, Marin D, Mehta R, Olson AL, Popat UR, Samaniego F, Qazilbash MH, Im JS, Rondon G, Champlin RE, Gulbis A, Young KH. Autologous Vs. Allogeneic Stem Cell Transplantation in Double-Expressor Lymphoma. ASH 2020 136(Supplement 1):24–25, 2020. e-Pub 2020.
48. Srour SA, Nieto Y, Iyer SP, Miranda RN, Maadani F, Rondon G, Saini N, Strati P, Daher M, Nair R, Dabaja BS, MD, Popat UR, MD, Qazilbash MH, MD, Shpall EJ, Flowers C, Champlin RE, Hosing C, Khouri IF. Autologous Stem Cell Transplantation for Angioimmunoblastic T-Cell Lymphoma. ASH 2020 136(Supplement 1):40–41, 2020. e-Pub 2020.
49. Mehta RS, Saliba RM, Jan A, Shigle TL, Wang E, Rondon G, Nieto Y, Ciurea S, Oran B, Im JS, Olson AL, Marin D, Qazilbash MH, Khouri IF, Anderlini P, Rezvani K, Popat UR, Kebriaei P, Shpall EJ, Champlin RE, Alousi AM. Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft Versus Host Disease. ASH 2020 136(Supplement 1):39–40, 2020. e-Pub 2020.
50. Bashir Q, Thall QF, Sui D, Knape C, Kawedia J, BPharm, Qazilbash MH. Trial in Progress: A Prospective Phase I/II Trial to Jointly Optimize the Administration Schedule(s) and Dose(s) of Melphalan for Injection (Evomela) As a Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma. ASH 2020 136(Supplement 1):37–38, 2020. e-Pub 2020.
51. Srour SA, Bashir Q, Milton DR, Nieto Y, Mehta RS, Saini N, Delgado R, Rondon G, Ciurea SO, Popat UR, Khouri IF, Kebriaei P, Manasanch EE, Hosing C, Patel KK, Lee HC, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH, MD. Long-Term Survival for Myeloma after Autologous Stem Cell Transplantation. ASH 2020 136(Supplement 1):23–24, 2020. e-Pub 2020.
52. Sidana S, Kumar SK, Fraser R, Estrada-Merly N, Norkin M, Giralt S, Qazilbash, Shah N, D'Souza A. Maintenance Use Is More Important Than the Choice of Bortezomib-Based Triplet Induction in Newly Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous Stem Cell Transplantation. ASH 2020 136(Supplement 1):36–37, 2020. e-Pub 2020.
53. Mehta RS, Bassett R, Chen J, Valdez BC, Kawedia J, BPharm, Alousi AM, Alatrash G, Bashir Q, Ciurea S, Hosing C, Im JS, Kebriaei P, Olson AL, Oran B, Qazilbash MH, Srour SA, Shpall EJ, Andersson BS, Champlin RE, Popat UR. Myeloablative Fractionated Busulfan with Fludarabine in Older Patients: Long Term Outcomes of Prospective Phase II Clinical Trial. ASH 2020 136(Supplement 1):10–11, 2020. e-Pub 2020.
54. Patel P, Girnius SK, Dhakal B, MBBS, Gowda L, Fraser R, Davila O, Shah ND, Qazilbash MH, Kumar SK, D'Souza A, Hari P. Primary Plasma Cell Leukemia Outcomes Remain Dismal Despite Novel Agents and Hematopoietic Cell Transplantation. ASH 2019 134(Supplement 1):266, 2019. e-Pub 2019.
55. Popat U, Mehta RS, Bassett R, Olson AL, Chen J, Ganesh C, Alousi AM, Anderlini P, Alatrash G, Bashir Q, Ciurea SO, Hosing C, Im JS, Kebriaei P, Khouri IF, Marin D, Nieto Y, Oran B, Saini N, Srour S, Rezvani K, Qazilbash MH, Molldrem JJ, Shpall EJ, Andersson BS, Champlin RE. Myeloablative Fractionated Busulfan Conditioning Regimen in Older Patients: Results of a Phase II Study. ASH 2019 134(Supplement 1):256, 2019. e-Pub 2019.
56. Khouri IF, Milton DR, Ledesma C, Nastoupil LJ, Jabbour E, Anderlini P, Bashir Q, Ciurea SO, Daher M, Fayad LE, Im JS, Iyer SP, Marin D, Mehta RS, Molldrem JJ, Olson AL, Oran B, Popat U, Qazilbash MH, Srour S, Samaniego F, Rondon G, Medeiros LJ, Gulbis A, Champlin RE. Nonmyeloablative Allogeneic Transplantation (NMAT) Confers an Overall Survival Benefit with Similar Non-Relapse Mortality When Compared to Autologous Stem Transplantation (ASCT) for Patients (pts) with Relapsed Follicular Lymphoma (FL). ASH 2019 134(Supplement 1):322, 2019. e-Pub 2019.
57. Munshi PN, Hari P, Vesole DH, Jurczyszyn A, Zaucha J, Davila O, Kumar SK, Shah ND, Qazilbash MH, D'Souza A. Breaking the Glass Ceiling of Age in Transplant in Multiple Myeloma. ASH 2019 134(Supplement 1):782, 2019. e-Pub 2019.
58. Dhakal B, MBBS, Fraser R, Gahvari Z, MD, Hall AC, Callander, NS, Chhabra S, Davila O, Kumar SK, Shah ND, Qazilbash MH, D'Souza A, Hari P. Novel Prognostic Scoring System for Autologous Hematopoietic Cell Transplantation (AHCT) in Multiple Myeloma (MM). ASH 2019 134(Supplement 1):783, 2019. e-Pub 2019.
59. Champlin RE, Popat U, Oran B, Ciurea SO, Kebriaei P, Alousi AM, Alatrash G, Bashir Q, Khouri IF, Hosing C, Anderlini P, Jones RB, Marin D, Mehta R, Nieto Y, Olson AL, Qazilbash MH, Rezvani K, Shpall EJ, Chen J, Rondon G, McMullin B, Jahdhami VP, Kawedia J, Valdez B, Ma J, Thall PF, Andersson BS. A Randomized Study of Fludarabine-Clofarabine Vs Fludarabine Alone Combined with Busulfan and Allogeneic Hematopoietic Transplantation for AML and MDS. ASH 2019 134(Supplement 1):257, 2019. e-Pub 2019.
60. Qazilbash MH, Bashir Q, Milton D, Patel R, Popat U, Hosing, Kebriaei P, Ciurea S, Konopleva M, Champlin RE, Pammaraju N. Outcomes of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation. EHA 2019, 2019. e-Pub 2019.
61. Kongtim P, Hasan O, Perez JMR, Varma A, Chen J, Rondon G, Srour S, Bashir Q, Qazilbash MH, Mehta R, Shpall EJ, Alousi AM, Khouri IF, Kebriaei P, Popat UR, Champlin RE, Ciurea SO. Development and validation of a novel disease risk model for patients with AML receiving allogeneic hematopoietic cell transplantation. ASCO 2019 37(Supplement 15):7016-7016, 2019. e-Pub 2019.
62. Rafei H, Imahashi N, Basar R, Banerjee PP, Daher M, Ganesh C, Hosing C, Kaur I, Kebriaei P, Khouri IF, Mehta R, Nieto Y, Olson AL, Qazilbash MH, Spencer BP, Srour S, Shpall EJ, Champlin RE, Marin D, Rezvani K. Off-the-shelf virus specific T-cells for therapy of adenovirus disease in immunosuppressed patients. ASCO 2019 37(Supplement 15):7008-7008, 2019. e-Pub 2019.
63. Kunacheewa C, Patel KK, Lee HC, Thomas SK, Amini B, Srour S, Bashir Q, Qazilbash MH, Weber DM, Neelapu SS, Orlowski RZ, Feng L, Lin P, Manasanch EE. Correlation of minimal residual disease negativity (MRD-) with prognosis in high-risk myeloma (HRM). ASCO 2019 37(Supplement 15):8024-8024, 2019. e-Pub 2019.
64. Popat UR, Mehta RS, Bassett R, Olson AL, Alousi AM, Anderlini P, Alatrash G, Bashir Q, Ciurea SO, Hosing C, Kebriaei P, Khouri IF, Marin D, Nieto Y, Oran B, Rezvani K, Qazilbash MH, Shpall EJ, Champlin RE, Andersson B. Post-transplant cyclophosphamide in matched and haploidentical transplant recipients receiving myeloablative timed sequential busulfan conditioning regimen: Results of a phase II study. ASCO 2019 37(Supplement 15):7007-7007, 2019. e-Pub 2019.
65. Abudayyeh A, Abdelrahim M, Lin HY, Saliba R, Martinez C, Delgado R, Page VD, Sanders PW, Qazilbash MH. Impact of autologous stem cell transplant in myeloma patients on renal function and overall survival. ASCO 2019 37(Supplement 15), 2019. e-Pub 2019.
66. Rafei H, Fernández-Viña M, Carmazzi Y, Moore B, Willis D, Basar R, Banerjee PB, Daher M, Hosing C, Kebriaei P, Khouri IF, Mehta R, Nieto Y, Qazilbash MH, Shpall RJ, Champlin RE, Marin D, Rezvani K, Cao K. Role of killer cell immunoglobulin-like receptor (KIR)-ligand interactions to prevent relapse in patients (pts) receiving matched unrelated stem cell transplant (SCT) for acute myeloid leukemia (AML). ASCO 2019 37(Supplement 15):7049-7049, 2019. e-Pub 2019.
67. Saini NY, Patel R, Varma A, Bashir Q, Delgado R, Popat U, Hosing C, Nieto Y, Kebriaei P, Alousi AM, Ahmed A, Mukherjee A, Mehta RS, Khouri IF, Ciurea SO, Shpall EJ, Hasan O, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Melphalan-Based Autologous Transplantation in the Octogenarian Multiple Myeloma Patient Population. ASH 2018 Abstracts 132(Supplement 1):4608, 2018. e-Pub 2018.
68. Saini NY, Varma A, Ma J, Milton DR, Patel R, Hasan O, Bashir Q, Nieto Y, Mukherjee A, Delgado R, Rondon G, Popat U, Hosing C, Kebriaei P, Alousi AM, Ahmed S, Mehta RS, Ciurea SO, Khouri IF, Shpall EJ, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Impact of t(11;14) on the Outcome of Autologous Transplantation in Multiple Myeloma: A Matched-Pair Analysis. ASH 2018 Abstracts 132(Supplement 1):4607, 2018. e-Pub 2018.
69. Cordas Dos Santos DM, Saliba RM, Patel R, Bashir Q, Hosing C, Kebriaei P, Khouri IF, Nieto Y, Popat U, Lee HC, Manasanch EE, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MH, MD. Older Age As a Prognostic Factor for Overall Survival for Multiple Myeloma Patients Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation. ASH 2018 Abstracts 132(Supplement 1):2144, 2018. e-Pub 2018.
70. Saini NY, Patel R, Varma A, Bashir Q, Hasan O, Delgado R, Rondon G, Mukherjee A, Popat U, Hosing C, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK. Long-Term Durable Responses after Autologous Stem Cell Transplantation in POEMS Syndrome. ASH 2018 Abstracts 132(Supplement 1):4606, 2018. e-Pub 2018.
71. Popat U, Mehta RS, Jr BR, Olson AL, Chen J, Ahmed S, Alousi AM, Anderlini P, Alatrash G, Bashir Q, Ciurea SO, Hosing C, Im JS, Kebriaei P, Khouri IF, Marin D, Nieto Y, Oran B, Rezvani K, Qazilbash MH, Shpall EJ, Champlin RE, Andersson BS. Timed Sequential Busulfan and Post-Transplantation Cyclophosphamide in Matched and Haploidentical Transplantation: Results of a Phase II Study. ASH 2018 Abstracts 132(Supplement 1):3373, 2018. e-Pub 2018.
72. Varma A, Saini NY, Sui D, Milton DR, Hasan O, Mukherjee A, Bashir Q, Rondon G, Srour SA, Popat U, Hosing C, Nieto Y, Kebriaei P, Alousi AM, Mehta RS, Khouri IF, Weber DM, Thomas AK, Manasanch EE, Lee HC, Patel KK, Ciurea SO, Shpall EJ, Orlowski FZ, Champlin RE, Qazilbash MH. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after High-Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation. ASH 2018 Abstracts 132(Supplement 1):4609, 2018. e-Pub 2018.
73. Lin P, Veltri LW, Rezvani R, Oran B, Ahmed S, Alatrash G, Mehta RS, Rondon G, Kebriaei P, Popat U, Nieto Y, Hosing C, Jones RB, Qazilbash MH, Khouri IF, Shpall EJ, Champlin RE, Marin D. Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid Leukemia. ASH 2018 Abstracts 132(Supplement 1):4667, 2018. e-Pub 2018.
74. Saini NY, Saliba RM, Rondon G, Maadani F, Popat U, Oran B, Hosing C, Bashir Q, Olson AL, Nieto Y, Alousi AM, Kebriaei P, Srour SA, Mehta RS, Anderlini P, Shpall EJ, Qazilbash, Khouri IF, Fayad LE, Lee HJ, Fowler NH, Parmar S, Westin JR, Hagemeister FB, Champlin RE, Ciurea SO. Allogeneic Transplantation for Lymphoid Malignancies with Fludarabine and Melphalan Conditioning and Different Donor Types. ASH 2018 Abstracts 132(Supplement 1):3356, 2018. e-Pub 2018.
75. Khouri IF, Milton DR, Ledesma C, Jabbour EJ, Alatrash G, Anderlini P, Alousi AM, Bashir Q, Ciurea SO, Hymes S, Marin D, Molldrem JJ, Olson AL, Oran B, Popat U, Qazilbash MH, Rondon G, Champlin RE, Gulbis A. Influence of the Intensity of the Conditioning Regimens on the Risks of Gvhd in Patients Receiving Rituximab Prophylaxis during Allogeneic Stem Cell Transplantation (alloSCT). ASH 2018 Abstracts 132(Supplement 1):4584, 2018. e-Pub 2018.
76. Khouri IF, Milton DR, Ledesma C, Erwin WD, Jabbour EJ, Alatrash G, Anderlini P, Bashir Q, Ciurea SO, Im JS, Marin D, Mehta RS, Molldrem JJ, Olson AL, Oran B, Popat U, Qazilbash MH, Rondon G, Champlin RE, Medeiros LJ, Gulbis A. Durability Results of Non-Myeloablative (NMA) Allogeneic Stem Cell Transplantation (alloSCT) for Relapsed Follicular Lymphoma: 17- Year Experience. ASH 2018 Abstracts 132(Supplement 1):4651, 2018. e-Pub 2018.
77. Patel R, Saini NY, Varma A, Hasan O, Bashir Q, Delgado R, Popat U, Hosing C, Mukherjee A, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, ManasanchEE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK. Outcome of Autologous Stem Cell Transplantation in Waldenström's Macroglobulinemia. ASH 2018 Abstracts 132(Supplement 1):2149, 2018. e-Pub 2018.
78. MH||B Q, Milton D, Bashir Q, Shah N, Nieto Y, Popat UR, Mehta RS, Kebriaei P, Delgado R, Rondon G, Weber D, Thomas S, Lee HC, Manasanch E, Patel K, Orlowski RZ, Champlin RE. Continuing Improvement in the Outcome of Patients with Multiple Myeloma Undergoing Auto-HCT Over Three Decades. ASBMT 2018 24(3):S50-S51, 2018. e-Pub 2018.
79. Bashir Q, Milton D, Popat UR, Oran B, Nieto Y, Kebriaei P, Ciurea SO, Ahmed S, Mehta RS, Olson A, Parmar S, Alatrash G, Hosing CM, Shah N, Patel K, Weber D, Thomas S, Manasanch E, Lee HC, Orlowski RZ, Champlin RE, Qazilbash MH. Impact of Maintenance Therapy in High-Risk Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. ASBMT 2018 24(3):S524, 2018. e-Pub 2018.
80. Gowda L, Shah MV, Badar I, Bashir Q, Shah N, Patel K, Kanagal-Shamanna R, Mehta RS, Weber D, Lee HC, Manasanch E, Shah AR, Thomas S, Parmar S, Nieto Y, Orlowski RZ, Champlin RE, Qazilbash MH. Primary Plasma Cell Leukemia: Stem Cell Transplant in an Era of Novel Induction Drugs. ASBMT 2018 24(3):S260-S261, 2018. e-Pub 2018.
81. Olson A, Marini F, Westin S, Coleman R, Thall P, Jhadhami VA, Qazilbash MH, Rezvani K, Timmons M, Heese L, Wang R, Champlin RE, Shpall EJ, Andreeff M. A Phase I Trial of Mesenchymal Stem Cells Transfected with a Plasmid Secreting Interferon Beta in Advanced Ovarian Cancer. ASBMT 2018 24(3):S473, 2018. e-Pub 2018.
82. Qazilbash MH, MD, Bashir Q, MD, MBBS, Thall PF, Milton DR, Shah N, MD, Patel KK, MSc MD, Andersson BS, MD, PhD, Nieto Y, MD, PhD, Kebriaei P, MD, Valdez BC, PhD, Kawedia J, BPharm, Parmar S, MBBS, Delgado R, Ahmed S, MD, Hosing C, MD, Popat U, MD, Shpall EJ, MD, Weber DM, MD, Thomas SK, MD, Manasanch EE, MD, Lee HC, MD, Orlowski RZ, MD, PhD, Champlin RE, MD. A Randomized Phase III Trial of Busulfan + Melphalan Vs Melphalan Alone for Multiple Myeloma. ASH 2017, 2017. e-Pub 2017.
83. Gowda O, MD, Saliba RM, PhD, Shah MV, MD, PhD, Rondon G, MD, Badar I, MBBS, Olson AL, MD, Ciurea SO, MD, Kebriaei P, MD, Srour SA, Parmar S, MBBS, Nieto Y, MD, PhD, Ahmed S, MD, Mehta RS, MD, MPH, MS, Alatrash G, DO, PhD, Marin DC, MD, Andersson BS, MD, PhD, Oran B, MD, MS, Bashir Q, MD, MBBS, Qazilbash MH, MD, Hosing C, MD, Khouri IF, Alousi AM, MD, Anderlini P, MD, Shpall EJ, MD, Rezvani K, MD, PhD, Champlin RE, MD, Popat U, MD. Graft Failure Post Allogeneic Stem Cell Transplant: Conditioning Regimen Improves Engraftment and Surviva. ASH 2017, 2017. e-Pub 2017.
84. Claussen AM, MS, Chuang T, Chaudhry M, MD, Lee HC, MD, Patel KK, MSc MD, Bashir Q, MD, MBBS, Parmar S, MBBS, Ahmed S, Mehta RS, MD, MPH, MS, Thomas SK, MD, Richards TA, Nieto Y, MD, PhD, Shpall EJ, MD, Qazilbash MH, MD, Amini B, MD, Davis RE, BSPharm, MS, Neelapu SS, MD, Weber DM, MD, Orlowski RZ, MD, PhD, Feng L, MS, Manasanch EE, MD. Gene Expression Profiling Is a Strong Predictor of Clinical Outcomes in Newly Diagnosed Multiple Myeloma. ASH 2017, 2017. e-Pub 2017.
85. Nieto Y, MD, PhD, Thall PF, Valdez BC, PhD, Ma J, MS, Timmons M, Trapp M, Ahmed S, MD, Shpall EJ, MD, Jones RB, PhD MD, Hosing C, MD, Anderlini P, Popat U, MD, Qazilbash MH, MD, Alousi A, MD, Gulbis AM, PharmD, Ledesma C, Champlin RE, MD, Andersson BS, PhD MD. Gemcitabine/Clofarabine/Busulfan: A New Myeloablative Reduced-Toxicity Conditioning Regimen with High Activity for Allogeneic Stem-Cell Transplant (alloSCT) in Aggressive Lymphomas. ASH 2017, 2017. e-Pub 2017.
86. Gowda L, MD, Alijadayeh M, MD, Marin DC, MD, Ledesma C, Rondon G, MD, Popat U, MD, Alousi AM, MD, Oran B, MD, MS, Shah MV, MD, PhD, Ahmed S, MD, Kanagal-Shamanna R, MD, Ciurea SO, MD, Shpall EJ, MD, Luthra R, Hosing C, MD, Qazilbash MH, MD, Rezvani K, MD, PhD, Jabbour EJ, MD, Patel KP, MBBS, PhD, Ravandi F, MBBS, Kantarjian HM, MD, Champlin RE, MD, Kebriaei P, MD. Early Maintenance with Tyrosine Kinase Inhibitors Post Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Improves Survival in Ph+ Acute Lymphoblastic Leukemia (ALL) Patients. ASH 2017, 2017. e-Pub 2017.
87. Kebriaei P, MD, Huls H, Olivares S, Orozco AF, Su S, Maiti SN, Groot ED, Smith A, Yang Y, PhD, Rondon G, MD, Qazilbash MH, MD, Ciurea SO, MD, Alousi AM, MD, Nieto Y, MD, PhD, Marin DC, MD, Popat U, MD, Hosing C, MD, Kantarjian HM, MD, Rezvani K, MD, PhD, Shpall EJ, MD, Champlin RE, MD, N Cooper LJ, MD, PhD, Singh H, MSc, PhD. Long Term Follow up after Adoptive Transfer of CD19-Specific CAR+ T Cells Genetically Modified Via Non-Viral Sleeping Beauty System Following Hematopoietic Stem Cell Transplantation (HSCT). ASH 2017, 2017. e-Pub 2017.
88. Qazilbash MH, Stadtmauer EA, Baladandayuthapani V, Lin H, Tross B, Honhar M, Cha S, Kim K, Popescu M, Shah N, Bashir Q, Patel KK, Lee VY, Shpall EJ, Weber DM, Thomas SK, Orlowski RZ, Kerr N, Garfall A, Cohen AD, Vogl DT, Dengel K, June CH, Champlin RE, Kwak LW. Randomized Phase II Trial of Combination Idiotype Vaccine and Adoptive Cell Transfer of Costimulated Autologous T Cells in Patients with Multiple Myeloma Post-Autotransplantation. ASH 2017 130(Supplement 1):3193, 2017. e-Pub 2017.
89. Pemmaraju N, Kantarjian HM, Khoury JF, O'Brien SM, Cortes JE, Garcia-Manero G, Jabbour EJ, Jain N, Alvarado Y, Duvic M, Aung P, Qazilbash MH, Yin CC, Konoplev S, Patel KP, Pierce S, Brandt M, Konopleva M. Long-Term Outcomes in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). ASH 2017 130(Supplement 1):3855, 2017. e-Pub 2017.
90. Patel KK, Shah JJ, Feng, L, Lee HC, Manasanch EE, Thomas SK, Weber DM, Munoz SC, Morphey A, Bashir Q, Qazilbash MH, Orlowski RZ. Update on a Phase II Study of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma. ASH 2017 130(Supplement 1):437, 2017. e-Pub 2017.
91. Malek E, Creger E, Kolk M, Covut F, Champlin RE, Cooper BW, Caimi P, Lazarus HM, Gupta V, Vatsayan A, Bashir Q, Lima MD, Qazilbash MH. Reducing Gastrointestinal Toxicity Associated with Autologous Transplantation for Multiple Myeloma without Compromising Its Anti-Myeloma Effect. ASH 2017 130(Supplement 1):680, 2017. e-Pub 2017.
92. Williams LA, Qazilbash MH, Shi Q, Bashir Q, Lin HK, Cleeland CS, Champlin RE. Symptom Burden of Busulfan and Melphalan Versus Melphalan Alone for Multiple Myeloma. ASH 2017 130(Supplement 1):681, 2017. e-Pub 2017.
93. Srour SA, MD, Saliba RM, PhD, Delgado R, Qazilbash MH, MD, Bashir Q, MD, Shah N, MD, Popat UR, MD, Ahmed S, MD, Patel K, MD, Jones R, MD, PhD, Rondon G, MD, Champlin RE, MD, Nieto Y, MD, PhD. Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. ASH 2016, 2016. e-Pub 2016.
94. Shah N, MD, Thall PF, PhD, Milton DR, Bashir Q, MD, Parmar S, MD, Lin P, MD, Kebriaei P, MD, Nieto Y, MD, PhD, Popat UR, MD, Hosing C, MD, Cornelison A, Delgado R, Shpall EJ, MD, Orlowski RZ, MD, PhD, Champlin RE, MD, Qazilbash M, MD. Phase I/II Trial of Lenalidomide and High-Dose Melphalan with Autologous Stem Cell Transplantation for Relapsed Myeloma: Updated Results. ASH 2016, 2016. e-Pub 2016.
95. Hill L, MD, Saliba RM, PhD, Chen J, Rondon G, MD, Qazilbash MH, MD, Popat UR, MD, Shah N, MD, Neumann JL, APN, PhD, Hymes SR, MD, Hosing C, MD, Kebriaei P, MD, Nieto Y, MD, PhD, Oran B, MD, Olson A, MD, Ciurea SO, MD, Rezvani K, MD, PhD, Marin D, MD, Champlin RE, MD, Shpall EJ, MD, Alousi AM, MD. Predictors for Steroid Tapering in Patients with Acute Graft-Versus-Host Disease and Their Impact on Graft-Versus-Host Disease Response and Non-Relapse Mortality: Older Age and Co-Morbidities Are Associated with Quicker Tapering and Worse Outcomes. ASH 2016, 2016. e-Pub 2016.
96. Kebriaei P, MD, Wei W, MS, Thall PF, PhD, Ledesma C, BS, Valdez BC, PhD, Popat UR, MD, Olson AL, MD, Alousi AM, MD, Oran B, MD, Ahmed S, MD, Ciurea SO, MD, Patel K, MD, Shpall EJ, MD, Hosing C, MD, Qazilbash MH, MD, Shah N, MD, Marin D, MD, Rezvani K, MD, PhD, Nieto Y, MD, PhD, Champlin RE, MD, Andersson BS, MD, PhD. Busulfan (Bu) in Combination with Double Nucleoside Analogues Fludarabine (Flu) and Clofarabine (Clo) Plus Vorinostat As a Novel Reduced Toxicity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients (pts) with Acute Leukemia. ASH 2016, 2016. e-Pub 2016.
97. Stadtmauer EA, MD, Pasquini MC, MD, Blackwell B, PhD, Knust K, MS, Bashey A, MD, PhD, Devine SM, MD, Efebera YA, MD, MPH, Ganguly S, MD, Gasparetto C, MD, Geller N, PhD, Giralt SA, MD, Hari P, MD, MRCP, MS, Horowitz MM, MD, MS, Koreth J, MD, Landau H, McCarthy PL, MD, McClune B, DO, Nelson C, BS, BA, Qazilbash MH, MD, Shah N, MD, Vesole DH, MD, PhD, Vij R, MD, Vogl DT, MD, Somlo G, MD, FACP, Krishnan A, MD. LBA-1 Comparison of Autologous Hematopoietic Cell Transplant (autoHCT), Bortezomib, Lenalidomide (Len) and Dexamethasone (RVD) Consolidation with Len Maintenance (ACM), Tandem Autohct with Len Maintenance (TAM) and Autohct with Len Maintenance (AM) for up-Front Treatment of Patients with Multiple Myeloma (MM): Primary Results from the Randomized Phase III Trial of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0702 – StaMINA Trial). ASH 2016, 2016. e-Pub 2016.
98. Chen CE, MD, Mao AY, Murray JG, Oran B, MD, Qazilbash MH, MD, Shah N, MD, Ahmed S, MD, Bashir Q, MD, Hosing C, MD, Shpall EJ, MD, Steele JR, MD, Champlin RE, MD, Parmar S, MD. Feasibility of a Smartphone-Based Health Coaching Intervention for Patient Self-Management of Nutrition in the Post-Chemotherapy Setting. ASH 2016, 2016. e-Pub 2016.
99. Srour SA, MD, Khouri IF, MD, Lozano-Cerrada S, MD, Nieto Y, MD, PhD, Alousi AM, MD, Popat UR, MD, Qazilbash MH, MD, Anderlini P, MD, Kebriaei P, MD, Shpall EJ, MD, Champlin RE, MD, Hosing C, MD. Rituximab Combined with BEAM and Autologous Stem Cell Transplantation for Older Patients with Relapsed Aggressive B-Cell Lymphomas. ASH 2016, 2016. e-Pub 2016.
100. Shah N, MD, Giralt SA, MD, Shi Q, PhD, Williams LA, PhD, APRN, Bashir Q, MD, Qazilbash M, MD, Champlin RE, MD, Cleeland CS, PhD, Wang XS, MD, MPH. Patient-Reported Outcomes and Patient-Performed Testing in Measuring Functional Impairment after Stem Cell Transplant in Patients with Multiple Myeloma. ASH 2016, 2016. e-Pub 2016.
101. Cerrada SL, MD, Marin D, MD, Rondon G, MD, Ledesma C, BS, Popat UR, MD, Olson AL, MD, Alousi AM, MD, Oran B, MD, Ahmed S, MD, Ciurea SO, MD, Patel K, MD, Shpall EJ, MD, Hosing C, MD, Qazilbash MH, MD, Shah N, MD, Rezvani K, MD, PhD, Jabbour E, MD, Kantarjian HM, MD, Champlin RE, MD, Kebriaei P, MD. Impact of New Anti-Leukemia Agents on Transplant Outcomes in Adults with Acute Lymphoblastic Leukemia (ALL) Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT) in Second Complete Remission. ASH 2016, 2016. e-Pub 2016.
102. Cerrada SL, MD, Marin D, MD, Rondon G, MD, Ledesma C, BS, Popat UR, MD, Olson AL, MD, Alousi AM, MD, Oran B, MD, Ahmed S, MD, Ciurea SO, MD, Patel K, MD, Shpall EJ, MD, Hosing C, MD, Qazilbash MH, MD, Shah N, MD, Rezvani K, MD, PhD, Jabbour E, MD, Kantarjian HM, MD, Champlin RE, MD, Kebriaei P, MD. Additional Consolidation after Attaining Second Complete Remission Results in Superior Outcomes after Allogeneic Hematopoietic Cell Transplantation in Adults with Acute Lymphoblastic Leukemia. ASH 2016, 2016. e-Pub 2016.
103. Qazilbash MH, MD, Stadtmauer EA, MD, Baladandayuthapani V, PhD, Lin H, MS, Tross BM, Honhar M, MBBS, Cha S, PhD, Kim K, MD, Rao SS, PhD, Popescu M, MD, Shah N, MD, Bashir Q, MD, Patel K, MD, Shpall EJ, MD, Weber DM, MD, Thomas SK, MD, Shah JJ, MD, Orlowski RZ, PhD, MD, Kerr ND, MPH, Garfall AL, Cohen MD, M, Dengel K, BSN, RN, June CH, MD, Champlin RE, MD, Kwak L, MD, PHD. Randomized Phase II Trial of Combination Idiotype Vaccine and Anti-CD3/Anti-CD28 Costimulated Autologous T Cells in Patients with Multiple Myeloma Post-Autotransplantation. ASH 2016, 2016. e-Pub 2016.
104. Veltri AW, MD, Milton DR, Shah N, MD, Patel K, MD, Nieto Y, MD, PhD, Kebriaei P, MD, Popat UR, MD, Parmar S, MD, Oran B, MD, Ciurea SO, MD, Hosing C, MD, Lee H, MD, Manasanch EE, MD, Orlowski RZ, PhD, MD, Shpall EJ, MD, Champlin RE, MD, Qazilbash MH, MD, Bashir Q, MD. Outcome of Autologous Hematopoietic Stem Cell Transplantation in Relapsed and Refractory Multiple Myeloma. ASH 2016, 2016. e-Pub 2016.
105. Mohyuddin GR, MD, Faisal MS, MBBS, Shah N, MD, Bashir Q, MD, Hosing C, MD, Patel K, MD, Popat UR, MD, Parmar S, MD, Rondon G, MD, Delgado R, Weber DM, MD, Shah JJ, MD, Thomas S, MD, Manasanch EE, MD, Orlowski RZ, PhD, MD, Champlin RE, MD, Qazilbash MH, MD. A Case Control Study of Syngeneic Transplantation Versus Autologous Transplantation for Multiple Myeloma: Two Decades of Experience at MD Anderson. ASH 2016, 2016. e-Pub 2016.
106. Bashir Q, MD, Shazly ME, Milton DR, Patel K, MD, Shah N, MD, Nieto Y, MD, PhD, Kebriaei P, MD, Popat UR, MD, Parmar S, MD, Oran B, MD, Ciurea SO, MD, Hosing C, MD, Lee H, MD, Manasanch EE, MD, Orlowski RZ, PhD, MD, Champlin RE, MD, Qazilbash M, MD. Outcome of Autologous Stem Cell Transplantation in Myeloma Patients Aged ≥ 75 Years. ASH 2016, 2016. e-Pub 2016.
107. Patel K, MD, Olivares S, BS, Singh H, PhD, Hurton LV, PhD, Huls MH, BS, Qazilbash MH, MD, Kebriaei P, MD, Champlin RE, MD, Cooper LJ, MD, PhD. Combination Immunotherapy with NY-ESO-1-Specific CAR+ T Cells with T-Cell Vaccine Improves Anti-Myeloma Effect. ASH 2016, 2016. e-Pub 2016.
108. Saski K, Bashir Q, Shah N, Hosing C, Popat U, Nieto Y, Parmar S, Shah J, Weber D, Thomas S, Orlowski R, Champlin R, Qazilbash M. Outcome of Patients with Multiple Myeloma by Ethnicity in the Setting of Autologous Stem Cell Transplant. ASBMT 2016, 2016. e-Pub 2016.
109. UPopat, Lyons G, Bassett R, Chen J, Valdez B, Kawedia J, Ahmed S, Alousi A, Anderlini P, Bashir Q, Ciurea S, Hosing C, Jones R, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Parmar S, Patel K, Qazilbash M, Rezvani K, Shah N, Shpall E, Andersson B, Champlin R. Myeloablative Timed Sequential Busulfan is Safe and Appears Promising in Older Patients with AML/MDS. ASBMT 2016, 2016. e-Pub 2016.
110. Qazilbash M, Chen J, Valdez B, Sasaki K, Kawedia J, Bashir Q, Hosing C, Kebriaei P, Nieto Y, Shah N, Patel K, Shpall E, Andersson B, Champlin R, Popat U. Myeloablative Timed Sequential Busulfan Is Safe in Patients with Relapsed or High-Risk Multiple Myeloma. ASBMT 2016, 2016. e-Pub 2016.
111. Badar T, Srour S, Bashir Q, Shah N, Altrash G, Hosing C, Popat U, Nieto Y, Shah J, Orlowshi R, Champlin R, Qazilbash M. Predictors of Inferior Clinical Outcome in Patients with Standard Risk Multiple Myeloma. ASBMT 2016, 2016. e-Pub 2016.
112. Nieto Y, Bassett R, Hosing C, Jones R, Valdez B, Kingham A, Ahmed S, Alousi A, Anderlini P, Popat U, Qazilbash M, Shpall E, Kebriaei P, Brammer J, Oki Y, Fanele M, Maadani F, Rondon G, Champlin R, Anderson B. Comparison of High-Dose Gemcitabine, Busulfan and Melphalan (GEM/BU/MEL) and BEAM in Concurrent Patient Cohorts with Mature T-CELL NON-Hodgkin's Lymphoma (T-NHL) Receiving an Autologous Stem Cell Transplantation (ASCT). ASBMT 2016, 2016. e-Pub 2016.
113. Pingali SR, MD, Saliba R, Anderlini P, MD, Hosing CM, MD, Khouri IF, MD, Alousi AM, MD, Kebriaei P, MD, Nieto Y, MD, PhD, Qazilbash MH, MD, Fanale MA, Shpall EJ, MD, Champlin RE, MD, Popat UR, MD. Age over 55 Years at Diagnosis Increases Risk of Second Malignancies after Auto-Transplantation for Hodgkin's Lymphoma Patients. ASH Abstract 2015, 2015. e-Pub 2015.
114. Pemmaraju N, MD, Kantarjian HM, MD, Cortes JE, MD, Duvic M, MD, Khoury JD, MD, Patel K, MD, Daver N, MD, O'Brien S, MD, Pierce S, BSN, BA, Garcia-Manero G, MD, Jabbour E, Jain N, MD, Faderl S, MD, Thomas D, MD, Frankel AE, MD, Qazilbash MH, MD, Konopleva M, MD, PhD. Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Large Single-Center Experience: Analysis of Clinical and Molecular Characteristics and Patient Outcomes. ASH Abstract 2015, 2015. e-Pub 2015.
115. Gaballa S, MD, Ge I, El Fakih RO, MD, Brammer JE, MD, Wang SA, MD, Lee DA, MD, PhD, Petropoulos D, MD, Cao K, MS, MD, Rondon G, MD, Chen J, Hammerstrom AE, PharmD, BCOP, Al-Atrash G, MD, PhD, Korbling M, MD, Oran B, MD, Kebriaei P, MD, Ahmed S, MD, Shah N, MD, Rezvani K, PhD MD, Marin D, MD, Bashir Q, MD, Alousi AM, MD, Nieto Y, MD, PhD, Qazilbash MH, MD, Hosing CM, MD, Popat UR, MD, Shpall EJ, MD, Khouri IF, Champlin RE, MD, Ciurea SO, MD. Results of a Two-Arm Phase II Clinical Trial Using Post-Transplantation Cyclophosphamide for Prevention of Graft-Versus-Host Disease in Haploidentical and Mismatched Unrelated Donors Hematopoietic Stem-Cell Transplantation. ASH Abstract 2015, 2015. e-Pub 2015.
116. Ragon BK, MD, Gulbis AM, Saliba RM, PhD, Chen J, Rondon G, MD, Popat UR, MD, Nieto Y, MD, PhD, Oran B, MD, Olson AL, MD, Patel K, MD, Hosing CM, MD, Qazilbash MH, MD, Shah N, MD, Kebriaei P, MD, Shpall EJ, MD, Champlin RE, MD, Alousi AM, MD. Pentostatin Therapy for Steroid-Refractory Acute Graft Versus Host Disease: Identifying Those Who May Benefit. ASH Abstract 2015, 2015. e-Pub 2015.
117. Shah JJ, MD, Feng L, MS, Manasanch EE, MD, Weber D, MD, Thomas SK, MD, Turturro F, MD, Shah N, MD, Popat UR, MD, Nieto Y, MD, PhD, Bashir Q, MD, Munoz SC, RN, Landry A, RN, Mendoza K, RN, Champlin RE, MD, Qazilbash MH, MD, Orlowski RZ, PhD, MD. Phase I/II Trial of the Efficacy and Safety of Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma. ASH Abstract 2015, 2015. e-Pub 2015.
118. Nieto Y, MD, PhD, Bassett R, MS, Anderlini P, MD, Hosing CM, Alousi MD, MD, Popat UR, MD, Andersson BS, MD, PhD, Valdez BC, PhD, Shpall EJ, MD, Ahmed S, MD, Qazilbash M, MD, Guillermo M, Oki Y, MD, Fanale MA, Hagemeister FB, MD, Dabaja BS, MD, Pinnix CC, PhD MD, Milgrom SA, MD, Tewari P, MD, Champlin RE, MD, Jones R, MD, PhD. Prospective Phase 2 Trial of High-Dose Gemcitabine/Busulfan/Melphalan (Gem/Bu/Mel) with Autologous Stem-Cell Transplant (ASCT) without Post-ASCT Maintenance, in Hodgkins Lymphoma Patients at High Risk of Post-Transplant Recurrence Comparison with a Concurrent Matched Cohort Treated with BEAM. ASH Abstract 2015, 2015. e-Pub 2015.
119. Mehta RS, MD, MPH, MS, Saliba RM, PhD, Chen J, Rondon G, MD, Hammerstrom AE, PharmD, BCOP, Alousi AM, MD, Qazilbash MH, MD, Bashir Q, MD, Ahmed S, MD, Popat UR, MD, Hosing CM, MD, Khouri IF, Shpall EJ, MD, Champlin RE, MD, Ciurea SO, MD. Post-Transplantation High Dose Cyclophosphamide As Gvhd Prophylaxis in 9/10 HLA-Matched Unrelated Donors Hematopoietic Stem Cell Transplantation. ASH Abstract 2015, 2015. e-Pub 2015.
120. Im JS, MD, PhD, Saliba RM, PhD, Abraham SC, MD, Ross W, MD, Rondon G, MD, Rashid A, MD, Shpall EJ, MD, Popat UR, MD, Qazilbash M, MD, Hosing CM, MD, Oran B, MD, Shah N, MD, Champlin RE, MD, Alousi AM, MD. Histologic Confirmation for Patients Presenting with Gastrointestinal Graft Versus Host Disease: How to Interpret Histologic Grade 1 (Does It Matter)?. ASH Abstract 2015, 2015. e-Pub 2015.
121. Nieto Y, MD, PhD, Valdez BC, PhD, Thall PF, PhD, Wei W, MS, Jones R, MD, PhD, Hosing CM, MD, Ahmed S, MD, Popat UR, MD, Shpall EJ, MD, Qazilbash M, MD, Gulbis AM, Anderlini P, MD, Shah N, MD, Bashir Q, MD, Alousi AM, MD, Oki Y, MD, Hagemeister FB, MD, Champlin RE, MD, Andersson BS, MD, PhD. Double Epigenetic Modulation of High-Dose Chemotherapy (HDC) with Autologous Stem-Cell Transplant (ASCT) for Patients with Refractory or Poor-Risk Relapsed Lymphoma. ASH Abstract 2015, 2015. e-Pub 2015.
122. Shah N, MD, Li L, MD, Kaur I, PhD, McCarty J, Yvon E, PhD, Shaim H, MD, Muftuoglu M, Liu E, MD, MS, Sobieski C, Orlowski RZ, PhD, MD, Cooper LJ, MD, PhD, Lee DA, MD, PhD, Parmar S, MD, Cao K, MS, MD, Hosing CM, MD, Ahmed S, MD, Nieto Y, MD, PhD, Bashir Q, MD, Patel KK, Bollard CM, MD, McNiece IK, PhD, Qazilbash M, MD, Champlin RE, MD, Rezvani K, Shpall EJ, MD. Infusion of Ex Vivo Expanded Allogeneic Cord Blood-Derived Natural Killer Cells in Combination with Autologous Stem Cell Transplantation for Multiple Myeloma: Results of a Phase I Study. ASH Abstract 2015, 2015. e-Pub 2015.
123. Im JS, MD, PhD, Saliba RM, PhD, Abraham SC, MD, Rashid A, MD, Ross W, MD, Nieto Y, MD, PhD, Shpall EJ, MD, Oran B, MD, Olson A, Ahmed S, MD, Popat UR, MD, Rondon G, MD, Qazilbash MH, MD, Shah N, MD, Champlin RE, MD, Alousi AM, MD. Gastrointestinal Acuity Score (GAS): A Comprehensive Risk Score Incorporating Histologic Grade and Clinical Factors to Predict Need for Second Line Therapy, Non-Relapse Mortality, and Overall Survival in Lower Gastrointestinal Graft Vs. Host Disease. ASH Abstract 2015, 2015. e-Pub 2015.
124. Popat UR, MD, Ray G, Bassett Jr RL, Poon MC, Valdez BC, PhD, Konoplev S, MD, PhD, Ahmed S, MD, Alousi AM, MD, Andersson B, MD, PhD, Bashir Q, MD, Ciurea SO, MD, Hosing CM, MD, Jones R, MD, PhD, Kebriaei P, MD, Khouri IF, MD, Kim S, Nieto Y, MD, PhD, Olson AL, MD, Oran B, MD, Parmar S, MD, Qazilbash MH, MD, Rezvani K, MD, PHD, Shah N, MD, Shpall EJ, MD, Champlin RE, MD. Eltrombopag for Post-Transplant Thrombocytopenia: Results of Phase II Randomized Double Blind Placebo Controlled Trial. ASH Abstract 2015, 2015. e-Pub 2015.
125. Alousi AM, MD, Bassett R, MS, Chen J, Overman BJ, BSN, Hosing CM, MD, Popat UR, MD, Shpall EJ, MD, Nieto Y, MD, PhD, Qazilbash MH, MD, Khouri IF, Kebriaei P, MD, Ahmed S, MD, Shah N, MD, Rezvani K, MD, PhD, Kondo K, PhD, Ciurea SO, MD, Hymes SR, MD, Neumann JL, APN, PhD, Molldrem JJ, MD, Plair TR, PA, Champlin RE, MD. A Bayesian, Phase II Randomized Trial of Extracorporeal Photopheresis (ECP) Plus Steroids Versus Steroids-Alone in Patients with Newly Diagnosed Acute Graft Vs. Host Disease (GVHD): The Addition of ECP Improves Gvhd Response and the Ability to Taper Steroids. ASH Abstract 2015, 2015. e-Pub 2015.
126. Khouri IF, Sui D, Turturro F, MD, Erwin WD, Bassett Jr RL, Korbling M, Valverde R, Ahmed S, Alousi AM, MD, Anderlini P, Bashir Q, MD, Ciurea SO, MD, Oran B, MD, Olson A, Popat UR, MD, Patel KK, Qazilbash MH, MD, Fanale MA, Fayad LE, MD, Nastoupil L, MD, Westin JR, MD, Gulbis AM, Medeiros L, Young KH, Jessop A. In-Vivo Purging with Rituximab (R) Followed By Z/BEAM Vs BEAM/R Autologous Stem Cell Conditioning for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): Mature Results from a Combined Analysis of 3 Trials. ASH Abstract 2015, 2015. e-Pub 2015.
127. Kebriaei P, MD, Basset Jr RL, Ledesma C, Rondon G, MD, Oran B, MD, Ciurea SO, MD, Alousi AM, MD, Popat UR, MD, Patel KK, Ahmed S, MD, Olson AL, MD, Bashir Q, MD, Shah N, MD, Jones R, MD, PhD, Rezvani K, MD, PH, Nieto Y, MD, PhD, Khouri IF, Qazilbash MH, MD, Hosing CM, MD, Shpall EJ, MD, Champlin RE, MD, Andersson BS, MD, PhD. Clofarabine (Clo) Plus Busulfan (Bu) Is an Effective Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients (pts) with Acute Lymphoblastic Leukemia (ALL): Long-Term Study Results. ASH Abstract 2015, 2015. e-Pub 2015.
128. Sasaki K, MD, Shah N, MD, Bashir Q, MD, Hosing CM, MD, Popat UR, MD, Nieto Y, MD, PhD, Parmar S, MD, Shah JJ, MD, Weber D, MD, Weissinger D, Thomas SK, MD, Orlowski RZ, MD, PhD, Champlin RE, MD, Qazilbash MH, MD. Outcome of Patients with Light Chain Multiple Myeloma Compared to IgG/IgA Myeloma after Autologous Stem Cell Transplant. ASH Abstract 2015, 2015. e-Pub 2015.
129. Ramlal R, MD, Gaballa S, MD, Chen J, Rondon G, MD, Oran B, MD, Ahmed S, MD, Bashir Q, MD, Rezvani K, MD, PhD, Marin D, MD, Alousi AM, MD, Kebriaei P, MD, Qazilbash M, MD, Hosing C, MD, Popat UR, MD, Shpall EJ, MD, Champlin R, MD, Ciurea SO, MD. Outcomes of Haploidentical Stem Cell Transplants for De Novo Acute Myeloid Leukemia, Myelodysplastic Syndrome and Acute Myeloid Leukemia Arising from MDS: The MD Anderson Experience. ASH Abstract 2015, 2015. e-Pub 2015.
130. Shah JJ, MD, Feng L, MS, Weber D, MD, Thomas SK, MD, Wang M, MD, Turturro F, MD, Qazilbash MH, MD, Shah N, MD, Bashir Q, MD, Popat UR, MD, Manasanch EE, MD, Munoz SC, RN, Landry A, RN, Mendoza K, RN, Nieto Y, MD, PhD, Champlin RE, MD, Orlowski RZ, PhD, MD. Phase II Study of the Combination of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma. ASH Abstract 2015, 2015. e-Pub 2015.
131. Francesca Jauch LBS, Popat UR, MD, Shafi MA, MD, Shah N, MD, Bashir Q, MD, Dinh Y, BS, Hosing C, MD, Champlin RE, MD, Qazilbash MH, MD. Impact of Hepatitis B Core Antibody (HBcAb) Seropositivity on the Outcome of High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. ASBMT 2014, 2014. e-Pub 2014.
132. Shah N, Thall PF, PhD, Fox PS, M, Bashir Q, Shah JJ, Parmar S, Kebriaei P, MD, Nieto Y, Popat UR, MD, Hosing CM, MD, Patel KK, MD, Lin P, MD, Shpall EJ, MD, Orlowski RZ, PhD, MD, Champlin RE, Qazilbash MH, MD. Phase I/II Trial of Lenalidomide and High Dose Melphalan with Autologous Stem Cell Transplantation for Relapsed Myeloma. ASH 2014, 2014. e-Pub 2014.
133. Patel KK, MD, Olivares S, Hurton LV, PhD, Huls H, BS, Qazilbash MH, Champlin RE, Cooper LJ, MD, PhD. T-Cell Therapy for Multiple Myeloma Using NY-ESO-1+ T-Cell Antigen Presenting Cells (T-APC) Combined with Adoptive Cellular Transfer (ACT) to Augment Immunotherapy. ASH 2014, 2014. e-Pub 2014.
134. Bock FM, Lu G, MD, Shah N, Bashir Q, Patel KK, MD, Popat UR, MD, Hosing CM, Gaballa S, MD, Korbling M, MD, Delgado R, Rondon G, MD, Orlowski RZ, MD, PhD, Shah JJ, Manasanch EE, MD, Champlin RE, Qazilbash MH, MD. Clinical Characteristics and Outcomes in Patients with Multiple Myeloma and CKS1B Gene Gain/Amplification after Autologous Stem Cell Transplantation. ASH 2014, 2014. e-Pub 2014.
135. Shah JJ, Feng L, MS, Manasanch EE, MD, Weber DM, MD, Thomas SK, MD, Turturro F, MD, Alexanian R, MD, Shah N, Popat UR, MD, Nieto Y, Bashir Q, Qazilbash MH, Champlin RE, MD, Orlowski RZ, MD, PhD. 33 Phase I/Ib Trial of the Efficacy and Safety of Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma. ASH 2014, 2014. e-Pub 2014.
136. Pemmaraju N, Thomas DA, Kantarjian HM, Cortes JE, Khoury J, Manning JT, Medeiros L, O'Brien SM, Daver NG, Pierce S, Garcia-Manero G, Jabbour E, Jain N, Qazilbash MH, Faderl S, Frankel AE, Konopleva M. Characteristics of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Male predominance, propensity for extramedullary involvement, and poor outcomes. ASCO 2014, 2014. e-Pub 2014.
137. Mian I, MD, Milton D, MS, Popat UR, MD, Shah N, Nieto Y, Kebriaei P, Parmar S, Ahmed S, MD, Shah JJ, Orlowski RZ, MD, PhD, Qazilbash MH, MD, Bashir Q, Champlin RE. Effect of Timing and Duration of Maintenance Lenalidomide in Myeloma Patients after Autologous Stem Cell Transplantations. ASH 2014, 2014. e-Pub 2014.
138. El Fakih RO, Nieto Y, Fox PS, Shah N, Parmar S, Oran B, Ciurea SO, Kebriaei P, Hosing C, Popat UR, Ahmed S, Shah JJ, Orlowski RZ, Dinh Y, Champlin RE, Qazilbash MH, Bashir Q. Autologous stem cell transplantation in dialysis-dependent myeloma patients. ASCO 2014, 2014. e-Pub 2014.
139. Ahmed S, MD, Shpall EJ, MD, Gulbis A, Jones R, Martinez CS, Rondon G, MD, Rezvani K, Oran B, MD, Olson A, Shah N, Parmar S, Popat UR, MD, Alousi AM, MD, Nieto Y, Hosing CM, Bashir Q, Kebriaei P, Qazilbash MH, Champlin RE, Mulanovich VE. Assessment of Incidence Toxoplasma Gondii Infection and Outcomes in Allogeneic Stem Cell Patients. ASH 2014, 2014. e-Pub 2014.
140. Pingali SR, MD, Milton D, Stasi AD, MD, Patel RD, MD, PhD, Kebriaei P, MD, Popat UR, MD, Alousi AM, MD, Anderlini P, MD, Qazilbash MH, MD, Hosing C, MD, Rezvani K, MD, Bashir Q, MD, Oran B, MD, Shpall EJ, MD, Khouri IF, MD, Champlin RE, MD, Ciurea SO, MD. Haploidentical Transplantation for Advanced Hematologic Malignancies Using Melphalan-Based Conditioning – Mature Results from a Single Center. ASBMT 2014, 2014. e-Pub 2014.
141. Pingali SR, MD, Milton D, MS, Popat UR, MD, Hosing CM, Bashir Q, Alousi AM, MD, Jones R, Nieto Y, Kebriaei P, Qazilbash MH, MD, Andersson BS, MD, PhD, Shpall EJ, MD, Khouri IF, MD, Champlin RE, Ciurea SO, MD. Transplant Outcomes of 9/10 HLA Matched Unrelated Donors (MUD) Treated with Post-Transplant Cyclophosphamide for Prevention of Graft Versus Host Disease, 2014. e-Pub 2014.
142. Saunders IM, Gulbis A, PharmD, Champlin RE, MD, Qazilbash MH, MD. A Lower Dose of Melphalan (140 mg/m2) As Preparative Regimen for Multiple Myeloma in Patients >65 or with Renal Dysfunction. ASBMT 2014, 2014. e-Pub 2014.
143. Qazilbash MH, Thall PF, Fox PS, Kebriaei P, Bashir Q, Shah N, Andersson B, Nieto Y, Valdez B, Parmar S, Dinh Y, Hosing C, Popat UR, Shah JJ, Orlowski RZ, Champlin RE. Randomized phase III trial of busulfan plus melphalan versus melphalan alone for multiple myeloma. ASCO 2014, 2014. e-Pub 2014.
144. Williams LA, PhD, R, Qazilbash MH, Shi Q, PhD, Shah N, Bashir Q, Champlin RE, Popat UR, MD, Kebriaei P, Parmar S, Limaye AR, BS, Cleeland CS, PhD. Symptom Burden of Busulfan + Melphalan Versus Melphalan Alone for Multiple Myeloma, 2014. e-Pub 2014.
145. Shi Q, Wang XS, Shah N, Orlowski RZ, Qazilbash MH, Williams LA, Mendoza TR, Cleeland CS. Prevalence of high symptom burden and its impact on functioning and quality of life in patients with multiple myeloma 3-9 months following autologous transplant. ASCO 2014, 2014. e-Pub 2014.
146. Qazilbash MH, MD, Thall P, S Fox PP, Shah MS, MD, Bashir Q, MD, Shah J, Parmar S, MD, Kebriaei P, MD, Nieto YL, MD, PhD, Dinh Y, BS, Popat UR, MD, Hosing C, MD, Lin P, MD, Shpall EJ, MD, Orlowski RZ, MD, Champlin RE, MD. Phase I/II Trial of Lenalidomide and High-Dose Melphalan As Preparative Regimen for Relapsed Myeloma. ASBMT 2014, 2014. e-Pub 2014.
147. Popat UR, MD, Fox PS, MS, Bassett R, Chen J, Valdez BC, PhD, Kawedia J, Ahmed S, MD, Alousi AM, MD, Bashir Q, Ciurea SO, MD, Hosing CM, Jones R, Kebriaei P, Khouri IF, MD, Nieto Y, Olson A, Oran B, MD, Parmar S, Qazilbash MH, MD, Shah N, Shpall EJ, MD, Andersson BS, MD, PhD, Champlin RE. Myeloablative Timed Sequential Busulfan Is Safe in Older Patients. ASH 2014, 2014. e-Pub 2014.
148. Jimenez AM, Lima MD, Popat UR, Borthakur G, Abruzzo L, Andersson B, Garcia-Manero G, Jabbour E, Chen J, Bashir Q, Ciurea SO, Kebriaei P, Ahmed S, Khouri IF, Kongtim P, Qazilbash MH, Rondon G, Shpall EJ, Champlin RE, Oran AB. Impact of monosomal karyotype and FLT3 status on post-transplant relapse in acute myeloid leukemia (AML). Journal of Clinical Oncology- ASCO Annual Meeting Volume 31(No 15):7010, 2013. e-Pub 2013.
149. Popat UR, Bassett R, Chen J, Alousi AM, Anderlini P, Ciurea SO, Hosing C, Jones RB, Kebriaei P, Khouri IF, Konoplev S, Lima MD, Nieto Y, Oran B, Qazilbash MH, Rondon G, Shpall EJ, Verstovsek S, Andersson B, Champlin RE. Allogeneic transplantation for myelofibrosis: Benefit of dose intensity. ournal of Clinical Oncology, 2013 ASCO Annual Meeting Proceedings (Post-Meeting Edition) Volume 31(No 15):7011, 2013. e-Pub 2013.
150. Popat UR, MD, Oran B, MD, Hosing CM, MD, Kebriaei P, MD, Rezvani K, MD, PhD, Parmar S, MD, Shah N, MD, Bollard CM, MBChB, MD, Molldrem JJ, MD, Nieto Y, MD, PhD, Andersson BS, MD, PhD, Alousi A, MD, Jones RB, MD, PhD, N Cooper LJ, MD, PhD, Qazilbash MH, MD, Bashir Q, MD, Ahmed S, MD, Bosque D, ADN, Chen J, McCarty J, Rondon G, MD, Munsell M, McNiece IK, PhD, Kaur I, PhD, Yvon E, PhD, Annandale K, Olchesky S, de Lima MJ, MD, Champlin RE, MD, Miller L, PhD, Paradiso L, DVMMBA, Koh L, MS, MBA, Zweidler-McKay PA, MD/PhD, Shpall EJ, MD. Ex Vivo Fucosylation Of Cord Blood Accelerates Neutrophil and Platelet Engraftment. ASH 20103 Abstracts, 2013. e-Pub 2013.
151. Pemmaraju N, MD, Shah D, MD, Kantarjian HM, MD, Wagner V, Orlowski RZ, MD, PhD, Garcia-Manero G, MD, Ravandi F, MD, Pierce S, Takahashi K, MD, Daver NG, MD, Nazha A, MD, Verstovsek S, MD, PhD, Jabbour EJ, MD, de Lima MJ, MD, Champlin RE, MD, Cortes JE, MD, Qazilbash MH, MD. Characteristics and Outcomes Of Patients (pts) With Multiple Myeloma (MM) Who Develop Therapy (t)-Related Myelodysplastic Syndrome (MDS), t-Chronic Myelomonocytic Leukemia (CMML), Or t-Acute Myeloid Leukemia (AML). ASH 2013 Abstracts, 2013. e-Pub 2013.
152. Adekola KU, MD, Bashir Q, MD, Shah N, MD, Pingali SR, MD, Parmar S, MD, Popat UR, MD, Hosing CM, MD, Champlin RE, MD, Qazilbash MH, MD. Characteristics Of Multiple Myeloma Patients With 6-Year Or Longer Progression-Free Survival After a Single Autologous Transplant. ASH 2013 Abstracts, 2013. e-Pub 2013.
153. Ghobadi A, MD, Hamdi A, MD, Kongtim P, MD, Milton D, Alousi A, MD, Anderlini P, MD, Ciurea SO, MD, Oran B, MD, Khouri I, MD, Parmar S, MD, Qazilbash MH, MD, Kebriaei P, MD, Popat UR, MD, Rezvani K, MD, PhD, Chemaly RF, MD, MPH, Shpall EJ, MD, Champlin RE, MD, Bashir Q, MD. The Effect Of CMV Reactivation On Relapse and Survival In Patients With AML and MDS After Allogeneic Stem Cell Transplant (allo-HCT). ASH 2013 Abstracts, 2013. e-Pub 2013.
154. Kongtim P, MD, Qazilbash MH, MD, Shah JJ, MD, Orlowski RZ, MD, PhD, Hamdi A, MD, Shah N, MD, Bashir Q, MD, Wang M, MD, Champlin RE, MD, Parmar S, MD. Autologous Stem Cell Transplantation Improves Survival For High Risk Cardiac Amyloidosis. ASh 2013 Abstracts, 2013. e-Pub 2013.
155. Nusrat M, MD, Kazmi SM, MD, Cornelison AM, MS, PA-C, Kebriaei P, MD, Nieto Y, MD, PhD, Oran B, MD, Orlowski RZ, MD, PhD, Parmar S, MD, Popat UR, MD, Shah JJ, MD, Shah N, MD, Champlin RE, MD, Qazilbash MH, MD, Bashir Q, MD. Outcomes Among High Risk and Standard Risk Multiple Myeloma Patients Treated With High Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation. ASH 2013 Abstracts, 2013. e-Pub 2013.
156. Nieto Y, MD, PhD, Shah N, MD, Popat UR, MD, Jones RB, PhD MD, Bashir Q, MD, Bassett R, MS, Valdez BC, PhD, Andersson BS, MD, PhD, Parmar S, MD, Orlowski RZ, MD, PhD, Shah JJ, MD, Thomas SK, MD, Wang M, MD, Champlin RE, MD, Qazilbash M, MD. High-Dose Gemcitabine Combined With Busulfan and Melphalan (Gem/Bu/Mel) With Autologous Stem-Cell Transplant (ASCT) In Refractory and Relapsed Myeloma. ASH 2013 Abstracts, 2013. e-Pub 2013.
157. Oran B, MD, Poon M, Chen J, Rondon G, MD, Ahmed S, MD, Andersson BS, MD, PhD, Bashir Q, MD, Ciurea SO, MD, Hosing CM, MD, Parmar S, MD, Qazilbash MH, MD, Popat UR, MD, Nieto Y, MD, PhD, Alousi A, MD, Jones RB, PhD MD, Rezvani K, MD, PhD, Lima MD, MD, Shpall EJ, MD, Champlin RE, MD, Kebriaei P, MD. Comparable Outcomes After Sibling and Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantations (HCT) In Adult Acute Lymphoblatic Leukemia (ALL) With First Complete Remission (CR). ASH 2013 Abstracts, 2013. e-Pub 2013.
158. Shah JJ, MD, Baladandayuthapani V, PhD, Weber DM, MD, Thomas SK, MD, Alexanian R, MD, Wang M, MD, Qazilbash MH, MD, Champlin RE, MD, Shah N, MD, Bashir Q, MD, Popat UR, MD, Nieto Y, MD, PhD, Ahmed S, MD, Parmar S, MD, Orlowski RZ, MD, PhD. Phase II Study Of The Combination Of MLN 9708 With Lenalidomide As Maintenance Therapy Post Autologous Stem Cell Transplant In Patients With Multiple Myeloma. ASH 2013 Abstracts, 2013. e-Pub 2013.
159. Thomas SK, MD, Haygood TM, MD, Qazilbash MH, MD, Melendez A, MD, Galvis R, Delasalle KB, BS, Feng L, MS, Richards TA, MS, Samaniego F, MD, MPH, Wang L, MD, Shah JJ, MD, Orlowski RZ, MD, PhD, Weber DM, MD. A Phase II Trial Of Bortezomib-Rituximab Followed By Autologous Stem Cell Harvest (SCH) and Cladribine-Cyclophosphamide-Rituximab (2CdA-Cy-Rit) Consolidation As Primary Therapy Of Waldenström's Macroglobulinemia (WM). ASH 2013 Abstracts, 2013. e-Pub 2013.
160. Gettys SC, PharmD, Gulbis AM, PharmD, BCOP, Wilhelm K, PharmD, BCOP, Dinh YT, Rondon G, MD, Qazilbash MH, MD. Modified-CVAD Or Modified-Cbad Compared To High Dose Cyclophosphamide For Peripheral Blood Stem Cell Mobilization In Patients With Multiple Myeloma. ASH 2013 Abstracts, 2013. e-Pub 2013.
161. Nieto Y, MD, PhD, Thall PF, PhD, Valdez BC, PhD, Hosing CM, MD, Ahmed S, MD, Jones RB, PhD MD, Shah N, MD, Anderlini P, MD, Qazilbash MH, MD, Popat UR, MD, Bashir Q, MD, Shpall EJ, MD, Alousi A, MD, Kebriaei P, MD, Fox P, MS, Bassett R, MS, Chancoco C, Oki Y, MD, Fanale MA, MD, Fowler N, MD, Hagemeister F, MD, Romaguera JE, MD, Champlin RE, MD, Andersson BS, MD, PhD. Vorinostat (SAHA) Combined With High-Dose Gemcitabine/Busulfan/Melphalan (SAHA/Gem/Bu/Mel) With Autologous Stem-Cell Transplant (ASCT) In Patients With Refractory Lymphomas. ASH 2013 Abstracts, 2013. e-Pub 2013.
162. Pingali SR, MD, Saliba RM, PhD, Smith VR, APN, Maadani F, Adekola KU, MBBS, Popat UR, MD, Qazilbash MH, MD, Bashir Q, MD, Khouri I, MD, Kebriaei P, MD, Ciurea SO, MD, Anderlini P, MD, Shah N, MD, Nieto Y, MD, PhD, Champlin RE, MD, Hosing CM, MD. Number Of Apheresis Days To Reach Target Stem Cell Dose May Be a Predictor Of Secondary Myelodysplastic Syndrome and Acute Myelogenous Leukemia. ASH 2013 Abstracts, 2013. e-Pub 2013.
163. Shah N, MD, Williams LA, PhD, RN, Worthing A, RN, Shi Q, PhD, Wang XS, MD, MPH, Johnson V, PhD, Mendoza TR, PhD, Qazilbash MH, MD, Champlin RE, MD, Giralt SA, MD, Cleeland CS, PhD. Higher Stem Cell Dose Infusion As Rescue After Intensive Chemotherapy Does Not Improve Symptom Burden In Older Patients With Multiple Myeloma and Amyloidosis. ASh 2013 Abstracts, 2013. e-Pub 2013.
164. Stasi AD, MD, Poon LM, MD, Ferro R, MD, Milton D, Rondon G, MD, Wang SA, MD, Hamdi A, MD, Qazilbash MH, MD, Ahmed S, MD, Khouri I, MD, Oran B, MD, Hosing CM, MD, Kebriaei P, MD, Alousi A, MD, Popat UR, MD, Shpall EJ, MD, Lee DA, MD, PhD, Rezvani K, MD, PhD, Champlin RE, MD, Ciurea SO, MD. Transplant Outcomes For Patients With AML/MDS Using Melphalan-Based Conditioning. ASH 2013 Abstracts, 2013. e-Pub 2013.
165. Patel K, MD, Feng L, MS, Oki Y, MD, Qazilbash M, MD, Muzzafar T, MBBS, Weber DM, MD, Fowler N, MD, Popat UR, MD, Thomas SK, MD, Fanale MA, MD, Nieto Y, MD, PhD, Shah N, MD, Bashir Q, MD, Hagemeister FB, MD, Orlowski RZ, MD, PhD, Shah JJ, MD. Plasmablastic Lymphoma: 28 Patient Single Institution Experience, 2013. e-Pub 2013.
166. Khan D, MBBS, Patel K, MD, Thomas SK, MD, Weber DM, MD, Delasalle KB, BS, Hosing CM, MD, Popat UR, MD, Bashir Q, MD, Shah N, MD, Parmar S, MD, Champlin RE, Qazilbash M, MD. Feasibility of Hematopoietic Stem Cell Collection and Cryopreservation in Waldenstrom’s Macroglobulinemia. ASH Annual Meeting 2012 Abstracts, 2012. e-Pub 2012.
167. Lee HC, MD, Yin C, MD, PhD, Qazilbash MH, MD, Wang I, MD, Lu V, Lu G, MD. Acquired Therapy-Related Cytogenetic Clones in Patients Treated for Multiple Myeloma. ASH Annual Meeting 2012 Abstracts, 2012. e-Pub 2012.
168. Shah AJ, MD, Thomas SK, MD, Weber DM, MD, Wang M, MD, Alexanian R, MD, Qazilbash MH, MD, Bashir Q, MD, Parmar S, MD, Shah N, MD, Popat UR, MD, Orlowski RZ, MD, PhD. Phase 1/1b Study of the Efficacy and Safety of the Combination of Panobinostat + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma. ASH Annual Meeting 2012 Abstracts, 2012. e-Pub 2012.
169. Alousi AM, MD, Saliba RM, PhD, Chen J, Andersson BS, MD, PhD, Khouri I, MD, Qazilbash MH, MD, Popat UR, MD, Hosing CM, MD, Ciurea SO, Shpall EJ, MD, Jones RB, MD, PhD, Kebriaei P, MD, Nieto Y, MD, PhD, Anderlini P, MD, DeLima M, MD, Rondon G, Champlin RE. A Matched Controlled Analysis of Post-Transplant Cyclophosphamide (CY) Versus Tacrolimus and Mini-Dose Methotrexate in Matched Sibling and Unrelated Donor Transplant Recipients Receiving Reduced-Intensity Conditioning: Post-Transplant CY Is Associated with Higher Rates of Acute Gvhd. ASH Annual Meeting 2012 Abstracts, 2012. e-Pub 2012.
170. Hamdi A, MD, Poon LM, MD, Saliba RM, PhD, Rondon G, MD, Ledesma C, Qazilbash M, MD, Hosing CM, MD, Jones RB, MD, PhD, Popat UR, MD, Nieto Y, MD, PhD, Alousi AM, MD, Ciurea SO, Shpall EJ, MD, Champlin RE, Kebriaei P, MD. Outcomes of Adults with Acute Lymphoblastic Leukemia (ALL) Following Relapse After First Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). ASH Annual Meeting 2012 Abstracts, 2012. e-Pub 2012.
171. Patel K, MD, Orlowski RZ, MD, PhD, Shah N, MD, Bashir Q, Parmar S, MD, Dinh YT, Rondon G, MD, Giralt SA, MD, Champlin RE, Qazilbash M, MD. Role of Serum Lactate Dehydrogenase (LDH) As a Prognostic Marker for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. ASH Annual Meeting 2012 Abstracts, 2012. e-Pub 2012.
172. Shah JJ, MD, Weber DM, MD, Thomas SK, MD, Alexanian R, MD, Wang M, MD, Qazilbash MH, MD, Parmar S, MD, Shah N, MD, Bashir Q, MD, Popat UR, MD, Hilder B, Orlowski RZ, MD, PhD. hase 1 Study of the Novel Kinesin Spindle Protein Inhibitor ARRY-520 + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma. ASH Annual Meeting 2012 Abstracts, 2012. e-Pub 2012.
173. Shah JJ, MD, Orlowski RZ, MD, PhD, Thomas SK, MD, Alexanian R, MD, Wang M, MD, Qazilbash MH, MD, Popat UR, MD, Parmar S, MD, Shah N, MD, Bashir Q, Champlin RE, Weber DM, MD. Final Results of a Phase I/II Trial of the Combination of Concurrent Lenalidomide, Thalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Myeloma. ASH Annual Meeting 2012 Abstracts, 2012. e-Pub 2012.
174. Parmar S, MD, Howell J, PharmD, Wang M, MD, Khan MA, , Bashir Q, MD, , Shah JJ, MD, Shah N, MD, Popat UR, MD, Giralt SA, MD, Orlowski RZ, MD, PhD, Qazilbash M, MD. High Dose Therapy Improves Survival in Systemic Light Chain Amyloidosis: 14 Year Follow up. ASH Annual Meeting 2012 Abstracts, 2012. e-Pub 2012.
175. Ahmed A, MD, Saliba RM, PhD, Lima MD, MD, Rondon G, MD, Kebriaei P, MD, Fisher TD, MPAS, Jabbour E, MD, Chen J, Kantarjian H, MD, Anderlini P, MD, Alousi AM, MD, Hosing CM, MD, Andersson B, MD, PhD, Jones RB, MD, PhD, Qazilbash MH, MD, Shpall EJ, MD, Giralt S, MD, Champlin RE, MD. Sequential Treatment After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia. ASH Annual Meeting 2012 Abstracts, 2012. e-Pub 2012.
176. Gul Z, MD, Bashir Q, MD, Nieto Y, MD, PhD, Sherwani N, Parmar S, MD, Shah N, MD, Dinh YT, Hosing CM, MD, Popat UR, MD, Kebriaei P, MD, Shpall EJ, MD, Giralt SA, MD, Champlin RE, Qazilbash MH, MD. Cardiac Toxicity After High-Dose Melphlan and Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. ASH Annual Meeting 2012 Abstracts, 2012. e-Pub 2012.
177. Gul Z, MD, Khan H, Bashir Q, MD, Shah N, MD, Parmar S, MD, Dinh YT, Hosing CM, MD, Popat UR, MD, Kebriaei P, MD, Anderlini P, MD, Shpall EJ, MD, Giralt S, MD, Champlin RE, Qazilbash MH, MD. EBMT Risk Score for Pre Transplant Risk Assessment in Patients with Multiple Myeloma. ASH Annual Meeting 2012 Abstracts, 2012. e-Pub 2012.
178. Hosing C, Saliba R, Singh L, Popat U, Qazilbash M, Anderlini P, Nieto Y, Alousi A, Frazier E, Dabaja E, Champlin R, Duvic M. Total Skin Electron Beam radiation therapy and allogeneic haematopoietic stem cell transplantation in advanced mycosis fungoides and Sézary syndrome. Nature/2012 EBMT Abstract Book 47(Supplement 1):S85, 2012. e-Pub 2012.
179. Khouri IF, MD, Saliba RM, PhD, Valverde R, Samuels BI, MD, Korbling M, MD, Alousi AM, MD, Anderlini P, MD, Bashir Q, MD, Lima MD, MD, Hosing C, MD, Kebriaei P, MD, Nieto Y, MD, PhD, Popat UR, MD, Qazilbash M, MD, Neelapu S, MD, Fowler NH, MD, Samaniego F, MD, Wang L, MD, Champlin R, MD, Macapinlac HA, MD. Nonmyeloablative Allogeneic Stem Cell Transplantation with/ or without 90yttrium Ibritumomab Tiuxetan (90YIT) Is Curative for Relapsed Follicular Lymphoma: Median 9 Year Follow-up Results. ASH Annual Meeting 2011 Abstract, 2011. e-Pub 2011.
180. Khouri IF, MD, Saliba RM, PhD, Korbling M, MD, Alousi AM, MD, Popat UR, MD, Anderlini P, MD, Ciurea SO, MD, Kebriaei P, MD, Qazilbash MH, MD, Champlin R, MD, Bassett Jr RL. Nonmyeoablative Allogeneic Conditioning with Bendamustine in Combination with Fludarabine and Rituximab for Lymphoid Malignancies: Immunosuppression without Myelosuppression and without Acute Gvhd. ASH Annual Meeting 2011 Abstract, 2011. e-Pub 2011.
181. Shah N, MD, Bashir Q, MD, Parmar S, MD, Dinh YT, Qureshi S, Rondon G, MD, Popat UR, MD, Nieto Y, MD, PhD, Jones R, MD, PhD, Champlin R, MD, Qazilbash MH, MD. Increased Bone Marrow Plasma Cell Infiltration Pre-Transplant Is Associated with Worse Outcomes in Patients Undergoing High Dose Chemotherapy and Autologous Stem Cell Transplantation for Multiple Myeloma. ASH Annual Meeting 2011 Abstract, 2011. e-Pub 2011.
182. Ahmed S, MD, Lin H, PhD, Baladandayuthapani V, PhD, Khan MA, Lu G, MD, Rondon G, MD, Qureshi S, Dinh YT, Bashir Q, MD, Shah N, MD, Parmar S, MD, Hosing CM, MD, Popat U, MD, Giralt SA, MD, Orlowski RZ, MD, PhD, Shah JJ, MD, Champlin R, MD, Qazilbash MH, MD. Impact of Non High-Risk Chromosomal Abnormalities on the Outcome of Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. ASH Annual Meeting 2011 Abstract, 2011. e-Pub 2011.
183. Ahmed S, MD, Dinh YT, Qureshi S, Rondon G, MD, Bashir Q, MD, Parmar S, MD, Avery T, MD, MPH, Orlowski RZ, MD, PhD, Champlin R, MD, Qazilbash M, MD, Shah N, MD. Survival Disparities Between African-American and Caucasian Patients Treated with Autologous Stem Cell Transplantation for Multiple Myeloma Are Eliminated in the Era of Novel Therapeutics. ASH Annual Meeting 2011 Abstract, 2011. e-Pub 2011.
184. Kota V, MBBS, Saliba RM, PhD, Bayraktar UD, MD, Beitinjaneh A, MD, Chen JJ, Parmar S, MD, Giralt SA, MD, Rondon G, MD, , Ciurea SO, MD, Kebriaei P, MD, Qazilbash MH, MD, Andersson BS, MD, PhD, , Champlin R, MD, Lima MD, MD. Chromosome 7 Abnormalities in Allogeneic Transplantation for AML and MDS. ASH Annual Meeting 2011 Abstract, 2011. e-Pub 2011.
185. Hari P, MBBS, MD, MRCP, Pasquini MC, MD, MS, Logan BR, PhD, Stadtmauer EA, MD, Krishnan A, MD, Howard A, PhD, Alvi S, PhD, Harding S, Carter SL, ScD, Rajkumar V, MD, Edwin P Alyea III, MD, Qazilbash M, MD, Laport GG, MD, Maloney DG, MD, PhD, Giralt S, MD, Vesole DH, MD, PhD. Immunoglobulin Free Light Chain (FLC) and Heavy Chain/Light Chain (HLC) Assays – Comparison with Electrophoretic Responses in Multiple Myeloma (MM). ASH Annual Meeting 2011 Abstract, 2011. e-Pub 2011.
186. Farhan S, MD, Lin H, PhD, Baladandayuthapani V, Shah N, MD, Bashir Q, MD, Hosing CM, MD, Popat U, MD, Parmar S, MD, Dinh YT, Qureshi S, Rondon G, MD, Giralt S, MD, Champlin R, MD, Qazilbash MH, MD. Response Before Autologous Hematopoietic Stem Cell Transplantation Is An Important Predictor of Outcome in Multiple Myeloma. ASH Annual Meeting 2011 Abstract, 2011. e-Pub 2011.
187. Ciurea SO, MD, Saliba RM, PhD, Bayraktar UD, MD, Xie S, Rondon G, MD, Parmar S, MD, Kebriaei P, MD, Montes N, PA, Sharma M, MD, Konopleva M, MD, PhD, Nieto Y, MD, PhD, Qazilbash MH, MD, Alousi AM, MD, Andersson BS, MD, PhD, Hosing CM, MD, Shpall EJ, MD, Khouri IF, MD, Lima MD, MD, Champlin R, MD. Improved Early Outcomes with T-Cell Replete (TCR) Compared with T-Cell Depleted (TCD) Haploidentical Stem Cell Transplantation (HaploSCT). ASH Annual Meeting 2011 Abstract, 2011. e-Pub 2011.
188. Nieto Y, MD, PhD, Thall PF, PhD, Andersson BS, MD, PhD, Popat UR, MD, Anderlini P, MD, Valdez BC, PhD, Shpall EJ, MD, Qazilbash M, MD, Alousi AM, MD, Chancoco C, Hosing CM, MD, Kebriaei P, MD, Bashir Q, MD, Shah N, MD, Khouri I, MD, Ciurea SO, MD, McMullin B, RN, Rondon G, MD, Champlin R, MD, Jones R, MD, PhD. High-Dose Infusional Gemcitabine (Gem) Combined with Busulfan (Bu) and Melphalan (Mel) (GemBuMel) with Autologous Stem-Cell Transplant (ASCT) in Patients with Refractory Lymphoid Malignancies. ASH Annual meeting 2011 Abstract, 2011. e-Pub 2011.
189. Popat U, MD, Andersson BS, MD, PhD, Bassett R, Ciurea S, Rondon G, MD, Alousi AM, MD, Anderlini P, MD, Hosing C, MD, Jones R, MD, PhD, Kebriaei P, MD, Nieto Y, MD, PhD, Khouri I, MD, Shpall EJ, MD, Verstovsek S, MD, PhD, Qazilbash M, MD, de Lima MJ, MD, Champlin R, MD. Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: PK Guided IV Busulfan Dose Intensity Results in Improved Event Free Survival. ASH Annual Meeting 2011 Abstract, 2011. e-Pub 2011.
190. Beitinjaneh A, MD, MPH, Saliba RM, PhD, Okoroji G, Korbling M, MD, Alousi AM, MD, Popat U, MD, Anderlini P, MD, Bashir Q, MD, Andersson BS, MD, PhD, Kebriaei P, MD, Hosing CM, MD, Qazilbash M, MD, Fanale MA, MD, Pro B, MD, Champlin R, MD, Khouri I, MD. Autologous and Allogeneic Stem Cell Transplantation for T-Cell Lymphoma: The M.D. Anderson Cancer Center Experience. ASH Annual Meeting 2011 Abstract, 2011. e-Pub 2011.
191. Zhou Y, MD, PhD, Jorgensen JL, MD, PhD, Saliba RM, PhD, Wang SA, MD, Rondon G, MD, Ledesma C, BS, Andersson BS, MD, PhD, de Lima MJ, MD, Shpall EJ, MD, Popat U, MD, Ciurea SO, MD, Alousi AM, MD, Qazilbash M, MD, Hosing CM, MD, Medeiros L, MD, Champlin R, MD, Kebriaei P, MD. Pre-Transplant Minimal Residual Disease Detected by Multiparameter Flow Cytometric Analysis Predicts for Disease Relapse in Adult Patients with Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Stem Cell transplantation. ASH Annual Meeting 2011 Abstract, 2011. e-Pub 2011.
192. Saliba RM, PhD, Chiattone A, MD, Majlis A, MD, Chiattone VC, RN, Rondon G, MD, Sakashita AM, MD, Hamerschlak N, MD, Kutner JM, MD, PhD, Shpall EJ, MD, Anderlini P, MD, Khouri I, MD, Qazilbash MH, MD, Popat U, MD, Champlin R, MD, Hosing CM, MD, Lima MD, MD. Predictors of Stem Cell Yield Via Apheresis in Patients Undergoing Stem Cell Mobilization. ASH Annual Meeting 2011 Abstract, 2011. e-Pub 2011.
193. Pemmaraju N, Ravandi F, Rondon G, Giralt S, Chen J, Pierce S, Champlin RE, de Lima M, Qazilbash M. Analysis of outcomes in patients (pts) with relapsed/refactory acute promyelocytic leukemia (APL) treated with and without high-dose chemotherapy and heamtopoietic stem cell transplantation (HCT). ASCO Meeting Abstracts. 2011 Vol 29(No 15_suppl):(May 20 Supplement), 2011, 2011. e-Pub 2011.
194. Beitinjaneh A, Saliba R, Okoroji G, Alousi AM, Popat UR, Korbling M, Anderlini P, Qazilbash M, Kebriaei P, Hosing C, Champlin RE, Khouri IF. Autologous stem cell transplantation (ASCT) as upfront or salvage therapy for noncutaneous T-cell lymphoma (TCL): The University of Texas M. D. Anderson Cancer Center (MDACC) experience. ASCO Meeting Abstracts. 2011 29(15):May 20 Supplement, 2011. e-Pub 2011.
195. Khouri IF, Saliba R, Alousi AM, Popat UR, Anderlini P, Kebriaei P, Qazilbash M, Champlin RE, Bassett RL. Bendamustine in combination with fludarabine and rituximab: A novel nonmyeloablative conditioning for allogeneic stem cell transplantation (AST) in patients with lymphoid malignancies. ASCO Meeting Abstracts. 2011 29(15):May 20 Supplement), 2011, 2011. e-Pub 2011.
196. Kazmi S, MD, Lu G, MD, Shah N, MD, Bashir Q, MD, Parmar S, MD, Orlowski RZ, MD, PhD, Shah JJ, MD, Hosing CM, MD, Popat U, MD, Dinh YT, Qureshi S, Rondon G, MD, Giralt S, MD, Champlin R, MD, Qazilbash MH, MD. A Comparative Study of the Outcome of High-Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation in Patients with High-Risk or Standard-Risk Myeloma Treated Concurrently. ASH Annual Meeting 2011 Abstract, 2011. e-Pub 2011.
197. Qazilbash M, MD, Thall PF, PhD, Liu P, Orlowski RZ, MD, PhD, Bashir Q, MD, Shah N, MD, Kebriaei P, MD, Parmar S, MD, Jones R, MD, PhD, Hosing CM, MD, Popat UR, MD, Dinh YT, Rondon G, MD, Shah JJ, MD, Lima MD, MD, Champlin R, MD, Giralt S, MD. A Randomized Phase II Trial of Fludarabine/Melphalan 140 Vs Fludarabine/ Melphalan 100 Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma. ASH Annual Meeting 2011 Abstract, 2011. e-Pub 2011.
198. Shah JJ, Orlowski RZ, Alexanian R, Wang M, Thomas S, Qazilbash MH, Parmar S, Shah N, Bashir Q, Popat U, Weber D. Phase I Trial of the Combination of Lenalidomide, Thalidomide and Dexamethasone In Relapsed/Refractory Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 116, 2010. e-Pub 2010.
199. Parmar S, Khan M, Rondon G, Shah N, Bashir Q, Tung S, Shah JJ, Weber D, Orlowski RZ, Giralt S, Champlin RE, Qazilbash MH. Outcome of High Dose Melphalan with Autologous Hematopoietic Stem Cell Transplant In Myeloma Associated with AL Amyloidosis. Blood (ASH Annual Meeting Abstracts) 116, 2010. e-Pub 2010.
200. Bashir Q, Wei W, Chiattone A, Rondon G, Parmar S, Shah N, Booc EH, Dinh Y, Qureshi S, Shah JH, Orlowski RZ, Weber D, Champlin R, Giralt S, Qazilbash MH. Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 116, 2010. e-Pub 2010.
201. Stadtmauer EA, Krishnan A, Pasquini MC, Ewell M, Alyea III EP, Antin JH, Castro-Malaspina H, Kissim AA, Negrin R, Qazilbash MH, Rizzo JD, Rowley SD, Sahebi F, Somlo G, Vesole DH, Vogl DT, Weisdorf DJ, Geller N, Horowitz MM, Maloney DG, Giralt S. Tandem Autologous Stem Cell Transplants (auto-auto) with or without Maintenance Therapy Versus Single Autologous Transplant Followed by HLA-Matched Sibling Non- Myeloablative Allogeneic Stem Cell Transplant (auto-allo) for Patients (pts) with High Risk (HR) Multiple Myeloma (MM): Results From the Blood and Marrow Transplant Clinical Trials Network (BMT-CTN) 0102 Trial. Blood (ASH Annual Meeting Abstracts) 116, 2010. e-Pub 2010.
202. Sharma MR, Ravandi F, Chiattone A, Kebriaei P, Popat U, Giralt S, Bashir Q, Qazilbash MH, Nieto Y, CH-L Y, Parmar S, Kantarjian HM, Cortes J, Kadia T, Borthakur G, Champlin RE, de Lima M. Treatment of FLT3-ITD Positive AML Relapsing After Allogeneic Hematopoietic Stem Cell Transplant (HSCT) with Sorafenib. Blood (ASH Annual Meeting Abstracts) 116, 2010. e-Pub 2010.
203. Nieto Y, Anderlini P, Popat U, Liu P, Andersson BS, Shpall EJ, Kebrieai P, Hosing C, Alousi AM, Qazilbash MH, Ciurea SO, Parmar S, Champlin RE, Jones R. Gemcitabine, Busulfan and Melphalan (GemBuMel) Is a New High-Dose Chemotherapy (HDC) Regimen with High Activity In Refractory Hodgkin's Lymphoma (HL) Patients Receiving An Autologous Stem-Cell Transplant (ASCT): A Contemporaneous Comparison with BEAM and Busulfan/Melphalan (BuMel). Blood (ASH Annual Meeting Abstracts) 116, 2010. e-Pub 2010.
204. McCarthy PL, Owzar K, Anderson KC, Hofmeister CC, Hurd DD, Hassoun H, Giralt S, Stadtmauer EA, Richardson PG, Weisdor DJ, Vij R, Moreb JS, Callander NS, Besien KV, Gentile T, Isola L, Maziarz RT, Gabriel DA, Bashey A, Landau H, Martin T, Qazilbash MH, Levitan D, McClune B, Hars V, Postiglione J, Jiang C, Bennett E, Barry SS, Bressler L, Kelly M, Sexton M, Rosenbaum C, Parameswaran H, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Linker C. Phase III Intergroup Study of Lenalidomide Versus Placebo Maintenance Therapy Following Single Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Myeloma: CALGB 100104. Blood (ASH Annual Meeting Abstracts) 116, 2010. e-Pub 2010.
205. Champlin R, Lee DA, Fernandez-Vina M, Rondon G, McAdams P, Chen J, Qazilbash MH, Kebriaei P, Parmar S, Shpall EJ, Popat U, Alousi A, Ciurea SO, Cooper L, Thall P, McMannis J. Alloreactive Nk Cells to Augment Antileukemia Cytotoxicity with Allogeneic Stem Cell Transplantation for Aml/Mds: A Phase I Study. Blood (ASH Annual Meeting Abstracts) 116, 2010. e-Pub 2010.
206. Sharma M, Saliba RM, Qazilbash MH, Okoroji GJ, Popat U, de Lima M, Champlin R, Hosing C. Poor FEV1 or DLco on Pre-Transplant PFT Does Not Compromise Outcomes In Patients Undergoing a Reduced-Intensity Allogeneic Progenitor Cell Transplant. Blood (ASH Annual Meeting Abstracts) 116, 2010. e-Pub 2010.
207. Okoroji GJ, de Padua Silva L, Saliba RM, Korbling M, McLaughlin P, Hosing C, Anderlini P, Alousi A, de Lima M, Kebriaei P, Popat U, Qazilbash M, Fayad L, Samaniego F, Fowler N, Champlin R, Hagemeister F, Khouri IF. Outcome In Follicular Lymphoma (FL) Patients (pts) Relapsing After Autologous Stem Cell Transplantation (ASCT): Allografting Vs. Conventional Therapy. Blood (ASH Annual Meeting Abstracts) 116, 2010. e-Pub 2010.
208. Alousi AM, Andersson BS, Saliba RM, Botnick W, Rondon G, Shpall EJ, de Lima M, Popat U, Hosing C, Kebriaei P, Khouri I, Qazilbash MH, Anderlini P, Nieto Y, Ciurea S, Jones R, Champlin R. Reduced Intensity Conditioning Combined with Post-Transplant Cyclophosphamide for Graft Vs. Host Disease Prophylaxis In Older-Aged or Medically Frail Patients with Advanced Hematological Malignancies. Blood (ASH Annual Meeting Abstracts) 116, 2010. e-Pub 2010.
209. Parmar S, Khan M, Rondon G, Shah N, Bashir Q, Tung S, Shah JJ, Weber D, Orlowski RZ, Giralt S, Champlin RE, Qazilbash MH. High Dose Melphalan with Autologous Stem Cell Transplantation Overcomes Poor Prognosis of Primary Amyloidosis. Blood (ASH Annual Meeting Abstracts) 116, 2010. e-Pub 2010.
210. Krishman A, Pasquini MC, Ewell M, Stadtmauer EA, Alyea III EP, Antin JH, Comenzo RL, Goodman S, Parameswaran H, Negrin R, Qazilbash MH, Rowley SD, Sahebi F, Somlo G, Vesole DH, Vogl DT, Weisdorf DJ, Geller N, Horowitz MM, Giralt S, Maloney DG. Tandem Autologous Hematopoietic Stem Cell Transplants (AuHCT) with or without Maintenance Therapy (auto-auto) Versus Single AuHCT Followed by HLA Matched Sibling Non- Myeloablative Allogeneic HCT (auto-allo) for Patients with Standard Risk (SR) Multiple Myeloma (MM): Results From the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 Trial. Blood (ASH Annual Meeting Abstracts) 116, 2010. e-Pub 2010.
211. Bashir Q, Wei W, Chiattone A, Rondon G, Parmar S, Shah N, Booc EH, Dinh Y, Qureshi S, Shah JJ, Orlowski RZ, Weber D, Champlin R, Giralt S, Qazilbash MH. Autologous Hematopoietic Cell Transplantation In Multiple Myeloma Patients Age 70 Years and Older. Blood (ASH Annual Meeting Abstracts) 116, 2010. e-Pub 2010.
212. Shah N, Weber DM, Wang M, Thomas S, Shah J, Giralt S, Alexanian R, Orlowski RZ, Qazilbash MH, Avery T. Survival Disparities Between African-American and Caucasian Patients with Multiple Myeloma Are Blunted in the Era of Novel Therapeutics and Autologous Stem Cell Transplantation. Blood (ASH Annual Abstracts) 114(22):568, 2009. e-Pub 2009.
213. Popat U, Hosing C, Fanale M, Mederios J, Alousi AM, Giralt SA, de Lima M, Qazilbash MH, Kebrieai P, Younes A, Khouri I, Andersson B, Champlin R, Anderlini P. Autologous Transplantation for Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). Blood (ASH Annual Abstracts) 114(22):912, 2009. e-Pub 2009.
214. Bashir Q, Thall P, Hosing C, Mendoza FL, Han E, Wang M, Shah J, Alousi A, Anderlini P, Kebriaei P, Khouri IF, Popat U, de Lima M, Champlin R, Giralt S, Qazilbash MH. Salvage Autologous or Allogeneic Stem Cell Transplantation After the Failure of First Autograft in Patients with Multiple Myeloma. Blood (ASH Annual Abstracts) 114(11):487, 2009. e-Pub 2009.
215. Khouri IF, Harrell R, Valverde R, Korbling M, Manshouri T, Samuels B, Maadani F, Okoroji GJ, Bassett Jr RL, Alousi A, Anderlini P, de Lima M, Giralt S, Hosing C, Kebriaei P, Popat U, Qazilbash M, Ueno N, Stachowiak AM, Erwin B, Fayad L, Pro B, Fowler N, McLaughlin P, Neelapu S, Younes A, Champlin R, Podoloff D. Stem Cell Transplantation with 90yttrium Ibritumomab Tiuxetan(90YIT) in Non-Hodgkin's Lymphoma (NHL): Observations From PET Pre-Treatment Imaging and Responses in Allografted Refractory Follicular Histologies. Blood (ASH Annual Abstracts) 114(22):354, 2009. e-Pub 2009.
216. Qureshi S, Sharma M, Hosing C, Mendoza FL, Shah J, Alousi A, Anderlini P, Kebrieai P, Khouri IF, Popat U, de Lima M, Champlin RE, Giralt S, Qazilbash MH. Outcome of IgD Myeloma After Autologous Hematopoietic Stem Cell Transplantation. Blood (ASH Annual Meeting) 114(22), 2009. e-Pub 2009.
217. Shah N, Ahmed KF, Qureshi S, Shah J, Orlowski RZ, Weber DM, Hosing C, Popat U, Alousi A, Champlin RE, Giralt S, Qazilbash M. Durable Remission with Salvage Autotransplants in Patients with Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 114(22):506, 2009. e-Pub 2009.
218. De Padua Silva L, Saliba R, McCormick D, Okoroji GJ, Alousi A, Anderlini P, Ciurea S, Hosing C, Kebrieai P, Popat U, Qazilbash M, Ueno N, McMannis J, Champlin R, Pro B, Khouri I. Autologous Stem Cell Mobilization with Cytokines and in-Vivo Alemtuzumab in Patients with T-Cell Non-Hodgkin's Lymphoma (T-NHL). Blood (ASH Annual Abstracts) 114(22):1245, 2009. e-Pub 2009.
219. Kebrieai P, Madden T, Kazerooni R, Shpall E, Wang X, Thall P, Hosing C, Qazilbash M, Popat U, Ledesma C, Khouri I, Champlin R, Jones R, Andersson BJ. Intravenous Busulfan Plus Melphalan Is a Highly Effective, Non-Toxic Preparative Regimen for Autologous Stem Cell Transplantation (ASCT) in Patients with Advanced Lymphoid Malignancies. Blood (ASH Annual Abstracts) 114(22):1326, 2009. e-Pub 2009.
220. Alousi AM, Rondon G, Okoroji GJ, Popat U, De Padua Silva L, Hymes S, Neumann J, Brunelle NM, Kebrieai P, Hosing C, Khouri IF, Shpall EJ, Qazilbash MH, Giralt S, Champlin R, Saliba RM. Co-Morbidity Score at the Time of Transplant Determines Prognosis in Older Patients Who Develop Acute Graft-Vs.-Host Disease (GVHD). Blood (ASH Annual Abstracts) 114(22):884, 2009. e-Pub 2009.
221. Sharma M, Thall P, Wang X, Hosing C, Mendoza FL, Han E, Wang M, Weber D, Shah J, Alousi A, Anderlini P, Kebriaei P, Khouri I, Popat U, de Lima M, Champlin RE, Giralt S, Qazilbash M. A Randomized Phase II Trial of High-Dose Melphalan, Ascorbic Acid and Arsenic Trioxide with or without Bortezomib in Multiple Myeloma. Blood (Ash Annual Meeting Abstracts) 114(22):912, 2009. e-Pub 2009.
222. Popat U, Rondon G, Alousi A, Anderlini P, Andersson B, Hosing C, de Lima M, Ciurea S, Giralt S, Kebriaei P, Nieto Y, Khouri I, Qazilbash MH, Jones R, Champlin R. Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis. Blood (ASH Annual Abstracts) 114(22):900, 2009. e-Pub 2009.
223. de Padua Silva L, Saliba RM, Giralt S, de Lima M, Hosing C, Khouri IF, Popat U, Qazilbash M, Shpall E, Thomas DA, Kantarjian H, Champlin R, Kebriaei P. Reduced Intensity Conditioning (RIC) Regimen Followed by Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Adult Patients with Acute Lymphoblastic Leukemia (ALL). ASBMT (Annual Meeting Abstracts) 2009 15(2(2)):62, 2009. e-Pub 2009.
224. Alatrash G, Andersson B, Pelosini M, Rondon G, Qazilbash M, Giralt S, de Padua S, Hosing C, Kebriaei P, Zhang W, Saliba R, Champlin R, de Lima M. Allogeneic Hematopoietic Stem Cell Transplant (HSCT) For Patients In the 6th and 7th Decades Of Life With AML OR MDS Using Myeloablative, Reduced Toxicity IV Busulfan/Fludarabine (BUFLU) Conditioning Regimen. ASBMT (Annual Meeting Abstracts) 2009 15(2(2)):106, 2009. e-Pub 2009.
225. Kebriaei P, Giralt S, Jones D, Gutierrez K, De Lima M, Korbling M, Khouri IF, Popat U, Qazilbash MH, Alousi A, Ciurea SO, Cooper L, Shpall E, Champlin R. Addition of Umbilical Cord Blood (UCB) Unit to Reduced Intensity Conditioning (RIC) Regimen to Augment Graft Versus Tumor (GVT) in Patients (pts) with Advanced Hematologic Malignancies. Blood (ASH Annual Meeting Abstracts) 2008 112(11):1132, 2008. e-Pub 2008.
226. de Padua Silva L, Saliba RM, Giralt S, De Lima M, Hosing C, Khouri IF, Popat U, Qazilbash M, Shpall E, Thomas DA, Kantarjian H, Champlin R, Kebriaei P. Reduced Intensity Conditioning (RIC) Regimen Followed by Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Adult Patients with Acute Lymphoblastic Leukemia (ALL). Blood (ASH Annual Meeting Abstracts) 2008 112(11), 2008. e-Pub 2008.
227. Popat U, Saliba R, de Padua Silva L, Andersson BS, Alousi AM, Anderlini P, de Lima M, Okoroji GJ, Hosin CM, Jones RB, Kebriaei P, Khouri I, Nieto Y, Qazilbash MH, Chanmplin R, Giralt S. Busulfan and Fludarabine Conditioning Regimen Negates the Impact of Comorbidity Score on Nonrelapse Mortality in Patients with AML/MDs. Blood(ASH Annual Meeting Abstracts) 2008 112(11):297, 2008. e-Pub 2008.
228. Koca E, Parikh G, Amjad AI, Mendoza FL, Hosing CM, Popat U, Champlin RE, Giralt S, Qazilbash MH. Role of Brain-Type Natriuretic Peptide and Cardiac Troponins as Predictors of Outcome in Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 2008 112(11), 2008. e-Pub 2008.
229. Ciurea SO, Kebriaei P, Khouri IF, Qazilbash MH, Jones RB, Petropoulos D, Worth LL, Alousi AM, Hosing CM, Patah P, Cano P, McMannis J, Giralt SA, Fernandez-Vina M, Champlin RE, Shpall EJ, De Lima M. High Rate of Engraftment and Low Regimen-Related Toxicity Using Fludarabine, Melphalan and Thiotepa Conditioning for Unrelated Donor Cord Blood Transplantation. Blood (ASH Annual Meeting Abstracts) 2008 112(11), 2008. e-Pub 2008.
230. Ciurea SO, De Lima M, Giralt M, Qazilbash MH, Alousi A, Kebriaei P, Khouri IF, Anderlini P, Andersson B, Hosing C, Verstovsek S, Kantarjian H, Champlin R, Popat U. Allogeneic Stem Cell Transplantation for Patients with Acute Leukemia Transformed from Myelofibrosis. Blood (ASH Annual Meeting Abstracts) 2008 112(11):1131, 2008. e-Pub 2008.
231. Popat U, De Lima MJ, Ativitavas T, Rondon G, de Padua Silva L, Koca E, Zhang W, Alousi A, Anderlini P, Giralt SA, Hosing CM, Jones R, Kebriaei P, Khouri I, Nieto Y, Qazilbash MH, Andersson BS, Champlin RE. Allogeneic Transplantation (HCT) for Myelodysplastic Syndrome:Recent MDACC Experience. Blood (ASH Annual Meeting Abstracts) 2008 112(11):413, 2008. e-Pub 2008.
232. Jabbour E, De Lima M, de Padua Silva L, Giralt S, Cortes J, Qazilbash M, Rondon G, Ciurea S, Jones R, Nieto Y, Korbling M, Couriel D, Kantarjian H, Champlin R. Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Patients (pts) with Advanced Chronic Myeloid Leukemia (CML) Post Imatinib Failure. Blood (ASH Annual Meeting Abstracts) 2008 112(11):360, 2008. e-Pub 2008.
233. de Padua Silva L, Cortes J, Jabbour E, Giralt S, Kebriaei P, O'Brien S, Alousi A, Qazilbash M, Rondon G, Ravandi F, Ribeiro R, Hosing C, Kantarjian H, Champlin R, De Lima M. Novel Tryosine Kinase Inhibitor Threapy Before Allogeneic Stem Cell Transplantation in Patients with Chronic Myeloid Leukemia. Blood (ASH Annual Meeting Abstracts) 2008 112(11):750, 2008. e-Pub 2008.
234. Khouri I, Bassett RL, Hsu Y, Dickason T, Acholonu S, Harrell R, Okorji GJ, de Padua Silva L, Korbling MJ, Alousi AM, Hosing C, Popat U, Giralt SA, Kebriaei P, Qazilbash MH, Ledesma C, Keating MJ, Champlin RE, Bueso-Ramos C. Prognostic Factors after Nonmyeloablative Allogeneic Stem Transplantation (NST) in Chronic Lymphocytic Leukemia (CLL): Expression of P53 May Not Predict Survival. Blood (ASH Annual Meeting Abstracts) 2008 112(11):412, 2008. e-Pub 2008.
235. Tam CS, bassett R, Ledesma C, Korbling MJ, Okoroji GJ, Harrell R, Hsu Y, De Padua Silva L, Alousi AM, Hosing CM, Kebriaei P, Rondon G, Giralt S, De Lima M, Anderlini P, Popat U, Qazilbash MH, Samuels B, Champlin RE, Khouri I. Rituximab Containing Autologous Stem Cell Transplantation May Be Curative in Mantle Cell Lymphoma for Patients in First Remission, but Not for Patients with Recurrent Disease. Blood (ASH Annual Meeting Abstracts) 2008 112(11):417, 2008. e-Pub 2008.
236. Khan ZU, Saliba RM, Qureshi S, Hosing C, Giralt SA, De Lima MJ, Yusuf SW, Popat UR, Champlin RE, Qazilbash MH. Outcome of Allogeneic Stem Cell Transplantation in Patients with Low Ventricular Ejection Fraction. Blood (ASH Annual Meeting Abstracts) 2008 112(11):1135, 2008. e-Pub 2008.
237. Alatrash G, Andersson BS, Pelosini M, Rondon G, Qazilbash MH, Giralt S, de Padua Silva L, Hosing C, Kebriaei P, Zhang W, Saliba R, Champlin RE, De Lima M. Myeloablative, Reduced Toxicity IV Busulfan/Fludarabine (BuFlu) and Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Patients in the 6th and 7th Decades of Life with AML or MDS. Blood (ASH Annual Meeting Abstracts) 2008 112(11):1031, 2008. e-Pub 2008.
238. Kazmi S MA, Mendoza FL, Weber D, Wang ML, Hosing C, Khouri IF, Anderlini P, De Lima M, Kebriaei P, Popat UR, Champlin RE, Giralt SA, Qazilbash MH. High-Dose Topotecan, Melphalan and Cyclophosphamide (TMC) with Autologous Stem Cell Support for Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 2008 112(11), 2008. e-Pub 2008.
239. Qazilbash MH, Saliba RM, Pelosini M, Hosing CM, Mendoza FL, Han E, Wang M, Weber DM, Alousi AM, Anderlini P, Kebriaei P, Khouri IF, Popat UR, De Lima M, Orlowski RZ, Champlin RE, Giralt SA. A Randomized Phase II Trial of High-Dose Melphalan, Ascorbic Acid and Arsenic Trioxide with or without Bortezomib in Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 2008 112(11):1140, 2008. e-Pub 2008.
240. Khouri IF, Lopez A, Okoroji GJ, Korbling M, McCormick G, Hsu Y, de Padua Silva L, Alousi AM, Hosing CM, Kebriaei P, Rondon G, Giralt SA, de Lima MJ, Anderlini P, Popat UR, Qazilbash MH, Champlin RE, Pro B. Myeloablative Chemotherapy for T-Cell Lymphoma: a Case for Autologous Stem Cell Transplantatin (Auto) in First Remission. Blood (ASH Annual Meeting Abstracts) 2008 112(11):417, 2008. e-Pub 2008.
241. Cole SM, Saliba R, Pelosini M, Mendoza FL, Weber D, Wang M, Thomas S, Orlowski RZ, Shah J, Alousi A, Hosing C, Popat U, Kebriaei P, Anderlini P, Khouri IF, Champlin R, Giralt S, Qazilbash MH. Reduced-Intensity Regimens for Allogeneic Stem Cell Transplantation Improve the Outcome in Advanced Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 2008 112(11):1132, 2008. e-Pub 2008.
242. De Lima M, McMannis JD, Saliba R, Worth L, Kebriaei P, Popat U, Qazilbash M, Jones R, Giralt S, de Padua Silva L, Cooper L, Petropoulos D, Lee D, Kelly S, Thall P, Robinson S, Khouri I, Hosing C, Korbling M, Alousi A, Rondon G, Andersson BS, Nieto Y, Ciurea S, Komanduri K, Champlin RE, Shpall E. Double Cord Blood Transplantation (CBT) with and without Ex-Vivo Expansion (EXP): A Randomized, Controlled Study. Blood (ASH Annual Meeting Abstracts) 2008 112(11):63, 2008. e-Pub 2008.
243. Hosing C, Smith VR, Rhodes BA, Walters KH, Qazilbash MH, McMannis JD, Alousi AM, De Lima M, Kebriaei P, Giralt S, Khouri I, Champlin R, Popat U. An Analysis of the Costs Associated with Peripheral Blood Hematopoietic Progenitor Cell Mobilization, Collection and Cryopreservation in Patients with Lymphomas Undergoing Autologous Stem Cell Transplantation. Blood (ASH Annual Meeting Abstracts) 2008 112(11):828, 2008. e-Pub 2008.
244. De Lima M, de Padua Silva L, Giralt S, Komanduri K, AnderssonBS, Hosing C, Qazilbash M, Shpall E, Thall P, Zhang W, McCormick G, Wang X, Popat U, Soriano A, Alousi A, Champlin R, Garcia-Manero G. Maintenance Therapy with Low-Dose Azacitidine (AZA) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Relapsed or Refractory AML or MDS: A Dose and Schedule Finding Study. Blood (ASH Annual Meeting Abstracts) 2008 112(11):414, 2008. e-Pub 2008.
245. Silva L, Weber D, Wang M, Han E, Mendoza F, de Lima M, Qazilbash M, Champlin RE, Giralt S. Myeloma With AL Amyloidosis: 10 Years Experience With Stem Cell Transplant. Biology of Blood and Marrow Transplantation 14(2):36, 2008. e-Pub 2008.
246. Popat U, Saliba R, Ablawat S, Okoroji GJ, Alousi A, Anderlini P, Andersson B, de Lima M, Jones R, Kebriaei P, Korbling M, Nieto Y, Qazilbash M, Shpall EJ, Khouri I, Giralt S, Champlin R, Hosing C. Incidence And Factors Influencing Stem Cell Mobilization In Patients With Non-Hodgkin's Lymphoma (NHL) And Hodgkin's Disease (HD). Biology of Blood and Marrow Transplantation 14(2):37, 2008. e-Pub 2008.
247. Anderlini P, Saliba R, Acholonu S, Giralt SA, Andersson B, Ueno NT, Hosing C, Khouri IF, Couriel D, de Lima M, Qazilbash MH, Pro B, Romaguera J, Fayad L, Hagemeister F, Younes A, Munsell MF, Champlin RE. Fludarabine-melphalan as a preparative regimen for. Haematologica 93(2):257-64, 2008. e-Pub 2008.
248. Williams LA, Giralt SA, Mendoza TR, Andersson KO, Mobley GM, Saliba RM, Qazilbash MH, Campagnaro EL, Cleeland CS. Larger Stem Cell Dose Is Associated With Decreased Symptom Severity After Autologous Stem Cell Transplantation For Multiple Myeloma. Biology of Blood and Marrow Transplantation 14(2):98, 2008. e-Pub 2008.
249. Ramos CA, Saliba RM, Giralt S, Khorshid O, de Padua L, Andersson BS, Nieto YL, Popat UR, Qazilbash MH, Qureshi S, Zhang W, Champlin RE, de Lima M. The Impact of Resolved Hepatitis B Infection on Allogeneic Hematopoietic Stem Cell Transplantation For Hematological Malignancies. Biology of Blood and Marrow Transplantation 14(2):8, 2008. e-Pub 2008.
250. Qazilbash MH, Saliba RM, Ahmed B, Parikh G, Mendoza F, Ashraf N, Hosing C, Flosser T, Weber DM, Wang M, Couriel DR, Popat U, Kebriaei P, Alousi AM, Anderlini P, Naeem RC, Champlin RE, Giralt SA. Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant. Biol Blood Marrow Transplant 9:1066-72, 2007. e-Pub 2007. PMID: 17697969.
251. Ozdemir E, Saliba RM, Champlin RE, Couriel DR, Giralt SA, de Lima M, Khouri IF, Hosing C, Kornblau SM, Anderlini P, Shpall EJ, Qazilbash MH, Molldrem JJ, Chemaly RF, Komanduri KV. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant 40(2):125-36, 2007. e-Pub 2007. PMID: 17530009.
252. Popat UR, de Lima M, Anderlini P, Andersson B, Couriel D, Hosing C, Kebriaei P, Qazilbash MH, Alousi A, Champlin R, Giralt S. Long-term survival of patients with AML in remission after reduced intensity allogeneic hematopoietic stem cell transplantation (RISCT). Journal of Clinical OncologyJournal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Vol 25, No. 18S (June 20 Supplement), 2007, 2007. e-Pub 2007.
253. Qureshi S, Bukhari F, Saliba RM, Hosing C, Champlin RE, Giralt SA, De Lima MJ, Yusuf SW, Qazilbash, MH. Outcome of allogenic SCT in patients with low left ventricular ejection fraction. Journal of Clinical Oncology,2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement, 2007. e-Pub 2007.
254. Saliba RM, de Lima M, Giralt S, Andersson B, Khouri IF, Hosing C, Ghosh S, Neumann J, Hsu Y, De Jesus J, Qazilbash MH, Champlin RE, Couriel DR. Hyperacute GVHD: risk factors, outcomes, and clinical implications. Blood 109(7):2751-8, 2007. e-Pub 2007. PMID: 17138825.
255. Qazilbash MH, Jindani S, Gul Z, Saliba R, Hosing C, Mendoza F, Qureshi SP, Weber DM, Wang M, Flosser T, Couriel DP, Kebriaei P, Popat U, Alousi AM, de Lima M, Champlin RE, Giralt. Arsenic trioxide with ascorbic acid and high-dose melphalan for autologous hematopoietic stem cell transplantation for multiple myeloma. Biology of Blood and Marrow Transplantation 13(2):9-10, 2007. e-Pub 2007.
256. Christoforidou AV, Saliba RM, Williams P, Qazilbash M, Roden L, Aleman A, Weber D, Mendoza F, Podoloff D, Rrd W, Breitz H, Alexanian R, Champlin R, Giralt S. Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes. Biol Blood Marrow Transplant 13(5):543-9, 2007. e-Pub 2007. PMID: 17448913.
257. Qazilbash MH, Gul Z, Jindani S, Saliba R, Hosing C, Mendoza F, Qureshi SP, Weber DM, Wang M, Flosser T, Couriel DP, de Lima M, Kebriaei P, Popat U, Alousi AM, Champlin RE, Giralt SA. Autologous stem cell transplantation for elderly patients with multiple myeloma. Biology of Blood and Marrow Transplant 13(2):10, 2007. e-Pub 2007.
258. Oran B, Giralt S, Saliba R, Hosing C, Popat U, Khouri I, Couriel D, Qazilbash M, Anderlini P, Kebriaei P, Ghosh S, Carrasco-Yalan A, de Meis E, Anagnostopoulos A, Donato M, Champlin RE, de Lima M. Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant 13(4):454-62, 2007. e-Pub 2007.
259. Qazilbash MH, Wieder ED, Thall PF, Wang X, Rios RL, Lu S, Kant S, Giralt S, Estey EH, Cortes J, Komanduri K, Champlin RE, Molldrem JJ. PR1 Peptide Vaccine-Induced Immune Response Is Associated with Better Event-Free Survival in Patients with Myeloid Leukemia. Blood (ASH Annual Meeting Abstracts) 2007 110, 2007. e-Pub 2007.
260. Qazilbash MH, Wieder ED, Thall PF, Wang X, Rios RL, Lu S, Kant S, Giralt SA, Estey EH, Cortes J, Komanduri K, Champlin RE, Molldrem JJ. PR1 Vaccine Elicited Immunological Response after Hematopoietic Stem Cell Transplantation Is Associated with Better Clinical Response and Event-Free Survival. Blood(ASH Annual Meeting Abstracts) 2007 110, 2007. e-Pub 2007.
261. Giralt SA, Thandi R, Qazilbash MH, Mendoza F, Han E, Hosing C, Wang M, Thomas S, Alexanian R, Champlin RE, Weber D. Retrospective Comparison of Transplant Outcomes in Patients with Multiple Myeloma According to Induction Therapy with Thalidomide/Dexamethasone (TD) with or without Bortezomib (VTD). Blood (ASH Annual Meeting Abstracts). 2007 110, 2007. e-Pub 2007.
262. Qazilbash MH, Saliba RM, Parikh GC, Hosing C, Mendoza F, Weber DM, Wang M, Thomas SK, Flosser TS, Kebriaei P, Popat U, Alousi AM, de Lima M, Champlin RE, Giralt SA. A Non-Myeloablative Regimen of Fludarabine and Melphalan Is Safe and Well Tolerated for Allogeneic Transplantation in Multiple Myeloma. Blood (ASH Annual Meeting Abstracts). 2007 110, 2007. e-Pub 2007.
263. Westin JR, Saliba RM, de Lima M, Alousi AM, Hosing C, Qazilbash MH, Khouri IF, Shpall EJ, Champlin RE, Couriel DR. Risk Factors for Response after Initial Therapy for Acute Graft-Versus-Host-Disease (aGVHD). Blood (ASH Annual Meeting Abstracts). 2007 110, 2007. e-Pub 2007.
264. de Lima M, Andersson B, Fernadez-Vina M, Giralt SA, Couriel D, Shpall EJ, Popat UR, Qazilbash MH, Alousi A, Cano P, Bosque D, Hosing C, Qureshi S, de Padua L, Munsell M, Anderlini P, Jones RB, Westmoreland M, Gulbis A, Champlin RE. Prophylaxis of Graft-Versus-Host Disease (GVHD) with Pentostatin, Tacrolimus, and "Mini"-Methotrexate (MTX): A Phase I/II Controlled, Randomized Study in Unrelated Donor (UD) Transplantation. Blood (ASH Annual Meeting Abstracts). 2007 110, 2007. e-Pub 2007.
265. Silva LD, Saliba RM, de Lima M, Okoroji GJ, Alousi A, Andersson B, Hosing C, Sphall EJ, Khouri I, Qazilbash MH, Anderlini P, Kebriaei P, Champlin RE, Jones RB, Giralt SA, Popat U. Obesity Does Not Impact Outcome in Patients with AML/MDS Undergoing Allogeneic Transplantation. Blood (ASH Annual Meeting Abstracts). 2007 110, 2007. e-Pub 2007.
266. Padua Silva LD, Weber D, Wang M, Han E, Mendoza F, Lima MD, Qazilbash M, Champlin RE, Giralt AS. Myeloma with AL Amyloidosis: 10 Years Experience with Stem Cell Transplant. Blood (ASH Annual Meeting Abstracts). 2007 110, 2007. e-Pub 2007.
267. Qazilbash MH, Saliba RM, Parikh G, Hosing F, Mendoza F, Qureshi SP, Weber DM, Wang M, Flosser T, Couriel DR, Kebriaei P, Popat UR, Alousi A, de Lima M, Champlin RE, Giralt S. Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan Is Safe and Effective for Autotransplantation for Multiple Myeloma. Blood (ASH Annual Meeting Abstracts). 2007 110, 2007. e-Pub 2007.
268. Champlin RE, Giralt SA, Shpall EJ, Kebriaei P, Anderlini P, Qazilbash MH, McMannis J, McCormick G, Fisher T, de Lima M, Rondon G. Nonmyeloablative Allogeneic Transplantation in the Imatinib Era: Three Chances To Achieve Molecular Remission in CML. Blood (ASH Annual Meeting Abstracts). 2007 110, 2007. e-Pub 2007.
269. Hosing C, Munsell M, Popat U, Körbling M, Valverde R, Maadani F, Kebriaei P, Alousi A, DeLima M, McMannis J, Shpall EJ, Qazilbash MH, Anderlini P, Giralt S, Champlin RE, Khouri I. Chemotherapy with Granulocyte Colony Stimulating Factor (G-CSF) Alone Versus Granulocyte Colony Stimulating Factor (G-CSF) Plus Granulocyte-Macrophage Stimulating Factor (GM-CSF) for Hematopoietic Progenitor Cell Mobilization in Patients with Relapsed Non-Hodgkin’s Lymphomas (NHLs). Blood (ASH Annual Meeting Abstracts). 2007 110, 2007. e-Pub 2007.
270. Popat UR, Rondon G, Alousi AM, Anderlini P, Andersson BS, de Lima MJ, Giralt SA, Hosing CM, Kebriaei P, Jones RB, Nieto YL, Shpall EJ, Verstovesek S, Qazilbash MH, Champlin RE. Myelofibrosis and Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation (RISCT). Blood (ASH Annual Meeting Abstracts). 2007 110, 2007. e-Pub 2007.
271. Giralt SA, Saliba RM, Mendoza F, Parikh G, Qureshi S, Zhang W, Popat U, Qazilbash MH, Khouri I, Hosing C, Alousi A, Anderlini P, Andersson B, Jones RB, Shpall EJ, Kebriaei P, Nieto YL, Ueno N, Champlin RE, de Lima M. Pre Transplant Values of C Reactive Protein (CRP) and Brain Natriuretic Peptide (BNP) as Predictors of Transplant Outcomes in Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndromes (AML/MDS) Undergoing Allogeneic Stem Cell Transplantation (AlloSCT). Blood (ASH Annual Meeting Abstracts). 2007 110, 2007. e-Pub 2007.
272. Parikh GC, Saliba RM, Lahoti A, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Popat UR, Alousi AM, Champlin RE, Giralt SA, Qazilbash MH. Autotransplantation in Patients with Multiple Myeloma and Concurrent Renal Failure Is Safe and Feasible and Associated with Recovery of Renal Function in > 30% of Patients. Blood (ASH Annual Meeting Abstracts). 2007 110, 2007. e-Pub 2007.
273. de Lima M, Padua L, Giralt SA, CHosing C, Komanduri K, Qazilbash MH, Shpall EJ, Thall P, Qureshi S, McCormick G, Tong W, Popat U, Soriano A, Champlin RE, Manero GG. A Dose and Schedule Finding Study of Maintenance Therapy with Low-Dose 5-Azacitidine (AZA) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for High-Risk AML or MDS. Blood (ASH Annual Meeting Abstracts) 110, 2007. e-Pub 2007.
274. Chu DT, Saliba R, Qureshi S, Alousi A, Anderlini P, Bukhari F, Delima M, Giralt SA, Kebriaei P, Khouri IF, Parikh G, Popat U, Shpall EJ, Yusuf WS, Champlin RE, Qazilbash MH, Hosing C. Cardiac Toxicity and Non-Relapse Mortality in Patients with Low Left Ventricular Ejection Fraction Undergoing Stem Cell Transplantation. Blood (ASH Annual Meeting Abstracts). 2007 110, 2007. e-Pub 2007.
275. Kurian S, Qazilbash M, Fay J, Wolff S, Herzig R, Hobbs G, Bunner P, Weisenborn R, Aya-Ay M, Lynch J, Ericson S. Complete response after high-dose chemotherapy and autologous hemopoietic stem cell transplatation in metastatic breast cancer results in survival benefit. British Journal 12(6):531-5, 2006. e-Pub 2006. PMID: 17238982.
276. Qazilbash MH, Saliba RM, Aleman A, Lei X, Weber D, Carrasco A, Champlin RE, Giralt SA. Risk factors for relapse after complete remission with high-dose therapy for multiple myeloma. Leuk Lymphoma 47(7):1360-4, 2006. e-Pub 2006. PMID: 16923569.
277. Hosing C, Qazilbash MH, Kebriaei P, Giralt S, Davis MS, Popat U, Anderlini P, Shpall EJ, McMannis J, Körbling M, Champlin RE. Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma. Br J Haematol 133(5):533-7, 2006. e-Pub 2006. PMID: 16681642.
278. Kebriaei P, Saliba RM, Ma C, Ippoliti C, Couriel DR, de Lima M, Giralt S, Qazilbash MH, Gajewski JL, Ha CS, Champlin RE, Khouri IF. Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia. Bone Marrow Transplant 38(3):203-9. e-Pub 2006.
279. Qazilbash MH, Hosing C, Saliba R, Okoroji G, Popat U, Couriel D, Kebriaei P, Ali T, De Lima M, Anderlini P, Giralt S, Champlin R, Khouri I. High-Dose Chemotherapy and Autologous hematopoietic Progenitor Cell Transplantation (AHCT) for Non-Hodgkin’s Lymphoma (NHL) in Patients over 65 Years of Age. ASH Annual Meeting Abstracts, 2006. e-Pub 2006.
280. Qazilbash MH, Saliba R, Mendoza F, Ronden L, Hosing C, Couriel DR, Kebriaei P, Popat U, de Lima M, Champlin RE, Giralt SA. Salvage non-myeloablative allogeneic transplantation after failure of an autologous transplantation in multiple myeloma. Biology of Blood and Marrow Transplantation, 2006. e-Pub 2006.
281. Qazilbash MH, Ahmed B, Saliba R, Ashraf N, Mendoza F, Hosing C, Flosser T, Weber D, Wang M, Couriel D, Popat U, Kebriaei P, Alousi A, Champlin R, Giralt S. Deletion of the Short Arm of Chromosome 1 (del 1p) Is the Strongest Predictor of Poor Outcome in Myeloma Patients Undergoing an Autotransplant. ASH Annual Meeting Abstracts, 2006. e-Pub 2006.
282. Qazilbash MH, Kebriaei P, Madden TL, Thapar L, Shpall EJ, Hosing C, De Lima M, Thall PF, Wright S, Khouri IF. Intravenous (i.v.) busulfan (Bu) plus melphalan (Mel) is a well-tolerated preparative regimen for stem cell transplantation (SCT) in patients (pts) with advanced lymphoid malignancies. Biology of Blood and Marrow Transplantation, 2006. e-Pub 2006.
283. Qazilbash MH, Libunao F, Ronden L, Davis M, Champlin R, Giralt S. Arsenic Trioxide in combination with Ascorbic Acid and High-Dose Melphalan is Safe for Patient with MM Undergoing an Autologous Transplan. Biology of Blood and Marrow Transplantation, 2006. e-Pub 2006.
284. Qazilbash MH, Saliba R, Davis M, Mendoz F, Hosing C, Couriel D, De Lima M, Kebriaei P, Weber D, Wang M, Alousi A, Matthes S, Jones R, Champlin R, Giralt S. Arsenic Trioxide with Ascorbic Acid and High-Hose Melphalan for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myleoma. ASH Annual Meeting Abstracts, 2006. e-Pub 2006.
285. Qazilbash MH, Kebriaei P, Giralt S, Madden T, Thapar N, Sphall E, Hosing C, Couriel D, Popat U Thall P, Champlin R, Jones R, Andersson B. Toxicity and Early Response after Intravenous (IV) Busulfan (Bu) Plus Melphalan (Mel) Conditioning for Autologous Stem Cell Transplantation (SCT) in Patients (pts) with Multiple Myeloma (MM). ASH Annual Meetings Abstracts, 2006. e-Pub 2006.
286. Qazilbash MH, Rios R, Thall P, Wang X, Wider E, Lu S, Kant S, Giralt S, Estey E, j C, Champlin R, Komanduri K, Molldrem J. PR1 Vaccine after Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2006. e-Pub 2006.
287. Qazilbash MH, Saliba, R, Hosing C, Mendoza F, Qureshi S, Weber D, Wang M, Flosser T, Couriel D, DeLima M, Kebriaei P, Alousi A, Champlin R, Giralt S. Autologous Stem Cell Transplantation for Elderly Multiple Myeloma. ASH Annual Meeting Abstracts, 2006. e-Pub 2006.
288. Qazilbash MH, Soriano A, Champlin R, McCormick, Giralt S, Thall P, Komanduri K, Garcia-Manero G, De Lima M. Maintenance Therapy with 5-Azacytidine (5-AC) after Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic (MDS): A Dose and Schedule Finding Study. ASH Annual Meeting Abstracts, 2006. e-Pub 2006.
289. Qazilbash MH, De Souza J, Saliba R, Patah P, Rondon G, Popat U, Champlin R, De Lima M. Renal Function Impairment and Outcomes of Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation. ASH Annual Meeting Abstracts, 2006. e-Pub 2006.
290. Qazilbash MH, Kebriaei P, Madden T, Thapar N, Shpall E, Hosing C, Thall P, Khouri I, Champlin R, Jones R, Andersson B. Intravenous (i.v.) busulfan (Bu) plus melphalan (Mel) is a well-tolerated preparative regimen for Stem Cell Transplantation (SCT) in patients (pts) with advanced lymphoid malignancies,. ASCO Meeting Abstracts, 2006. e-Pub 2006.
291. Qazilbash MH, Khouri I, Saliba R, Hosing C, Valverde R, Erwin W, Fayad L, Maadani F, Korbling M, Okoroji G, Stachowiak A, Samuels B, Anderlini P, Couriel D, De Lima M, Giralt S, Popat U, Kebriaei P, Ueno N, McLaughlin P, Gagemeister F, Youn A, Podoloff D, Champlin R. Efficacy and Safety of Yttrium 90 (90Y) Ibritumon Tiuxetan in Autologous and Nonmyeloablative Stem Cell Transplantation (NST) for Relapsed Non-Hodgkin’s Lymphoma (NHL). ASH Annual Meeting Abstracts, 2006. e-Pub 2006.
292. Couriel DR, Hosing C, Saliba R, Shpall EJ, Anderlini P, Rhodes B, Smith V, Khouri I, Giralt S, de Lima M, Hsu Y, Ghosh S, Neumann J, Andersson B, Qazilbash M, Hymes S, Kim S, Champlin R, Donato M. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood 107(8):3074-80, 2005. e-Pub 2005. PMID: 16368882.
293. Qazilbash MH, Couriel D, Thall P, Mickler K, de Lima M, Giralt S, Hosing C, Khouri I, Kebriaei P, Hsu Y, Saliba R, Ippoliti C, Champlin R. Phase II/III Randomized study comparing two different Tacrolimus Blood Levels for the Prevention of Graft-Versus-Host Disease. Blood, 2005. e-Pub 2005.
294. Qazilbash MH, Davis MS, Aleman A, Ronden L, Libunao F, Thall P, Wang X, Couriel D, de Lima M, Hosing C, Kebriaei P, Weber D, Wang M, Jones R, Matthes S, Champlin R, Giralt S. Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan: A new Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Blood, 2005. e-Pub 2005.
295. Qazilbash MH, Couriel D, Thall P, Mickler K, de Lima M, Giralt S, Hosing C, Khouri I, Kebriaei P, Hsu Y, Saliba R, Ippoliti C, Champlin R. Phase II/III Randomized study comparing two different Tacrolimus Blood Levels for the Prevention of Graft-Versus-Host Disease. Blood, 2005. e-Pub 2005.
296. Qazilbash MH, Hosing C, Kebriaei P, Giralt S, Davis M, Rhodes B, Smith V, Shpall E, McMannis J, Korbling M, Champlin R. Fixed-Dose Single Agent Pegfilgrastim for Peripheral Blood Progenitor Cell Mobilization in Patients with Multiple Myeloma, 2005. e-Pub 2005.
297. Qazilbash MH, Kebriaei P, Saliba R, Ma C, Ippoliti C, Couriel DR, de Lima M, Giralt S. The Impact of Rituximab in the Development of Acute Graft Versus Host Disease following Allogeneic Stem Cell Transplantation for Acute Lymphoblastic Leukemia, 2005. e-Pub 2005.
298. Jones J A, Qazilbash M H, Shih Y T, Cantor S B, Cooksley C D, Elting L S. Economic implication of outcomes complicating hematopoetic stem cell transplant (HSCT) for multiple myeloma (MM), Hodgkin’s (HD) and non-Hodgkin’s lymphoma (NHL). . J Clin Oncol 23(16S):531s, 2005. e-Pub 2005.
299. Qazilbash MH, Kebriaei P, Saliba R, Ma C, Ippoliti C, Couriel D, de Lima M, Giralt S, Gajewski J, Ha C, Champlin R, Khouri I. Allogeneic Transplantation after an Alemtuzumab-Containing Myeloablative conditioning Regimen for CD52 Positive Acute Lymphoblastic Leukemia. Blood, 2005. e-Pub 2005.
300. Qazilbash MH, Saliba R, Aleman A, Roden L, de Lima M, Couriel D, Hosing C, Kebriaei P, Champlin R, Giralt S. Arsenic trioxide with ascorbic acid and high-dose melphalan: a new preparative regimen for autologous hematopoietic stem cell transplantation for multiple myeloma, 2005. e-Pub 2005.
301. Qazilbash MH, Qu Z, Hosing C, Couriel D, Donato M, Giralt S, Champlin R. Rituximab-induced acute liver failure after an allogeneic transplantation for Chronic Myeloid Leukemia. Blood, 2005. e-Pub 2005.
302. Qazilbash, M, Saliba, R, Lima D, M, Couriel, D, Hosing, C, Aleman, A, Lei, X, Champlin, R, Giralt, S. Second Autologous Or Allogeneic Transplantation After The Failure Of First Autograft In Multiple Myeloma. Blood 104(11):909a, 2004. e-Pub 2004.
303. Qazilbash M H, Wieder E, Rios R, Kant S, Lu S, Wang C, Molldrem J. PR1 Vaccine – Induced Immunological and Clinical responses in Myeloid malignancies. Fourth International Workshop on Haploidentical Transplants, Naples, Italy, 2004. e-Pub 2004.
304. Lima D, M, Thall, P, Shahjahan, M, Xuemei, W, Couriel, D, Anderlini, P, Hosing, C, Qazilbash, M, McCormick, G, Ippoliti, C, Donato, M, Martin, T, Metoyer, L, Griffin, L, Kebriaei, P, Champlin, R, Giralt, S. Phase I/Ii Study Of Low-Dose Gemtuzumab Ozogamicin (GO), Fludarabine And Melphalan (Fm) Conditioning Regimen For Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In AML/MDS. Blood 104(11):505a, 2004. e-Pub 2004.
305. Khouri, I, Saliba, R, Partow, K, Ma, C, Ippoliti, C, Couriel, D, Lima D, M, Giralt, S, Qazilbash, M, Gajewski, J, Champlin, R. Allogeneic Transplantation for Adult Acute Lymphoblastic Leukemis (ALL) with Rituximab or Campath I-H. Blood 104(11):366b, 2004. e-Pub 2004.
306. Champlin, R, Ghosh, S, McCormick, G, Andersson, B, Lima D, M, Anderlini, P, Qazilbash, M, Giralt S, S, Cortes, J. Sequential Treatment With Reduced Intensity Allogeneic Stem Cell Transplantation And Imatinib For Chronic Myelogenous Leukemia (Cml): Three Chances For Cure. Blood 104(11):232a, 2004. e-Pub 2004.
307. Qazilbash, M, Wieder, E, Rios, R, Lu, S, Kant, S, Giralt, S, Estey, E, Thall, P, Lima D, M, Couriel, D, Champlin, R, Komanduri, K, Molldrem, J. Vaccination With The PR1 Leukemia-Associated Antigen Can Induce Complete Remission In Patients With Myeloid Leukemia. Blood 104(11):77a, 2004. e-Pub 2004.
308. Qazilbash, M, Saliba, R, Aleman, A, Lei, X, Weber, D, Carrasco, A, Champlin, R, Giralt, S. Risk factors for relapse after CR with high-dose therapy for multiple myeloma. . Blood 102(11):982a, 2003. e-Pub 2003.
309. Qazilbash, M, Devetten, M, Lynch, J, Beall C, Auber, M, Weisenborn, R, Bumer, P, Ericson, S. High-dose therapy with autologous transplantation for low-grade non-Hodgkin’s lymphoma. Pan-Pacific Lymphoma Conference, 2001. e-Pub 2001.
310. Ericson, S, Henderson, A, Watkins, K, Buckhalter, G, Weisenborn, R, Bunner, P, Beall, C, Devetten, M, Qazilbash, M, Lynch, J. Administration of G-CSF based on WBC count rather than a fixed day after autologous PBSCT results in decreased utilization of G-CSF without compromising neutrophil engraftment. ISHAGE, 2001. e-Pub 2001.
311. Qazilbash, M, Lynch, J, Beall C, Auber, M, Weisenborn, R, Bumer, P, Ericson, S. The impact of histology on high-dose therapy and autologous stem cell transplantation in patients with relapsed non-hodgkin’s lymphoma. Biol Blood Marrow Transplant 7(2):85, 2001. e-Pub 2001.
312. Qazilbash, M, Devetten, M, Lynch, J, Beall C, Auber, M, Weisenborn, R, Bumer, P, Ericson, S. High-dose therapy and autologous stem cell transplantation in relapsed and refractory hodgkin’s disease: outcome based on a prognostic model. Pan-Pacific Lymphoma Conference, 2001. e-Pub 2001.
313. Qazilbash, M, Lynch, J, Beall C, Auber, M, Weisenborn, R, Bumer, P, Ericson, S. The utility of a prognostic scoring system for allogeneic stem cell transplantation in patients with chronic myelogenous leukemia. Biol Blood Marrow Transplant 7:103, 2001. e-Pub 2001.
314. Qazilbash, M, Lynch, J, Beall, C, et al. High-dose therapy with autologous stem cell transplantation in multiple myeloma: experience of a single academic BMT Center. Tenth International Symposium on Autologous Blood and Marrow Transplantation, 2000. e-Pub 2000.
315. Qazilbash, M, Lynch, J, Beall C, Weisenborn, R, Bumer, P, Hobbs, G, Auber, M, Ericson, S. Outcome of unrelated donor stem cell transplantation for hematologic malignancies: preliminary data from a single academic transplant center. Blood 96(11):364b, 2000. e-Pub 2000.
316. Kurian, S, Qazilbash, M, Lynch, J, Beall, C, Weisenborn, R, Bummer, P, Hobbs, G, Auber, M, Ericson, S. High-dose Ara-C/Idarubicin induction and high-dose etoposide/cytoxan intensification in AML. Blood 96(11):213b, 2000. e-Pub 2000.
317. Qazilbash, M, Lynch, J, Beall, C, Weisenborn, R, Bumer, P, Hobbs, G, Auber, M, Ericson, S. Safety and efficacy of high-dose busulfan and cyclophosphamide for chronic myelogenous leukemia: effect cytoxan dose on outcome. Blood 96(11):357b, 2000. e-Pub 2000.
318. Qazilbash, M, Lynch, J, Beall C, Weisenborn, R, Bumer, P, Hobbs, G, Auber, M, Ericson, S. High-dose therapy (HDT) with autologous hematopoietic stem cell transplantation (HSCT) in multiple myeloma: experience of a single academic BMT center. Blood 96(11):374b, 2000. e-Pub 2000.
319. Qazilbash, M, Lynch, J, Beall C, Weisenborn, R, Bumer, P, Hobbs, G, Auber, M, Ericson, S. Efficacy of a BCNU-based high-dose conditioning regimen(CBVi) followed by autologous hematopoietic stem cell transplantation (HSCT) in relapsed or refractory Hodgkin’s disease (HD). Blood 96(11):374b, 2000. e-Pub 2000.
320. Qazilbash, M, Saliba, R, Aleman, A, Roden, L, Lima D, M, Couriel, D, Hosing, C, Kebriaei, P, Champlin, R, Giralt, S. Arsenic trioxide with ascorbic acid and high-dose melphalan: a new preparative regimen for autologous hematopoietic stem cell transplantation for multiple myeloma, 2000. e-Pub 2000.
321. Paul, D, Qazilbash, MH, Seth, P, Liu, J, Cowan, KH. Construction of a recombinant adeno-associated virus (rAAV) vector for interleukin-12 (IL-12) mediated cancer gene therapy. Cancer Research 39:3520, 1998. e-Pub 1998.
322. Qazilbash, MH, Xiao, X, Paul, D, et al. Anti-tumor activity of a recombinant adeno-associated virus vector expressing wild-type p53 in vivo. Journal of Investigative Medicine 45:266A, 1997. e-Pub 1997.
323. Qazilbash MH, Xiao X, Seth P, Cowan KH, Walsh CE. Cancer gene therapy with a novel adeno-associated virus vector expressing p53. Gene Therapy Meeting, Cold Spring Harbor Laboratory, New York:245, 1996. e-Pub 1996.
324. Qazilbash MH, Walsh CE, Young NS, Liu JM. Progress towards gene therapy of X-linked SCID. Clinical Research 42:202A, 1994. e-Pub 1994.
325. Qazilbash MH, Liu JM, Vlachos A, et al. Familial aplastic anemia associated with liver disease. Blood Suppl 84:8A, 1994. e-Pub 1994.

Book Chapters

1. Ghanem, S, Qazilbash, MH. Hematopoietic Cell Transplantation in Multiple Myeloma, 297-307, 2023.
2. Ahmed S, Qazilbash M. Chronic Myeloid Leukemia. In: The Bethesda Handbook of Clinical Oncology. 4th Edition, 328-334, 2014.
3. Qazilbash MH, Giralt SA. Hematopoietic Cell Transplantation for Multiple Myeloma. In: Thomas' Hematopoietic Cell Transplantation. 4. Wiley Blackwell, 845-59, 2009.
4. Qazilbash MH, Cortes JE. Myeloid Leukemia. In: Bethesda Handbook of Clinical Oncology. Second. Lippincott Williams & Wilkins, 331, 2005.
5. Qazilbash M. Chronic Leukemias. In: Bethesda Handbook of Clinical Oncology. Lippincott Williams & Wilkins, 2004.
6. Qazilbash M. Chronic Myeloid Leukemia. In: Bethesda Handbook of Clinical Oncology. Lippincott Williams & Wilkins, 2004.
7. Qazilbash MH. Peptide Vaccines for AML. In: Immunotherapy and Gene Therapy. Springer Science.

Letters to the Editor

1. Marcoux C, Pasyar S, Milton DR, Khan HN, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Neupane N, Lee HC, Patel KK, Tang G, Aljawai Y, Kebriaei P, Thomas SK, Orlowski RZ, Shpall EJ, Champlin R, Qazilbash MH, Pasvolsky O. Impact of body mass index on outcomes of multiple myeloma patients undergoing upfront autologous stem cell transplant. Br J Haematol 206: 763-765, 2024.